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ABSTRACT 
Fractures are a global health concern, leading to morbidity and mortality. 
Individuals with reduced kidney function experience bone mineral metabolism changes 
which can increase fracture risk. Yet, there is little consensus on the fundamentals: 
prediction, incidence, risk factors, and screening of fractures in kidney disease patients. 
This thesis addressed these critical areas helping decrease the health burden of fracture in 
this unique population.  
This research used data from the Canadian Multicentre Osteoporosis Study 
(CaMos) to examine individuals with chronic kidney disease (CKD) (n=320). CaMos is a 
national longitudinal study designed to collect information on fractures. To examine 
kidney transplant recipients data from Ontario administrative healthcare databases was 
used (n=4821).  The predictive ability of the Fracture Risk Assessment Tool (FRAX) in 
individuals with CKD was evaluated using area under the receiver operator characteristic 
curves and survival analyses. The incidence and risk factors for fracture in kidney 
transplant recipients were assessed using incidence rates and Cox hazard regression 
analysis. 
The first manuscript systematically summarized the incidence and risk factors for 
fracture in kidney transplant recipients; fracture incidence and risk factors were variable 
across studies. 
The second manuscript examined the predictive value of FRAX in individuals 
with CKD compared to individuals with normal kidney function. The discriminative 
ability of FRAX for fracture prediction was comparable in both groups.  
The third manuscript examined the incidence of fracture in kidney transplant 
recipients. The cumulative incidence of fracture was low with approximately 2% 
sustaining a hip fracture over 10-years.  
The fourth manuscript examined risk factors for fracture in kidney transplant 
recipients.  Transplant-specific risk factors (i.e., diabetes or cystic kidney disease as the 
cause of end-stage renal disease and donor age) and general risk factors (i.e., older 
recipient age and female sex) were significantly associated with fractures.  
The fifth manuscript examined the frequency and variability in bone mineral 
density (BMD) testing across Ontario transplant centres.  Over half of kidney transplant 
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recipients received at least one BMD and the ordering of BMD tests varied widely by 
centre – from 15% to 92%.  
Results can be used to improve prognostication, advance clinical guidelines, 
clarify fracture incidence, and guide informed consent.  
 
Keywords: fracture, kidney disease, chronic kidney disease, kidney transplant recipient, 
epidemiology, bone 
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KDIGO  Kidney Disease Improving Global Outcomes 
MAR  Missing At Random 
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MNAR Missing Not At Random 
NACRS National Ambulatory Care Reporting System 
NPV  Negative Predictive Value 
NR  Not Reported 
OHIP  Ontario Health Insurance Plan 
OR  Odds Ratio 
PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
PPV  Positive Predictive Value 
RR  Relative Risk 
SAS  Statistical Analysis Software 
SD  Standard Deviation 
SF-36  Short Form (36) Health Survey 
TGLN  Trillium Gift of Life Network 
USRDS  United States Renal Data System 
UTD  Unable To Determine 
WHO             World Health Organization 
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GLOSSARY 
Bisphosphonate: A drug given to help prevent fracture. 
Bone Mineral Density (BMD): The quantity of minerals present in a specific volume of 
the bone (1). In the general population as BMD decreases fracture risk has been shown to 
increase (2, 3). 
Bone Mineral Density Test: A tool used to measure bone mineral density which 
provides information on bone mass. 
Chronic Kidney Disease (CKD): Estimated glomerular filtration rate (eGFR) (measure 
of kidney function) less than 60 ml/min/1.73 m
2 
for at least 3 months  or the presence of 
kidney damage (4). In this thesis CKD was defined by evidence of one eGFR 
measurement <60 mL/min/1.73 m
2
 (Chapter 3) or using diagnostic codes for CKD 
(Chapter 4). 
Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD): A disorder caused 
by chronic kidney disease that affects bone and mineral metabolism and is characterized 
by at least one of the following: 
- Abnormal metabolism of calcium, phosphorous, parathyroid hormone, or 
vitamin D  
- Abnormal bone mineralization, bone volume, bone turnover, bone strength, 
or bone growth 
- Calcification of the soft tissue or calcification of vasculature (5). 
Dialysis: A process that removes wastes and excess water from the body when an 
individual has kidney failure (eGFR <15 mL/min/1.73 m
2
) (6). 
End Stage Renal Disease: A loss in kidney function so severe that the kidneys cannot 
function at a level required in day to day life and at which point dialysis is required (7). 
Generally this occurs with an eGFR <15 mL/min/1.73 m
2
. 
Estimated glomerular filtration rate: A measure of kidney function quantified by the 
amount of blood that travels through the glomeruli per minute (8).  
Fracture Risk Assessment Tool (FRAX): A tool developed and validated in the general 
population that predicts the ten-year probability of  hip or major osteoporotic fracture  
(hip, proximal humerus, forearm, or clinical vertebral) through the use of the following 
variables: age, sex, clinical risk factors, and with or without bone mineral density (9). 
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Kidney Disease: A range of diseases that adversely affect the kidney (8). In this thesis 
kidney disease refers to chronic kidney disease without transplantation and chronic 
kidney disease with kidney transplantation. 
Non-vertebral Fracture: For the purposes of this thesis includes: forearm (radius and 
ulna), proximal humerus, and hip fractures.  
Osteoporosis: A bone disease that increases an individual’s susceptibility to fracture 
(10). 
Osteoporotic Fracture: Fractures that occur due to a bone disease (osteoporosis) that 
causes reduced bone mass and a weakening of the bone microarchitecture, resulting in 
diminished bone strength (10). Hip, forearm, vertebral, and humerus fractures are 
considered major osteoporotic fracture locations. 
T-score:  Bone density compared to white females aged 20-29 years and is expressed in 
the number of standard deviations above normal (normal defined as ≥ -1) (11, 12). 
United States Renal Data System (USRDS): An American national dataset that 
contains information on end-stage renal disease patients (13).  
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1.1 Background and Overview 
The number of individuals in Canada living with kidney disease is increasing with 
a 40% increase in the number of Canadians living with kidney failure from 2003-2012 
(1). The reasons for this increase are multifactorial, including an aging population and an 
increase in type II diabetes and hypertension (two of the most common causes of kidney 
disease) (1). There is a desire for the 3 million Canadians living with chronic kidney 
disease and over 17,000 living with a kidney transplant to live long and healthy lives (2, 
3). One often overlooked complication of kidney disease is fracture. When kidney 
function declines changes in bone mineral metabolism occur which adversely affects the 
skeleton and increases fracture risk (4). Specifically, many individuals with kidney 
disease have a complex bone disorder called chronic kidney disease-mineral and bone 
disorder which is characterized by increased phosphate levels, decreased vitamin D and 
calcium levels, and secondary hyperparathyroidism (4). Although kidney transplantation 
improves kidney function many recipients continue to have chronic kidney disease-
mineral and bone disorder post-transplant (4). Therefore, fracture risk is thought to be 
high, relative to the non-kidney disease general population, across the spectrum of kidney 
disease (mild kidney dysfunction to kidney failure to kidney transplantation) (5-8). 
Fractures are a concern as they are associated with mortality, morbidity, and economic 
costs (9-11). Yet, there is little consensus on the fundamentals: prediction, incidence, risk 
factors, and frequency of preventative screening for fractures in kidney disease patients 
(defined in this thesis as chronic kidney disease without kidney transplantation and 
kidney transplantation). This thesis will address this critical area, and will inform future 
interventional strategies to reduce the health burden of fracture in the kidney disease 
population. 
 
1.2 Overall Aim  
The overall aim of this thesis is to better understand the epidemiology of fracture 
in adults with kidney disease and to use this information in the care of this unique patient 
population.  Despite the health and economic impact of fractures, there is currently a gap 
in knowledge about the epidemiology of fracture in patients with kidney disease. 
Addressing the objectives outlined in this thesis will inform future strategies to reduce the 
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incidence of fracture in this growing patient population. This thesis is part of a larger 
body of research I developed throughout my PhD studying bone health in individuals 
with kidney disease. The five objectives described below will address this overall 
objective. 
 
1.3 Study Objectives 
Objective 1: To efficiently and systematically summarize the incidence and risk factors 
for fracture in kidney transplant recipients. 
 
Objective 2a: To determine if kidney function modifies the predictive model 
performance of the Fracture Risk Assessment tool (FRAX). This will be done by 
assessing the discrimination and calibration of FRAX in individuals who have reduced 
kidney function compared to individuals with normal kidney function. 
Objective 2b: To assess the discrimination and calibration of FRAX (without bone 
mineral density) after the addition of chronic kidney disease as a variable in the model.  
Objective 2c: To assess the ability of the following variables to predict fracture in 
individuals with normal kidney function and reduced kidney function: age, T-score, and 
T-score with a history of fall. 
 
Objective 3a: To estimate the age- and sex- specific three-year incidence of non-
vertebral fractures (proximal humerus, forearm, hip) in kidney transplant recipients. 
Secondary Objectives  
i) To estimate the age- and sex-specific three-year incidence of fracture 
(including all fracture locations) in kidney transplant recipients. 
ii) To estimate the age- and sex-specific five-year incidence of non-vertebral 
fractures in kidney transplant recipients.  
iii) To estimate the age- and sex-specific ten-year incidence of non-vertebral 
fractures in kidney transplant recipients. 
iv) To estimate the age- and sex-specific three-year incidence of non-vertebral 
fractures in kidney transplant recipients who received a transplant in more 
recent years (2002-2009). 
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v) To estimate the age- and sex-specific three-year incidence of falls with 
hospitalization among kidney transplant recipients. 
Objective 3b: To assess whether kidney transplant recipients have a higher incidence of 
non-vertebral fractures compared to the following age-, sex-, and cohort entry date 
matched reference groups: healthy segment of the general population with no bone 
disease and no kidney disease, healthy segment of the general population with no 
evidence of kidney disease and a history of a non-vertebral fracture, individuals with 
chronic kidney disease (excluding individuals on dialysis), and individuals with 
rheumatoid arthritis. 
Objective 3c: To assess whether kidney transplant recipients have a higher incidence of 
non-vertebral fractures compared to patients receiving dialysis controlling for age, sex, 
cohort entry date, and comorbidities in the analysis. 
 
Objective 4: To determine the transplant specific (e.g. type of donor [living vs. 
deceased]) and general risk factors (e.g. age) for major fractures (proximal humerus, 
forearm, hip, and clinical vertebral) and other fractures (excluding major fractures, and 
those of the skull, fingers, and toes) in kidney transplant recipients.  
 
Objective 5a: To determine the frequency, total cost, and the variability in bone mineral 
density testing across the six Ontario transplant centres in the first three years after 
kidney transplantation.  
Objective 5b: To compare the frequency of bone mineral density testing in kidney 
transplant recipients to two non-transplant reference groups matching on age-, sex-, and 
cohort entry date (individuals with no evidence of kidney disease and with no prior non-
vertebral fracture; individuals with no evidence of kidney disease and a history of a non-
vertebral fracture).  
 
1.4 Structure of the Thesis Document 
An integrated manuscript style will be used to present the work of this thesis in a 
series of five manuscripts. A brief description of each manuscript is provided below. An 
in-depth description of the methods and additional results are provided in several 
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appendices (Appendix A for Chapter 2, Appendix C for Chapter 3, Appendix D for 
Chapter 4, and Appendix E for Chapter 5). Appendix B contains information on the 
ethics approval, consent form, and questionnaire for Chapter 3. Appendix F provides 
documentation for the privacy impact assessment approval for Chapters 4, 5, and 6. 
Appendix G provides copyright information. 
The second chapter of this thesis contains the literature review, conceptual model, 
and a version of the first manuscript entitled “Fracture Risk in Kidney Transplant 
Recipients: A Systematic Review” which was published in Transplantation. This 
manuscript addresses objective 1 of this thesis and systematically summarizes the 
incidence and risk factors for fracture in kidney transplant recipients. 
The second manuscript entitled “Comparison of fracture risk prediction among 
individuals with reduced and normal kidney function” was published in the Clinical 
Journal of the American Society of Nephrology and represents a version of Chapter 3. 
This manuscript addresses objective 2 of this thesis and assesses the prognostic value of 
the Fracture Risk Assessment Tool (FRAX) in adults with reduced and normal kidney 
function. 
The third manuscript entitled “Fracture incidence in adult kidney transplant 
recipients” was published in Transplantation and represents a version of Chapter 4. This 
manuscript addresses objective 3 of this thesis and provides a comprehensive 
examination of the incidence of fracture in adult kidney transplant recipients. 
The fourth manuscript entitled “Risk factors for fracture in adult kidney transplant 
recipients” is being prepared for submission to the Canadian Journal of Kidney Health 
and Disease. This manuscript addresses objective 4 of this thesis and provides 
information on risk factors for fracture in adult kidney transplant recipients. 
The fifth manuscript entitled “Frequency of bone mineral density testing in adult 
kidney transplant recipients” has been submitted to the Canadian Journal of Kidney 
Health and Disease. This manuscript addresses objective 5 of this thesis and examines 
the frequency, total cost, and the variability in bone mineral density testing in kidney 
transplant recipients across the six Ontario transplant centres. This manuscript was 
initially a secondary objective in Chapter 4; however, given the importance of the 
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findings and the additional analyses that were performed, a chapter dedicated to these 
findings was warranted. 
The last chapter of this thesis is the Discussion (Chapter 7). This chapter 
summarizes the major findings of this thesis and links all chapters of the thesis together. 
Information on implications for clinical practice, strengths and limitations, future 
directions, and conclusions are also discussed. 
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An extensive literature review was performed through searching PubMed, 
Embase, Medline, and Google Scholar for all objectives. For objectives 3 and 4 there was 
a large amount of literature assessing the incidence and risk factors for fracture in kidney 
transplant recipients, therefore, a systematic review was performed and is highlighted in 
part of this chapter.  
  
2.1 Osteoporotic Fracture 
Osteoporotic fractures are fractures that occur due to a bone disease 
(osteoporosis) that causes reduced bone mass and a weakening of the bone 
microarchitecture, resulting in diminished bone strength (1). The most common 
osteoporotic fracture sites include hip, vertebrae, forearm, and proximal humerus (2). 
These fractures are a global health concern for several reasons (3-7). First, these fractures 
are associated with morbidity (7, 8). For example, hip fractures have been found to be 
associated with chronic pain and loss of mobility (9). Second, these fractures can 
adversely impact quality of life (10, 11), with Adachi et al., finding women with a prior 
hip fracture had a significantly lower health-related quality of life score with particularly 
low scores in self-care (4). Last, these fractures increase mortality (12, 13). For example, 
compared to women and men without a major osteoporotic fracture individuals with a 
fracture had a significantly higher age-standardized mortality ratio (proximal femur: 2.18, 
95% [confidence interval] CI 2.03-2.32; vertebral 1.66, 95% CI 1.51-1.80) (6). The 
adverse effects of these fracture are troublesome as from 1985-2005 there were over 
570,000 hip fractures in Canada, with more than 145,000 hip fractures from 2001 to 2005 
(14). The monetary cost of these fractures can also place a large economic burden on the 
healthcare system. The direct healthcare costs of osteoporotic fractures in Canada 
currently exceed $2 billion each year with the cost of hip fracture alone estimated to 
reach $2.4 billion / year in the next three decades (3, 15).   
 
2.2 Kidney Disease 
The kidneys are important organs in our body that are needed to remove waste 
and filter blood (16). When the kidneys are not functioning properly an individual can 
develop kidney disease which is a broad term used to describe a range of diseases that 
11 
 
 
adversely affect the kidney (16). A permanent and meaningful decrement in kidney 
function is called chronic kidney disease (CKD) (16). Chronic kidney disease can 
progress to kidney failure (end-stage renal disease) at which point an individual requires 
either dialysis or a kidney transplant to survive (16). An in-depth description of CKD and 
kidney transplantation, which are the exposures of interest in this thesis, is provided 
below. 
2.2.1 Chronic Kidney Disease 
The Kidney Disease Improving Global Outcomes (KDIGO) guidelines define 
CKD as an estimated glomerular filtration rate [eGFR] <60mL/min/1.73 m
2 
(lower eGFR 
indicative of worse kidney function)
 
for at least three months or a higher eGFR with the 
presence of kidney damage (17). The KDIGO guidelines further categorize CKD into 5 
stages (Table 2.1) (17). The number of Canadians with CKD is increasing with 
approximately 3 million adult Canadians living with CKD (18, 19). This increase is 
partially attributable to the aging population and an increase in the number of Canadians 
with type II diabetes and hypertension (20, 21). CKD can advance to kidney failure, at 
which point an individual would require dialysis or a kidney transplant to sustain life. 
From 2003 to 2012, there has been an approximate  40%  increase in the number of 
Canadians living with kidney failure (n=40,000) (20).  The large number of Canadians 
with CKD is concerning given the large number of comorbidities, increased mortality, 
and high economic costs (dialysis costs over $1 billion per year in Canada) associated 
with the disease (22-25).  
 
Table 2. 1. Description of the stages of chronic kidney disease (17) 
Stage Estimated Glomerular Filtration Rate (eGFR) and Description 
Stage 1: Estimated glomerular filtration rate (eGFR) is normal (≥ 90 mL/min/1.73m2) or 
increased with evidence of kidney damage 
Stage 2: Mild decrease in kidney function (eGFR 60-80 mL/min/1.73m2) with evidence 
of kidney damage 
Stage 3a: Moderate decrease in kidney function (eGFR 45-59 mL/min/1.73m
2 ) 
Stage 3b: Moderate to severe declines in kidney function (eGFR 30-44mL/min /1.73m
2) 
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Stage 4: Severe decline in kidney function (eGFR 15-29 mL/min/1.73m
2) 
Stage 5: Kidney failure (eGFR <15 ml/min/1.73m
2) 
 
2.2.2 Kidney Transplantation 
While dialysis can be used to maintain life, kidney transplantation is considered 
the best treatment for kidney failure as it improves survival and decreases costs to the 
healthcare system (26, 27). The number of kidney transplants performed in Canada, as in 
most countries, has increased over the last decade (with 1,193 kidney transplants 
performed in 2003 and 1,358 in 2012) (20, 28). As of 2012, over 17,000 Canadians were 
living with a functioning kidney transplant (20). With over  90% of kidney transplant 
recipients surviving one-year post-transplant and over 80% of kidney transplant 
recipients surviving five-years post-transplant, the focus is now on maximizing long-term 
recipient health (27).  
 
2.3 Changes in Bone Mineral Metabolism in Kidney Disease 
It is well established that individuals with CKD are at an increased fracture risk 
(29-38). For example, Naylor et al., found women aged 40-65 years with an eGFR of 15-
29 mL/min/1.73 m
2 
had approximately a two-time higher fracture risk compared to  
similarly aged women with normal kidney function (rate ratio 2.4, 95% CI 1.5-4.0) (29). 
Conversely, in kidney transplant recipients the risk of fracture has not been well 
quantified but many studies suggest that the fracture risk is higher than the non-kidney 
disease population (39-41).  For example, Ramsey-Goldman et al. reported that the risk 
of fracture in female kidney transplant recipients aged 45-64 years was 34 times higher 
than their counterparts in the general population (41).  Similar to the non-kidney disease 
population, these fractures are concerning in individuals with kidney disease as they are 
associated with mortality and morbidity (32, 39, 42). Nitsch et al., reported that compared 
to individuals with an eGFR ≥ 60 mL/min/1.73 m2 (normal kidney function) individuals 
with an eGFR < 45 mL/min/1.73 m
2
 had almost a two-fold higher age- and sex-adjusted 
hazard ratio of death related to hip fracture (hazard ratio 1.98, 95% CI 1.12-3.50) (43). 
Abbott et al., found that the 1-year mortality for kidney transplant recipients after hip 
fracture was 14% compared to 7% in recipients who did not fracture (P <0.01) (39). 
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The reasons for the higher fracture risk amongst individuals with kidney disease 
are not fully understood but are likely multifactorial. Figure 2.1 provides a schematic on 
the pathways that lead to fracture. As kidney function declines individuals may develop a 
complex disorder of bone and mineral metabolism called chronic kidney disease-mineral 
and bone disorder (CKD-MBD). CKD-MBD is characterized by at least one of the 
following 1) abnormal metabolism of calcium, phosphorous, parathyroid hormone or 
vitamin D; 2) abnormal bone mineralization, bone volume, bone turnover, bone strength 
or bone growth; and 3) calcification of the soft tissue or calcification of vasculature (44).  
In summary, changes in bone mineral metabolism occur when kidney function declines 
and often continues after kidney transplantation. Specifically, these changes include 
declining levels of serum calcium and calcitriol (active form of vitamin D), and 
increasing levels of serum phosphate, and fibroblast growth factor 23 (44-46). Many 
individuals on dialysis develop secondary hyperparathyroidism which increases bone 
turnover, thereby weakening the bone (47). Post-transplant, after some of the kidney 
function has been restored, serum calcium levels and phosphate levels may normalize 
(48, 49); however, secondary hyperparathyroidism often persists (47, 50-52). Drugs 
administered to kidney transplant recipients may also play a role in fracture. Specifically, 
corticosteroids used to prevent transplant rejection have been found to promote bone loss 
(apoptosis of osteoblasts; decrease in gonadal function; decrease in intestinal calcium 
absorption) (53, 54). The role of cyclosporine (an immunosuppressant) in bone loss is 
controversial with in vivo studies finding cyclosporine increases bone resorption and in 
vitro studies finding it impedes bone resorption (55-61). In summary, individuals with 
kidney disease experience numerous bone mineral metabolism changes that are 
detrimental to the skeletal system raising a concern about fracture risk. 
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Figure 2. 1. Mechanisms for increased fracture risk in individuals with kidney disease 
 
2.4 Fracture Risk Prediction in Chronic Kidney Disease 
As previously discussed, it is well established that individuals with chronic kidney 
disease (CKD) have a higher risk of fracture compared to individuals with normal kidney 
function (29-38). Even individuals with a more moderate decline in kidney function 
experience a high fracture risk with risk increasing in a graded manner as kidney function 
declines (P for trend <0.0001; Figure 2.2) (29). For example, Naylor et al., found women 
aged > 65 years with  an estimated glomerular filtration rate (eGFR) 45-59 mL/min/1.73 
m
2
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compared to individuals with normal kidney function (defined as an eGFR ≥ 60 
mL/min/1.73 m
2
 ) (rate ratio 1.4, 95% CI 1.3-1.5) (29). However, the best technique to 
identify individuals with CKD who are at a high fracture risk is not known. This is 
concerning as to decrease the economic costs, morbidity, and mortality associated with 
fractures we must identify those at high risk and target treatments to these individuals. 
Moreover, early therapeutic intervention is particularly important in individuals with 
reduced kidney function as there is a concern about the safety and efficacy of 
bisphosphonates (fracture prevention therapy) in individuals with an eGFR < 
30ml/min/1.73 m
2
 (17, 62). 
 
Figure 2. 2. Three-year cumulative incidence of fracture in women (29)  
Source: Naylor KL, McArthur E, Leslie WD, Fraser LA, Jamal SA et al. The three-year incidence of fracture in chronic 
kidney disease. Kidney International 2014;86 :810-818. 
 
2.4.1 Fracture Risk Assessment Tool (FRAX) 
The fracture risk assessment tool (FRAX) is widely used in clinical practice to 
predict fracture and to help guide treatment decisions in individuals with normal kidney 
function (63).  FRAX was developed by the World Health Organization and can be 
described as a computer-based algorithm which can be easily used by physicians to 
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population using eleven validation cohorts and has been found to be accurate (average 
area under the receiver operating characteristic curve >0.6) (65). Specifically, FRAX 
predicts the 10-year probability of  major osteoporotic fracture (hip, humerus, forearm or 
clinical spine) or hip fracture alone through the use of the following variables: age, sex, 
and clinical risk factors (with or without bone mineral density [BMD]) (66).These 
clinical risk factors were identified through meta-analyses assessing risk factors for 
fracture and include: high alcohol intake (defined as ≥3 units per day), previous fracture, 
current smoking,  parental hip fracture, secondary osteoporosis, rheumatoid arthritis, low 
body mass index (defined as <19 kg/m
2
), and extended glucocorticoid use (defined as 
exposure for ≥3 months at a dose of 5mg/day) (63, 64, 67-69) (Table 2.2). However, 
given the complex pathophysiology of bone disease in CKD this patient population may 
have unique risk factors for fracture. For example, Nickolas et al., found low BMD, older 
age, and female sex, common risk factors in the non-kidney disease population, were not 
associated with an increased hip fracture risk in individuals with CKD (36).  
Figure 2. 3. Screen shot of the Canadian FRAX input page and the results (67) 
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Table 2. 2. FRAX variables (67, 69) 
Variables 
Age 
Sex 
Body mass index (kg/m
2
) 
Previous fracture 
Parental hip fracture 
Current smoking 
Prolonged use of glucocorticoids 
Rheumatoid arthritis 
Secondary osteoporosis (chronic liver disease, type I diabetes, hyperthyroidism, 
hypogonadism, premature menopause (<45 years), chronic malnutrition/malabsorption 
and osteogenesis imperfect) 
Alcohol use ≥3 units/day 
Femoral neck BMD (g/cm
2
 or T-score) is optional 
 
2.4.2 Fracture Risk Assessment Tool (FRAX) in Chronic Kidney Disease 
One previous study has assessed the ability of FRAX to predict fracture in 
individuals with CKD, finding that FRAX was able to discriminate between individuals 
with and without a clinical non-spine fracture (area under the receiver operating 
characteristic curve 0.72, 95% CI 0.65-0.78)  (70). However, this study had limitations. 
First, the study was cross-sectional preventing the calibration (comparison between the 
observed and FRAX predicted fracture risk) of the tool to be assessed. Second, CKD was 
defined as an eGFR <90 mL/min/1.73 m
2
. The KDIGO guidelines define CKD as an 
eGFR < 60 mL/min/1.73 m
2
 and an eGFR ≥ 60 mL/min/1.73 m2 requires other evidence 
of kidney disease (e.g. proteinuria) (17). Third, there was no comparison group of 
individuals with normal kidney function to determine how the tool’s performance in 
individuals with CKD compares (70). Fourth, the study did not assess several other 
potential predictors of fracture in addition to FRAX. For example,  T-score and previous 
falls may be accurate predictors of fracture in the CKD population; in the general 
population a lower T-score and a previous fall have been found to increase fracture risk 
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(71-73). Fifth, all the FRAX variables were not able to be included in the FRAX model; 
information on previous fracture was not available (70). Last, the study included both 
Canadian and American CKD patients (70); this is problematic as FRAX needs to be 
calibrated for each country given the variability in fracture rates across countries (74). 
Therefore, the best way to identify individuals with CKD who are at a high fracture risk 
is unknown. 
 
2.5 Kidney Transplantation and Fracture Risk 
2.5.1 Fracture Incidence 
As previously discussed, literature suggests that fracture risk remains high in 
kidney transplant recipients relative to the non-kidney disease population despite 
improvements in kidney function after transplantation (39-41). However, there remains 
poor consensus on the incidence of fracture in kidney transplant recipients with values 
varying widely in the literature.  
Ten studies published between 1996 and 2012 reported on the incidence of 
fracture in kidney transplant recipients (39, 41, 75-82). The incidence rate of fractures 
across studies varied from 3.3 to 99.6 fractures per 1000 person-years (Tables 2.3 and 
2.4).  Similarly, the cumulative incidence was highly variable.  There are several 
potential reasons for this variation. First, recipient characteristics varied across studies. 
For example, Kalker et al. only included diabetic recipients which likely resulted in a 
high cumulative incidence of fracture (diabetes has been found to increase fracture risk 
(83)) (79). Specifically, Kalker et al. found that the 5-year cumulative incidence of ankle 
fracture was 27% (79). In contrast, other studies that included both diabetic and non-
diabetic recipients found that the 5-year cumulative incidence of fracture ranged from 5% 
to 22% (76, 80). Second, studies included different fracture sites. Ball et al. only included 
hip fractures and found an incidence rate of 3.3 fractures per 1000 person-years (77). In 
contrast, Conley et al., included multiple fracture locations and found a fracture incidence 
rate of 99.6 fractures per 1000 person-years (78).  Last, previous studies had variable 
methodological quality, with study methods’ quality scores ranging from 8 to 13 (with 
higher quality studies receiving a higher score, range 0 to 17) (Table 2.4); methodological 
quality was assessed using a modified version of the Downs and Black checklist for 
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nonrandomized studies which assesses the completeness and clarity of reporting, bias, 
and external validity (84) (Appendix A). 
20 
 
 
Table 2. 3. Study characteristics of kidney transplant recipients 
Study, First Author, 
Country 
Number of patients Age, years 
(mean ± SD) 
 
 Women, 
percent 
Time zero Year 
transplanted  
 
Mean follow-up, 
years (mean ± SD)   
Diabetic,  
percent  
Prospective Cohort 
de Sévaux et al., 
(2003) 
Netherlands 
61 42.0 ± 13.0 37.7% Transplant date 1995-1996 2.0 
€
 3.3%  
Rizzari et al.,  
(2012) 
United States 
Living Donor: 791 
 
NR 38% 
 
Transplant date 
 
1999-2010 5.3* Type 1 Diabetes 27% , 
Type 2 Diabetes 11% 
Deceased Donor: 450 NR 41% Transplant date 1999-2010 3.0* Type 1 Diabetes 22%, 
Type 2 Diabetes 20% 
Retrospective Cohort 
Abbott et al.,  
(2001) 
United States 
Fracture: 379 
 
47.7 ± 14.0 48.5% Transplant date 1994- 1997  
 
1.7 ± 1.1 49.9%
†
 
No Fracture: 33 100 42.8 ± 14.6 
 
39.7% 
 
Transplant date 1994- 1997 1.7 ± 1.1 26.4%
† 
Ball et al., 
(2002) 
United States 
59 944 NR 39.2% Transplant date 1990-1999 NR 26.1%
‡ 
Conley et al., 
(2008) 
United States 
No Bisphosphonate: 
239  
46.9 ± 0.2 
 
46%  
 
1.2 ± 0.05 years 
after transplant 
1998-2006  
 
2.5 ± 0.05 Type 1 Diabetes 17%, 
Type 2 Diabetes 12%; 
Bisphosphonate: 315 45.9 ± 0.7 40% 1.2 ± 0.05 years 
after transplant 
1998-2006 2.5 ± 0.05 Type 1 Diabetes 32%, 
Type 2 Diabetes 9% 
Kalker et al., 
(1996) 
 United States 
214 39
ß
 38% 6 months after 
transplant 
1985-1992 3.8 100% 
Nikkel et al., 
(2009) 
United States 
No Fracture: 53 344 
 
43.3 38% Transplant date 1988-1998 5 
€
 22.9%
†
 
Fracture: 15 470 44.2 45.5% Transplant date 1988-1998 5
 €
 36%
†
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Table 2.3. Study characteristics of kidney transplant recipients (continued) 
Study, First 
Author, Country 
Number of patients Age, years 
(mean ± 
SD) 
 
 Women, 
percent 
Time zero Year 
transplanted  
 
Mean follow-up, 
years (mean ± 
SD)   
Diabetic,  
percent  
Retrospective Cohort 
Nikkel et al., 
(2012) 
United States 
Early  Corticosteroid 
Withdrawal : 11 164   
49.9 ± 13.4  
 
38% Transplant date 
 
2000 to 2006 4.1  26%
† 
Corticosteroid-base 
immunosuppression: 
66 266 
48.9 ± 13.4 40% Transplant date 2000 to 2006 2.5* 24.1%
†
 
Opelz et al., 
(2011) 
Multinational 
20 509 47.9 ± 13.0 38.4% 1 year after 
transplant 
1995 to 2008 5
€
 8.6%
‡
 
Ramsey-Goldman 
et al., 
(1999) 
United States 
432  
 
41.3 ± 12.3 40%  
 
30 days after 
transplant 
1992 to 1996 2.1 ± 1.5 40%
 ¥
 
 NR - not reported  
 ß reported as an average 
 € reported as total time since transplant 
 *reported as median 
 †type 1 and type 2 diabetes are combined  
 ‡reported as diabetic neuropathy  
 ¥ combined diabetes and hypertension 
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Table 2.4. Fracture incidence in kidney transplant recipients 
Study Incidence/Cumulative incidence Most common 
fracture location  
Time to fracture Quality 
score 
Incidence 
Abbott et al. Males: 6.90 fractures per 1000 person-years 
Females: 9.93 fractures per 1000 person-years 
Femur (34.8%) Linear increase in cumulative hazard of fracture after 
transplant. 
13 
Ball et al. 
 
 
3.3 fractures per 1000 person-years Hip† (100%) Shortly after transplant  hip fracture risk was higher in 
transplant recipients compared to dialysis patients on the 
transplant wait list (RR 1.34 , 95% CI 1.12-1.61); 630 days 
after transplant, patients who were on dialysis had a similar 
fracture risk as  recipients (RR 1.00, 95% CI 0.87-1.15) 
12 
Conley et al. 
 
 
No bisphosphonate 36.7 fracture per 1000 patient years; 
Bisphosphonate 99.6 fractures per 1000 patient years 
Fractures other 
than vertebral and 
femoral neck 
(91.7%) 
Fracture free survival was over 90% at 2 years and 
decreased to approximately 40% at 6 years 
12 
Nikkel et al. 
 
Early corticosteroid withdrawal :5.8 fractures per 1000 
patient years; Corticosteroid-based 
immunosuppression:8.0 fractures per 1000 patient years 
Femur (29%) Fracture incidence was significantly less than those  with 
early corticosteroid withdrawal compared to corticosteroid-
based immunosuppression 24 months after fracture 
13 
Ramsey-Goldman 
et al. 
 
39 fractures per 1000 person-years Foot (42.4%) Mean time to first fracture after transplant was 1.64±1.18 
years 
8 
de Sévaux et al.  34 fractures per 1000 person-years  Hip (50%) NR 10 
Cumulative Incidence 
Kalker et al. 
 
~10% at 2 years 
~27% at 5 years 
Foot¶ (100%) Incidence increased from 0- 2 years post-transplant, 
plateaued from 2-3 years and increased up until 5 years 
8 
Nikkel et al. 
 
22.5% in 5 years Foot/ankle(28.2%
) 
Mean time to first fracture 2.5 years 12 
Opelz et al. 0.85% over 5 years Hip
† (100%) Cumulative rate of fracture increases over 5 years 12 
Rizzari et al. 
 
Living Donor:  Recipients w/ Diabetes: 4% 1 year; 16% 
5 years; 33% 10 years 
w/o Diabetes:1% 1 year; 5%  years; 10% 10 years 
Deceased Donor: Recipients w/ Diabetes: 6%1 year; 
15% 5 years; 23% 10 years 
w/o Diabetes:3% 1 year; 7%  5 years; 9% 10 years 
NR NR 11 
NR-not reported; RR, relative risk; CI, confidence interval. 
† hip only location assessed;¶ foot only region assessed 
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The aforementioned studies have several limitations worth noting. First, none of 
the studies included Canadian kidney transplant recipients and therefore may not 
accurately reflect Canadian recipients’ fracture rate. In the general population fracture 
rates have been found to vary as much as 15-fold across countries (74).  For example, 
Leslie et al. found that proximal femoral fracture rates were significantly lower in 
Canadian women compared to women from the U.S. with Canadian women having a 
30% lower fracture rate (85).  Additionally, differences in transplant outcomes and 
transplant characteristics exist across countries (86). For example, there are differences in 
mortality in recipients from the United States and Canada (e.g. 29.8 deaths per 1000 
person-years, Canada: 40.9 deaths per 1000 person-years, United States) and differences 
in recipient characteristics (e.g. Canadians have more male kidney transplant recipients 
[63.8% versus 60.0%]) (86). Previous work supports that Canadian kidney transplant 
recipients may have a different fracture rate compared to recipients from other countries. 
For example, in a study which included kidney transplant recipients (n=458) from 
Manitoba, Canada, Naylor et al. found the 10-year observed major osteoporotic fracture 
risk was only 6.3% (defined as a composite of hip, forearm, proximal humeurs, and 
clinical vertebral fractures) (87); clinical guidelines define high fracture risk as a 10-year 
major osteoporotic risk ≥ 20% and low fracture risk < 10% (2, 88, 89). However, the low 
observed fracture risk in the Naylor et al. study may not accurately reflect the fracture 
rate of Canadian recipients as recipients were approximately 5 years younger (mean age 
45 years) than the average age of a Canadian recipient (87).  Moreover, cohort entry was 
an average of 1-year post-transplant (87); recipients may have a rapid loss in bone 
mineral density and a higher fracture risk in the first year post-transplant, consequently 
fracture events may have been missed (77, 90-93). Second, previous studies did not have 
long-term follow-up. The largest studies to assess fracture risk in kidney transplant 
recipients have all used the United States Renal Data System (USRDS) (19, 41-43); a 
major limitation of this data source is that after 3 years all data is censored for recipients 
less than 65 years of age, preventing long-term follow-up. Specifically, the average 
follow-up of previous studies was less than 6 years, limiting discussion on long term 
fracture risk.  With over 80% of recipients surviving 5 years post-transplant long-term 
follow-up is crucial (27). Third, close to half of studies included only one fracture 
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location (e.g. foot fractures) preventing a precise estimate of fracture incidence (63).  
Fourth, studies may not be representative of the current recipient population. Only four 
out of ten studies included recipients of kidney transplants after the year 2000 (63); the 
characteristics of recipients (e.g. comorbidities) and clinical practice patterns have 
changed in the last 10 years, potentially impacting fracture rates (20, 94). Specifically, 
the age of Canadian recipients has increased with approximately 27% over the age of 60 
years in 2003 and 35% in 2012 (increasing age is a risk factor for fracture (68, 73, 95)) 
(20); there has also been a trend towards decreasing corticosteroid dose (81, 96). This 
hypothesis is supported by a study which found hip fracture rates in kidney transplant 
recipients from the United States have decreased from 1997 to 2010  (P<0.001); they 
hypothesized that potential reasons for this decrease were decreased corticosteroid dose, 
decrease in acute rejection episodes, increase in tacrolimus (may decrease bone loss 
compared to cyclosporine) (97), and lifestyle changes (e.g. physical activity) (93). Last, 
only one study reported on loss to follow-up and reasons for losses (63). This is a serious 
concern that threatens the validity of most prior studies, particularly if there were 
differential losses to follow-up (80).  Therefore, the true incidence of fracture in kidney 
transplant recipients is unknown. 
2.5.2 Fracture Risk in Kidney Transplant Recipients Compared to Several 
Referent Groups 
Previous studies have compared fracture rates in kidney transplant recipients to 
the non-kidney disease population and to the dialysis population (39, 77, 87, 98). 
However, no previous studies have compared fracture rates in kidney transplant 
recipients to other referent groups. The use of referent groups is crucial to help quantify 
fracture risk among kidney transplant recipients. One group that is defined by 
Osteoporosis Canada as low fracture risk and four groups that are defined as having an 
increased fracture risk are described in detail below (99).  
2.5.2a Healthy Segment of the General Population with No Kidney 
Disease and No Previous Non-vertebral Fracture (Low fracture risk) 
Three previous studies have compared fracture risk in kidney transplant recipients 
to the general population (39-41). However, no previous studies have compared fracture 
rates in kidney transplant recipients to individuals without kidney disease excluding 
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individuals who have had a prior non-vertebral fracture and/or an osteoporosis diagnosis. 
The benefit of the aforementioned exclusion criteria is it helps ensure this is truly a low 
risk referent group. Studies that have compared kidney transplant recipients to individuals 
from the general population have suggested that kidney transplant recipients are at an 
increased risk of fracture, with Abbott et al. describing an incidence ratio of 4.59 (95% 
CI 3.29-6.31)
 
(39). Similarly, Ramsey-Goldman et al. found that male kidney transplant 
recipients ages 25-44 and 45-64 years had a five-time higher fracture risk compared to 
the general male population of a similar age (41). Particularly concerning is the 
potentially high hip fracture rate in kidney transplant recipients compared to the general 
population (39, 81). Ball et al. found an incidence rate of 3.3 hip fractures per 1000 
person-years (approximately 80% of the sample was ≤  54 years) (77). In contrast, hip 
fracture rates in the general Canadian population (age <54 years) are less than 0.1 
fractures per 1000 person-years (14).   
2.5.2b Healthy Segment of the General Population with No Kidney 
Disease and a History of Non-vertebral Fracture (Increased fracture risk) 
No previous studies have compared fracture rates in kidney transplant recipients 
to individuals without kidney disease who have previously sustained a non-vertebral 
fracture. In the non-transplant population, one of the strongest risk factors for a future 
fracture is sustaining a previous osteoporotic fracture (100). A meta-analysis conducted 
in the non-transplant population found that individuals who had sustained a previous 
fracture had an 86% relative increase in fracture compared to individuals who had not 
sustained a previous fracture (relative risk [RR] 1.86, 95% CI 1.75-1.98) (100).  
2.5.2c Non-dialysis Chronic Kidney Disease (CKD) (Increased fracture 
risk) 
No previous studies have compared fracture rates in kidney transplant recipients 
to individuals with CKD (excluding patients on dialysis).  As described in section 2.4, 
previous literature has found that individuals with CKD are at an increased risk of 
fracture compared to individuals with normal kidney function (35-37). For example,  
Dooley et al. found that there was a 439% relative increase in hip fracture risk in 
individuals with stage 4 CKD compared to individuals with normal kidney function (RR 
5.39, 95% CI 2.86  to 10.15) (37).   
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2.5.2d Rheumatoid Arthritis (Increased fracture risk) 
No previous studies have compared fracture rates in kidney transplant recipients 
to individuals with rheumatoid arthritis.  Rheumatoid arthritis is a well-established risk 
factor for fracture due to the use of steroids and the disease itself (101, 102). Van Staa et 
al. found that individuals with rheumatoid arthritis have a 100% relative increase in hip 
fracture (RR 2.0, 95% CI 1.8-2.3) compared to age- and sex-matched individuals without 
rheumatoid arthritis (102).  
2.5.2e Dialysis (Increased fracture risk) 
It is well established that dialysis patients have a high fracture risk with 1 in 10 
(9.6%) women aged ≥ 65 years sustaining a fracture (defined as proximal humerus, 
forearm, hip, or pelvis) in the first 3 years of end-stage renal disease (29). Two previous 
studies have compared fracture risk in kidney transplant recipients to the dialysis 
population (77, 87). Ball et al. found that shortly after transplant hip fracture risk was 
higher in recipients compared to the dialysis population on the transplant waitlist (RR 
1.34, 95% CI 1.12-1.61). However, this study only assessed hip fracture and included 
recipients who received a transplant over 10 years ago; as previously discussed changes 
in recipient characteristics and practice patterns may have affected fracture rates (7, 77).  
In contrast, Stehman-Breen et al. found that kidney transplant recipients and the 
hemodialysis population had a comparable hip fracture risk with kidney transplant 
recipients having a slightly higher risk, but this did not reach statistical significance (RR 
1.1, 95% CI 0.4-2.9) (87). However, this study included all end-stage renal disease 
patients instead of restricting to individuals on the transplant waitlist; to make health 
status comparable previous literature recommends comparing recipients to individuals on 
the transplant waitlist (77, 103).  
 
2.6 Risk Factors for Fracture in Kidney Transplant Recipients  
Six previous studies reported on risk factors for fracture in kidney transplant 
recipients and their associated effect measures (39, 77, 78, 80-82) (Table 2.5). Risk 
factors for fracture in kidney transplant recipients were variable across studies. The most 
common factors found to be associated with an increased risk of fracture included: older 
age, female sex, diabetes, and dialysis prior to transplant. Other risk factors associated 
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with fracture in recipients included previous history of fracture, the induction regimen 
used to immunosuppress the recipient, type of donor (living versus deceased), and year of 
transplant. Potential reasons for the variation in risk factors across studies include 
inclusion of different recipient populations, inclusion of different fracture locations, and 
the use of different statistical models (i.e., backward elimination versus forward 
selection) with different p-values to determine which variables should be included in the 
multivariable model (104).  
Unlike the transplant population, risk factors for fracture in the general population 
are well-established and include: older age, female sex, low body mass index (BMI), 
history of fracture, family history of a parent fracturing a hip, glucocorticoid use, 
rheumatoid arthritis, smoking, low bone mineral density (BMD [g/cm
2
]), secondary 
osteoporosis (e.g. type 1 diabetes), previous fall and drinking  ≥ 3 units of alcohol a day 
(2). Kidney transplant recipients may have different risk factors for fracture given the 
unique pathophysiology that underlies their bone disease (105). For example, many of the 
common risk factors for fracture in the general population (e.g. age, sex, BMI) are not 
consistently associated with fracture in kidney transplant recipients (Table 2.5).  In a 
study conducted by Naylor et al. it was found that the only common risk factor for major 
osteoporotic fracture in the general population that reached statistical significance in 
kidney transplant recipients was high alcohol use (87). However, this study had a small 
sample size (n=326) and therefore may have had inadequate statistical power (87). 
Moreover, a recent study found that a parathyroid hormone level >130 ng/L was a unique 
and independent risk factor for fracture (adjusted hazard ratio 7.5, 95% CI 2.2 -25.5) in 
kidney transplant recipients while age, sex, and BMI did not reach statistical significance; 
however, this may have been due to limited power (106). 
The aforementioned studies had a few limitations.  Previous studies failed to 
assess potentially relevant risk factors of fracture. In the kidney transplant population  no 
previous studies have assessed fall in the year prior to transplant as  a risk factor for 
fracture.  Falls have been found to be associated with an increased fracture risk in the 
general population (72, 107). Previous studies have also failed to assess risk factors 
specific to different fracture locations; in the general population different fractures sites 
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have been found to have unique risk factors (108, 109). For example, increasing age may 
not be associated with an increased risk of ankle fracture (110).  
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Table 2. 5. Fracture risk factors in kidney transplant recipients 
Risk factor Number of studies that 
assessed risk factor  
Number of studies 
with significance  
Author, Effect measures* 
(95% Confidence Interval) 
Older age 
45-65 
50-65 
>65 years 
 
 
Continuous (per year) 
4 
1 
1 
2 
 
 
2 
3 
1 
1 
2 
 
 
1 
 
Nikkel (2012), HR 1.14 (1.10-1.18) Reference (<45 years) 
Nikkel (2009), HR 1.76 (1.59-1.94)  Reference 18-50 
Nikkel (2009), HR 3.27 (2.91-3.67)  Reference 18-50 
Nikkel (2012), HR 1.69 (1.58-1.81)  Reference (<45 years) 
 
Abbott, OR 1.02 (1.03-1.04) 
Female sex 
 
4 3 
 
 
Nikkel (2012), HR 1.36 (1.32-1.40) Reference male 
Nikkel (2009), HR 1.42 (1.31-1.55) Reference male 
Abbott, OR 1.29 (1.02-1.64) Reference male 
Combined age gender interaction 
Female aged 40 to 59 
Female recipients ≥ 60 years of age 
Male recipients ≥ 60 years of age 
1 
1 
1 
1 
 
1 
1 
1 
1 
Opelz  
HR 2.26 (1.09-4.68)  
HR 5.14 (2.43-10.9)  
HR 2.39 (1.10-5.20)  
Diabetes   
Diabetes (Type 1 and Type2) 
 
 
 
Type 1 diabetes 
5 4 
3 
 
 
 
1 
 
Abbott, OR 1.97 (1.46-2.66) Reference no diabetes 
Nikkel (2009), HR 1.39 (1.18-1.64) Reference hypertension 
Nikkel (2012), HR 1.41 (1.25-1.59) Reference no diabetes 
 
Conley, HR 2.02 (1.18-3.48)  Reference no diabetes 
Pre-transplant dialysis  
Per year of dialysis prior to transplantation 
 
 
Dialysis treatment 3 to 12 months before 
transplantation 
 
Administration of pre-transplant dialysis 
6 4 
2 
 
 
1 
 
 
1 
 
Abbott, OR 1.74 (1.02-2.96)  
Nikkel (2009), HR 1.04 (1.03–1.06)  
 
Ball, RR 1.67  (1.22- 2.29 ) Reference recipients on dialysis for less than 
3 months 
 
Nikkel (2012), HR 1.08 (1.04-1.13) Reference no pre-transplant dialysis 
Prior Fracture 
Hospitalization for fracture prior to 
transplant 
Fracture  between ESRD and transplant 
2 2 
1 
 
1 
 
Abbott, OR 2.82 (1.06-5.14) Reference no prior fracture 
 
Nikkel (2009), HR 2.82 (2.33-3.43) Reference no prior fracture 
Donor type 
Deceased 
 
4 2 
2 
 
Nikkel (2012), HR 1.30 (1.19-1.42) Reference living donor 
Nikkel (2009), HR 1.36 (1.24-1.49) Reference living donor 
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Table 2.5. Fracture risk factors in kidney transplant recipients (continued) 
Risk factor Number of studies 
that assessed risk 
factor  
Number of studies 
with significance  
Author, Effect measures* 
(95% Confidence Interval) 
Race 
White 
 
Asian 
 
Black 
 
 
Other 
5 
1 
 
1 
 
2 
 
 
2 
3 
1 
 
1 
 
2 
 
 
1 
 
Abbott, OR 1.66 (1.24-2.24)  Reference black 
 
Nikkel (2012), HR 0.34 (0.26-0.47) Reference white 
 
Nikkel (2009), HR 0.81  (0.78-0.85) Reference white 
Nikkel (2012), HR 0.63 (0.56- 0.7) Reference white 
 
Nikkel (2009), HR 0.54 other (0.48-0 .61) Reference white 
Donor Age 
Donor age ≥ 60 years of age 
1 1 
1 
 
Opelz, HR 1.75 (1.15 -2.66) reference donors < 60 years of age 
Body Mass Index (Kg/m2) 
<18  
25-30  
>30 
5 1 
1 
1 
1 
Nikkel (2012) 
OR 1.39 (1.08-1.78) Reference BMI 18-25 
OR 0.87 (0.78-0.96)  Reference BMI 18-25 
OR 0.83 (0.75-0.93)  Reference BMI 18-25 
Weight 
< 48.6 kg  
 48.6–72.3 kg  
72.4–95.9 kg  
1 1 
1 
1 
1 
Abbott  
OR 2.01 (1.38-2.94) Reference Weight >95.9 kg  
OR 1.86 (1.32-2.63)  Reference Weight >95.9 kg 
OR 1.77 (1.26-2.49)  Reference Weight >95.9 kg 
Glomerulonephritis (as cause of kidney failure) 4 2 
 
Abbott,  OR 0.51 (0.32-0.82) Reference no glomerulonephritis 
Nikkel (2009), HR 0.53 (0.51-0.56) Reference diabetes  
Hypertension (as cause of kidney failure) 3 1 Nikkel (2009), HR 0.56 (0.53-0.59) Reference diabetes  
Femoral neck T-score at baseline† (lower T-score 
indicative of greater risk) (continuous: SD) 
1 1 Conley,  HR 0.69 (0.57 -0.86)  
Interleukin-2 receptor blockade 
 
1 1 Conley,  HR 0.40 (0.25-0.66) Reference no Interleukin-2 
receptor blockade 
y-GT, gamma-glutamyltransferase (continuous: 
units/litre) 
1 1 Conley,  HR 1.005 (1.0034-1.0076)  
urine protein to creatinine ratio (continuous: 
gram/gram) 
1 1 Conley,  HR 1.23 (1.05-1.45)  
Human leukocyte antigen mismatches 
1 HLA-DR mismatch 
 
2 HLA-DR mismatch 
3 1 
1 
 
1 
 
Opelz, HR 1.85 (1.18 -2.89) Reference zero HLA-DR mismatch 
 
Opelz,  HR 2.24 (1.25-4.02) Reference  zero HLA-DR mismatch 
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Table 2.5. Fracture risk factors in kidney transplant recipients (continued) 
Risk factor Number of studies that 
assessed  risk factor  
Number of studies 
with significance  
Author, Effect measures* 
(95% Confidence Interval) 
Induction regimen 
Early steroid withdrawal  
 
Dual induction¥ vs no induction 
5 
 
 
 
 
2 
1 
 
1 
 
 
Nikkel (2012),  HR 0.69 (0.59-0.81) Reference steroid-
based regimen 
Nikkel (2012), HR 1.14 (1.08-1.20)  Reference no 
induction 
Transplant date 
Quartiles of transplant date (continuous: per 
increase in quartile)‡  
3 
 
1 
1 
 
 
Abbott, OR 0.82 (0.72-0.92)  
Note: Nikkel (09), Nikkel (12), Abbott and Ball all provided adjusted effect measures.  We excluded four studies from the risk factor analysis that did not use 
multivariable methods to ascertain risk factors. Therefore, five studies is the highest number of studies assessed for this risk factor. One additional study was included for 
pre-transplant dialysis resulting in six studies as the maximum number of studies assessed for this risk factor 
*A value greater than 1 indicates that the group of patients with the factor had a higher risk of fracture compared to the reference group and a value lower than 1 
indicates that the group of patients with the factor had a lower risk of fracture compared to the reference group.  
Abbreviations: ESRD, end stage renal disease; HLA-DR mismatch, human leukocyte antigen-DR mismatch 
†t-score measured as the number of standard deviations below the average peak bone density of a young adult  
¥ Dual induction is defined as a combination of methylprednisolone and an antibody-based induction agent 
‡ Quartiles of transplant date defined as July 1, 1994-Apriil 12, 1995, April 13, 1995- January 9, 1996, January 10, 1996 –October 3, 1996, October 4, 1996 –June 30, 
1997 
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2.7 Bone Mineral Density Testing in Kidney Transplant Recipients 
Kidney transplant recipients may be a high risk group for fracture and as a result 
assessing bone health may be beneficial. One way to assess bone health is to perform a 
bone mineral density (BMD) test; the results of the test are used to guide treatment 
decisions for fracture prevention and to monitor the effectiveness of treatment (2, 111, 
112). In the general population a lower BMD associates with a higher fracture risk and 
higher mortality risk (113-116).  Osteoporosis Canada guidelines recommend that in the 
general population all individuals ≥ 65 years of age have a BMD test (2). Conversely, in 
the kidney transplant population the KDIGO guidelines for  CKD-MBD recommend 
testing in the first three months after transplantation when  kidney function is adequate 
(defined as an eGFR > 30 mL/min/1.73 m
2
) and there is evidence of osteoporosis risk 
factors or corticosteroid administration (44). However, this guideline received a weak 
recommendation given the lack of evidence that BMD can accurately predict fracture in 
kidney transplant recipients (44). Moreover, it is suggested by the KDIGO guidelines that 
given the high prevalence of adynamic bone disease (i.e., low turnover bone disease) it is 
reasonable to use a bone biopsy to guide treatment decisions instead of  the result of the 
BMD test; however, this recommendation was not graded (44).  
Despite the lack of evidence in the literature demonstrating the benefit of BMD 
testing in kidney transplant recipients, previous single centre studies describe a large 
number of BMD tests  in this population (117, 118). For example, Naylor et al. reported 
more than 1000 BMD tests over an 8 year period in kidney transplant recipients (n=326)  
from Manitoba, Canada (117).  Similarly, Akaberi et al., reported more than 600 BMD 
tests over a 12 year period in kidney transplant recipients (n=238) from Sweden (118). 
However, both of these studies were performed at a single centre which mandated routine 
BMD testing. No studies have assessed the frequency of BMD testing in Ontario, where 
many transplant centers have no fixed protocol for BMD testing post-transplant (personal 
communication with the centres).  Given the negative impact of unwarranted screening 
and the financial costs to the healthcare system this deserves further investigation (119, 
120). 
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2.8 Conclusion 
Despite the health and economic impact of fractures, there is currently a gap in 
knowledge about the epidemiology of fracture in adults with kidney disease. As 
highlighted in this literature review, many questions remain unanswered and several 
limitations of previous studies need to be addressed. As the kidney disease population 
continues to increase and survival continues to improve the economic burden this 
population may place on the healthcare system due to fracture events may increase. In the 
non-kidney disease population fracture prevention therapies (e.g. bisphosphonates) have 
proven successful (121-123); however, in the kidney disease population the efficacy and 
safety of such therapies has not been determined (44, 124). Furthermore, many of the 
KDIGO guideline’s for the evaluation and treatment of bone disease in kidney disease 
patients received a weak grade of evidence or are ungraded (44).  Therefore, it is crucial 
that a paradigm shift in bone disease research occurs towards understudied populations 
who have not experienced success in fracture prevention.  This research will provide a 
better understanding of the epidemiology of fracture in kidney disease patients which is 
required before much needed well designed clinical trials and prospective cohort studies 
can be conducted. Moreover, an improved understanding of fracture will provide the 
information needed for an in-depth discussion of fracture in kidney disease patients in 
future kidney disease guidelines and osteoporosis guidelines. 
 
2.9 Conceptual Model 
Figure 2.4 demonstrates the hypothesized relationship between kidney disease and 
fracture. 
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Figure 2. 4. Conceptual model of the hypothesized relationship between kidney disease 
and fracture.  
*It is important to note that the word that is bolded and underlined is only specific to 
kidney transplant recipients. 
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CHAPTER 3: Comparison of fracture risk prediction among individuals with 
reduced and normal kidney function
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3.1 Introduction 
The World Health Organization’s Fracture Risk Assessment Tool (FRAX) is used 
commonly in the general population to predict the 10-year probability of a major 
osteoporotic fracture (defined as hip, forearm, clinical vertebral, and humerus fractures)  
using an algorithm that includes age, sex, and several clinical risk factors for fracture 
(bone mineral density optional) (1, 2). The clinical risk factors for fracture incorporated 
in the FRAX algorithm include: parental hip fracture, previous fragility fracture, 
rheumatoid arthritis, current smoking, secondary osteoporosis (which does not include 
chronic kidney disease), low body mass index (<19 kg/m
2
), prolonged glucocorticoid use, 
and excessive alcohol intake (3-7).  
Men and women with chronic kidney disease (CKD) have a high fracture risk (8-
11).  For example, women with moderate declines in kidney function (estimated 
glomerular filtrate rate 45-59 mL/min/1.73 m
2
) are at almost a 4-fold increased risk of 
fracture compared to women with normal kidney function (11). The clinical utility of 
FRAX in predicting fracture risk in patients with reduced kidney function is uncertain. 
CKD is associated with disturbances in mineral metabolism including changes in 
calcium, phosphate, and parathyroid hormone which likely alter bone volume, turnover, 
and mineralization increasing fracture risk (12). Therefore, factors in the FRAX 
algorithm that are associated with fracture risk in the general population may not 
accurately predict fracture in individuals with reduced kidney function.  One prior study 
has reported on the prognostic value of FRAX in individuals with reduced kidney 
function, however, this study was cross-sectional and did not include a comparison group 
of individuals with normal kidney function (13).  The current study addresses these 
limitations.  We utilized data from a multicentre cohort study (Canadian Multicentre 
Osteoporosis Study – CaMos) to characterize the predictive ability of FRAX in patients 
with reduced kidney function, and to determine if the predictive ability differs from 
individuals with normal kidney function. As a secondary analysis we examined the 
ability of FRAX to predict fracture when adding CKD as a secondary cause of 
osteoporosis in individuals with reduced kidney function. We also assessed the ability of 
age, T-score, and T-score with a history of fall to predict fractures in both groups.  
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3.2 Methods 
3.2.1 Canadian Multicentre Osteoporosis Study (CaMos) 
CaMos is a prospective observational study that began in January 1996 (14). 
Detailed methods concerning CaMos have been published elsewhere (14, 15) (Appendix 
C). Briefly, non-institutionalized individuals were eligible to participate in CaMos if they 
were ≥ 25 years of age at the start of the study, lived within a 50 kilometer radius of 1 of 
9 major Canadian cities (St. John’s, Halifax, Quebec City, Toronto, Hamilton, Kingston, 
Calgary, Vancouver, and Saskatoon) and could speak English, French or Chinese (14). 
Residential phone numbers were used to randomly select households and within 
households one member who met eligibility criteria was randomly selected; at baseline 
interview 42% of participants contacted agreed to participate (14). In January 1996 
participants completed a standardized interviewer-administered questionnaire; the 
questionnaire was subsequently administered every 5 years. The questionnaire assessed 
demographics, medication use, nutrition, general health, medical history, fracture risk 
factors, and fracture events (14). Bone mineral density, weight and height were also 
assessed at baseline and every five years (14). In year 10 blood samples were obtained 
and serum stored from participants in 8 out of the 9 study centres. Serum creatinine was 
analyzed by CDL Labs, Montreal. In agreement with the Helsinki Declaration, written 
informed consent was provided by study participants.  Ethics approval was obtained from 
McGill University and from each study centre’s applicable ethic review board. 
3.2.2 Cohort 
The beginning date of our present study (cohort entry) was the CaMos study year 
10 – the first time 8 out of the 9 centres assessed blood work. For this analysis, we 
included individuals who met the following criteria at cohort entry: 1) men and women 
who were ≥40 years of age, 2) those who had a creatinine value, 3) femoral neck bone 
mineral density (BMD) measurement, and 4) no prior organ transplant. Creatinine values 
were missing in those who did not sign the consent form for blood and in those who were 
from Hamilton (centre that did not collect blood work). We calculated the estimated 
glomerular filtration rate (eGFR) using the CKD epidemiology collaboration equation 
(16).  We defined kidney function at cohort entry using thresholds defined in the 2012 
Kidney Disease Improving Global Outcomes (KDIGO) guidelines (17); an eGFR <60 
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mL/min/1.73 m
2
 was defined as reduced kidney function and an eGFR ≥60 mL/min/1.73 
m
2 
 was defined as normal kidney function. We used this classification for our primary 
analysis.  To characterize the degree of renal impairment we further stratified kidney 
function in individuals with an eGFR <60 mL/min/1.73 m
2
 according to the 2012 
KDIGO guidelines: 45–59 (stage 3a), 30–44 (stage 3b), 15–29 (stage 4), and <15 
mL/min/1.73 m
2
 (stage 5) (17). 
3.2.3 Bone Mineral Density  
Bone mineral density (BMD) was measured at the femoral neck using the Hologic 
QDR dual energy x-ray absorptiometry scanner (Marlborough, MA, USA) at four centres 
and the Lunar scanner (Piscataway, NJ, USA) at 5 centres. Each centre used a spine 
phantom to monitor longitudinal stability. Standard methods were used to convert lunar 
data to corresponding Hologic values (18-21). The Bio-Imaging Bona Fide Phantom 
(Bio-Imaging Technologies, Newtown, PA, USA) was used to calibrate densitometers at 
all centres and the coordinating centre re-analyzed measurements from each centre. 
Details on the BMD quality assurance-quality control program and cross-calibration have 
been published elsewhere (22). As recommended by the World Health Organization we 
calculated femoral neck T-scores for both genders by comparing each individual’s BMD 
to the Third National Health and Nutrition Examination Survey reference range for white 
females aged 20-29 years (23). 
3.2.4 Fracture Ascertainment 
Data on incident clinical fractures were collected over 5 years after cohort entry 
by self-report from a yearly postal questionnaire or in-person assessment (year 15 of the 
CaMos study) (15). Fractures were confirmed by: structured interview to determine 
further information (date, fracture location, medical treatment, and cause of fracture [i.e., 
fall]) and/or verification from the treating physician or hospital (15). We defined fracture 
as a composite of incident clinical spine, hip, forearm/wrist, and humerus fractures 
(major osteoporotic fractures) that resulted from low trauma.  
3.2.5 Fracture Risk Assessment using FRAX 
We used the Canadian FRAX tool (FRAX® Desktop Multi-Patient Entry, version 
3.7) to calculate the 10-year probability of a major osteoporotic fracture (with and 
without BMD).(3) The US and Canadian versions of FRAX are derived using identical 
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methodology and give similar results with regards to fracture prediction (24, 25).  A 
complete list of the variables we used to calculate the FRAX score is provided in Table 
3.1. Body mass index (BMI) was calculated at cohort entry by dividing weight (kg) by 
height squared (m
2
). When BMI (kg/m
2
) was missing at year 10 we carried forward 
values from year 5 of the CaMos study (<0.5% missing). We defined rheumatoid arthritis 
as a self-report of a diagnosis of rheumatoid arthritis combined with evidence of 
treatment (prednisone, betamethasone, methotrexate, hydroxychloroquine, leflunomide, 
etanercept, infliximab, sulfasalazine, adalimumab). Prior corticosteroid use was defined 
as use of intravenous or oral glucocorticoids for ≥ 3 months from baseline to cohort entry. 
Previous fracture was defined as any low trauma fracture (excluding hands, feet, head, 
and ankle) occurring prior to cohort entry. History of parental hip fracture was defined 
using self-report at year 5 of CaMos. All other clinical risk factors were based on self-
report at cohort entry or before.   
 
Table 3. 1. Variables used in FRAX Tool 
Variable 
Age 
Sex 
Weight (kg) 
Height (cm) 
Parental hip fracture  
Previous fracture 
Prolonged use of glucocorticoids  
Current smoking 
Alcohol use ≥ 3 units/day  
Secondary osteoporosis (Defined as: chronic liver disease, type I diabetes, hyperthyroidism, 
hypogonadism, premature menopause (<45 years), chronic malnutrition/malabsorption and osteogenesis 
imperfect) 
Rheumatoid arthritis 
Femoral neck BMD (T-score) is optional 
Sources: 1. FRAX World Health Organization Fracture Risk Assessment Tool [Internet].  World Health Organization; 
2011. Available from http://www.shef.ac.uk/FRAX/index.aspx. 2. Kanis JA, McCloskey EV, Johansson H, Strom O, 
Borgstrom F, Oden A. How to decide who to treat. Best Pract Res Clin Rheumatol 2009; 23: 711. 
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3.2.6 Statistical Analysis 
We described continuous variables as means (±SD) or median (interquartile 
range) and categorical variables as proportions. To compare baseline characteristics 
between adults with an eGFR <60 versus ≥60 mL/min/ 1.73 m2 we used the Student t test 
or Mann-Whitney U for continuous variables and chi-square test or the Fisher’s Exact 
tests where appropriate for categorical variables.  We used area under the receiver 
operator characteristic curve to determine how well FRAX could discriminate between 
individuals with a fracture and without a fracture (null value was defined as an area under 
the curve value of 0.5 which indicates that the ability of FRAX to discriminate fracture is 
no better than chance) (26). To assess differences in fracture discrimination between 
individuals with an eGFR <60 and ≥60 mL/min/1.73 m2 we calculated mean differences 
(95% confidence interval) using the two-tailed z test. In an additional analysis we 
assessed the predictive discrimination of FRAX (without BMD) including CKD as a 
cause of secondary osteoporosis in all individuals with an eGFR <60 mL/min/1.73 m
2
. 
The rationale for this was that we wanted to capture some of the unique risk factors for 
fracture in CKD patients that are currently not included in the FRAX algorithm (12). It is 
important to note that only FRAX without BMD can be assessed when including CKD as 
a secondary cause of osteoporosis because FRAX assumes that secondary causes of 
osteoporosis effect fracture risk through lowering BMD. We had a maximum of 5 years 
of follow up. As a result, to calculate the estimated fracture risk in the cohort using 
FRAX we divided the FRAX 10-year risk by two. The 5-year observed fracture 
probabilities and 95% confidence intervals were calculated using a survival analysis 
method that adjusts for the competing risk of death (27). To assess calibration (defined as 
the agreement between observed and predicted values) we compared the 5-year FRAX 
estimated fracture risk with the 5-year observed fracture risk. We performed all statistical 
analysis using the Statistical Analysis System (SAS version 9.3, SAS Institute, Cary, NC, 
USA). We considered two-sided p-values <0.05 as statistically significant.  
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3.3 Results 
3.3.1 Baseline Characteristics 
We included 320 adults with an eGFR <60 mL/min/1.73 m
2
 and 1787 adults with 
an eGFR ≥60 mL/min/1.73 m2 (Figure 3.1).  During follow-up, 3.3% (n=69) died (5.9% 
[n=19] with an eGFR <60 and 2.8% [n=50] with an eGFR ≥60 mL/min/ 1.73 m2) and 
3.8% (n=81) were lost to follow-up (8.4% [n=27] with an eGFR <60 and 3.0% [n=54] 
with an eGFR ≥60 mL/min/ 1.73 m2). Of the adults with an eGFR <60 mL/min/1.73 m2 
72.2% (n=231) had stage 3a CKD, 23.8% stage 3b (n=76), and 4.0% (n=13) had stage 4 
or stage 5. Compared to individuals with an eGFR ≥60 individuals with an eGFR <60 
mL/min/1.73 m
2 
were older (75.9 vs. 65.6 years; P<0.001) (Table 3.2).  When comparing 
individuals with an eGFR <60 to individuals with an eGFR ≥60 mL/min/1.73 m2 
individuals with reduced kidney function were more likely to have type 2 diabetes 
(13.1% vs. 6.6%; P<0.001), more likely to have sustained a previous fracture (25.3% vs. 
17.1%; P<0.001), were less likely to report good, very good or excellent health (87.5% 
vs. 93.6%; P<0.001), and self-reported bisphosphonate  use was similar between the two 
groups (26.9% vs. 23.5%; P=0.19).  
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Figure 3. 1. Study Cohort 
†
Individuals who died or were not reachable at year 11 were excluded as we would not able to 
obtain fracture data from these individuals. 
 
 
 
 
 
 
 
 
 
5569 individuals in the CaMos 
study at year 10 
3301 Individuals Excluded: 
646 from Hamilton (no blood drawn at 
this centre)  
72 <40 years of age  
11 with a previous organ transplant 
2520 without a valid eGFR  
52 without femoral neck bone mineral 
density  
2107 individuals included 
161 individuals excluded who died 
between year 10-11, were 
unreachable at year 11 or refused to 
participate at year 11
†
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Table 3. 2. Baseline characteristics by estimated glomerular filtration rate
¥
 
Characteristic Estimated glomerular filtration rate (eGFR)  
 <60  mL/min/1.73 m2‡ 
(n=320) 
≥60  mL/min/1.73 m2 
(n=1787) 
P Value 
FRAX Variables 
Women 227 (70.9%) 1258 (70.4%) 0.85 
Age (yrs) 75.9 ± 7.2 65.6 ± 9.9 <0.001 
Body mass index (kg/m2) 
<18.5 
18.5-24.9 
25-29.9 
≥30 
27.6 ± 4.6 
1 (0.3%) 
102 (31.9%) 
134 (41.9%) 
83 (25.9%) 
27.1 ± 4.7 
23 (1.3%) 
595 (33.3%) 
737 (41.2%) 
432 (24.2%) 
0.09 
Previous fracture 81 (25.3%) 306 (17.1%) <0.001 
Parent fractured hip 35 (10.9%) 232 (13.0%) 0.31 
Current smoking 24 (7.5%) 156 (8.7%) 0.47 
Corticosteroid use for >3 months 11 (3.4%) 22 (1.2%) 0.003 
Rheumatoid arthritis 3 (0.94%) 13 (0.7%) 0.72 
Secondary osteoporosis¶ 22 (6.9%) 66 (3.7%) 0.009 
≥ 3 alcoholic beverages per day 0 (0%) 21 (1.2%) 0.06 
Femoral neck T-score -1.27 ± 0.96 -1.01 ± 1.02 <0.001 
Comorbidities 
Estimated glomerular filtration rate† 
Stage 3a 
Stage 3b 
Stage 4/5 
49.5 ± 9.0 
231 (72.2%) 
76 (23.8%) 
13 (4.0%) 
81.3 ± 11.5 
 
<0.001 
Fall in the past 12 months 77 (24.1%) 465 (26.0%) 0.46 
Bisphosphonate use€ 86 (26.9%) 420 (23.5%) 0.19 
Hypertension 186 (58.1%) 577 (32.3%) <0.001 
Type 2 Diabetes 42 (13.1%) 117 (6.6%) <0.001 
Kidney stones 37 (11.6%) 140 (7.8%) 0.03 
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Excellent, very good or good self-
reported current health 
280 (87.5%) 1673 (93.6%) <0.001 
≥ Post-secondary education 154 (48.1%) 1067 (59.7%) <0.001 
Lab Values    
Albumin (g/L) 43.7 ± 2.7 44.6 ± 2.5 <0.001 
Parathyroid hormone* (pg/mL) 
Missing  
Hyperparathyroidism (defined as >65 
pg/mL) 
62.6 (48.0-85.4) 
36 (11.3%) 
126 (44.4%) 
56.1 (44.2-71.1) 
293 (16.4%) 
491 (32.9%) 
<0.001 
 
<0.001 
Serum 25(OH)D (ng/mL) 
Missing 
Low serum 25(OH)D (defined as <30 
ng/mL) 
28.2± 10.6 
30 (9.4%) 
172 (59.3%) 
28.3± 9.7 
262 (14.7%) 
914 (60.1%) 
0.89 
 
0.84 
Serum calcium (mg/dL) 9.6 ± 0.5 9.5 ± 0.4 0.02 
Serum phosphate ( mg/dL) 3.7 ± 0.5 3.4 ± 0.5 0.007 
Total vitamin D (includes supplements, 
mcg/day) 
6.7  (0-16.3) 6.7 (0-15.0) 0.61 
Total Calcium (includes food and 
supplements, mg/day) 
1249.5 (782.9-1697.2) 1211.6 (764.5-1719.8) 0.94 
Data are Mean ± SD, median (interquartile range), or N (%).   
Abbreviations: BMD, bone mineral density; FRAX, Fracture Risk Assessment tool 
 ¥Baseline characteristics were taken at year 10 of the study.   
†eGFR calculated using the chronic kidney disease epidemiology collaboration equation 
‡ Estimated glomerular filtration rate <60 mL/min/ 1.73 m2 encompasses stages 3a, 3b, 4, and 5 chronic kidney disease 
as defined by the Kidney Disease Improving Global Outcomes Guidelines. 
 € Defined as a composite of alendronate, clodronate, etidronate, risedronate, ibandronate, pamidronate, zoledronate at 
cohort entry. 
¶Defined as any of the following: chronic liver disease, type I diabetes, hyperthyroidism, hypogonadism, premature 
menopause (<45 years), chronic malnutrition/malabsorption and osteogenesis imperfecta. Source: World Health 
Organization: FRAX World Health Organization Fracture Risk Assessment Tool, 2011. Available at: 
http://www.shef.ac.uk/FRAX/index.aspx. Accessed May 20, 2014. 
* Reference range for the PTH assay was 21.8-104.5 pg/mL and was measured by the Liaison (Diasorin Incorporated) 
assay. 
 
3.3.2 Fracture Risk Prediction and Discrimination 
Over an average of 4.8 years of follow-up, there were a total of 64 (3.0%) major 
osteoporotic fractures events (16 [5.0%] with an eGFR <60 mL/min/1.73 m
2
 [2.5% stage 
3a, 2.2% stage 3b, and 0.3% stage 4/5]
 and 48 [2.7%] with an eGFR ≥60 mL/min/1.73 
m
2
). The area under the curve (AUC) values for the FRAX models, femoral neck T-score 
alone, age alone, and T-score with a previous fall are presented in Table 3.3. We found 
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that all AUC values were statistically significant (greater than 0.5) regardless of renal 
function. The major osteoporotic fracture FRAX AUC values were higher in individuals 
with an eGFR ≥60 mL/min/1.73 m2 compared to individuals with an eGFR <60 
mL/min/1.73 m
2
. However, these differences did not reach statistical significance (Table 
3.3). Moreover,
 
there were no statistically significant differences in the predictive 
discrimination of T-scores alone, age alone, and T-scores with previous falls between 
individuals with an eGFR <60 versus ≥60 mL/min/1.73 m2 for major osteoporotic 
fractures (Table 3.3).  
 
Table 3. 3. Area under the curve for incident fracture prediction for major osteoporotic 
fracture according to estimated glomerular filtration rate 
 <60 mL/min/1.73 m
2
 ≥60 mL/min/1.73 m2   
 
Risk Factor  
 
AUC 
 
95% CI 
 
 
AUC 
 
95% CI 
 
 
AUC 
Difference, 
95% CI 
 
P 
Value 
FRAX with BMD 0.69 0.54 to 0.83 0.76 0.70 to 0.82 -0.07 
(-0.23 to  0.09) 
0.38 
FRAX without BMD 0.65 0.52 to 0.79 0.74 0.67 to 0.81 -0.09 
(-0.24 to 0.06) 
0.25 
FRAX without BMD and 
with secondary 
osteoporosis 
0.65 0.51 to 0.80     
 
Femoral neck T-score 
 
0.65 
 
0.52 to 0.80 
 
0.72 
 
0.65 to 0.79 
 
-0.07 
(-0.23 to 0.09) 
 
0.39 
Femoral neck T-score and 
prior history of fall 
0.71 0.58 to 0.84 0.75 0.68 to 0.82           -0.04 
(-0.19 to 0.11) 
0.59 
 
Age 
 
0.70 
 
0.56 to 0.83 
 
0.69 
 
0.62 to 0.77 
           
0.01 
(-0.14 to 0.16) 
 
0.90 
Abbreviations: AUC, area under the curve; BMD, bone mineral density; CI, confidence interval; FRAX, Fracture Risk 
Assessment tool 
 
3.3.3 Fracture Events and Fracture Risk Calibration 
In individuals with an eGFR <60 mL/min/1.73 m
2
 the observed major 
osteoporotic fracture risk (5.3%, 95% CI 3.3 to 8.6%), calculated using a survival 
analysis method that adjusts for the competing risk of death (27), was slightly lower than 
the FRAX predicted major osteoporotic fracture risk with BMD (6.4%, 95% CI 6.0 to 
6.9%) and also slightly lower than the FRAX predicted major osteoporotic fracture risk 
without BMD (8.2%, 95% CI 7.6 to 8.7%) (Figure 3.2); however, the observed and 
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FRAX predicted fracture risks were concordant with the FRAX predicted fracture risk 
within the observed fracture risk 95% CI. In individuals with an eGFR ≥60 mL/min/1.73 
m
2
 the observed major osteoporotic fracture risk (2.7%, 95% CI, 2.1 to 3.6%) was lower 
than the FRAX predicted major osteoporotic fracture risk with BMD (4.6%, 95% CI 4.5 
to 4.8%) and lower than the FRAX predicted major osteoporotic fracture risk without 
BMD (5.3%, 95% CI, 5.0 to 5.4%). When including CKD as a cause of secondary 
osteoporosis in individuals with an eGFR <60 mL/min/1.73 m
2
 the calibration of FRAX 
without BMD did not improve; the FRAX predicted risk in our cohort was 11.0% (95% 
CI 10.3 to 11.7%) compared to an observed major osteoporotic fracture risk of 5.3% 
(95% CI, 3.3 to 8.6%).   
 
 
Figure 3. 2. Mean predicted 5-year fracture risk from the Canadian FRAX tool (with and 
without bone mineral density [BMD]) and observed 5-year major osteoporotic fracture 
risk (Kaplan-Meier) according to estimated glomerular filtration rate. Error bars are 95% 
confidence intervals. 
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3.4 Discussion 
We found that the discriminative ability of FRAX to predict major osteoporotic 
fractures was similar and independent of renal function.   Further, in individuals with an 
eGFR <60 mL/min/1.73 m
2 
the FRAX predicted probabilities were comparable to the 
observed major osteoporotic fracture probabilities.  Our finding suggests that FRAX may 
be a valuable tool for clinicians to accurately assess fracture risk in individuals with 
reduced kidney function.  
Area under the curve values in individuals with an eGFR <60 mL/min/1.73 m
2
 
that we found were similar, although slightly lower, to the values found in a cross-
sectional study assessing the ability of FRAX to discriminate fracture status in 
individuals with reduced kidney function (13). Jamal et al. included individuals with an 
eGFR <90 mL/min/1.73 m
2 
and found an AUC of 0.72 (95% CI, 0.65 to 0.78) for FRAX 
with BMD while we found an AUC of 0.69 (95% CI, 0.54 to 0.83) (13).  The AUC 
values in our study were also similar to average AUC values found in 11 international 
FRAX validation cohorts (n= 230,486) performed in the general population for both 
FRAX with BMD (AUC 0.62) and FRAX without BMD (AUC 0.60) (2).  
In individuals with an eGFR <60 mL/min/1.73 m
2
 the AUC values for FRAX 
with (0.69) and without BMD (0.65) were lower than the AUC value for age alone (0.70) 
which might suggest that FRAX performs no better than age alone; however, similar 
results have been found in studies conducted in the general population (28-30)  and 
comparison of AUC values has been criticized as insensitive (31-33). Moreover, due to 
the small number of fractures in our study we were not able to test whether these results 
reached statistical significance as thousands of individuals are required to test whether a 
statistically significant difference occurs in correlated receiver operator characteristic 
curves (2, 34, 35).   
In individuals with an eGFR <60 mL/min/1.73 m
2 
the observed major 
osteoporotic fracture risk (5.3%) and FRAX predicted probability of major osteoporotic 
fracture risk were similar (6.4% with BMD and 8.2% without BMD). We found that the 
calibration of FRAX without BMD did not improve when adding CKD as a cause of 
secondary osteoporosis in individuals with an eGFR <60 mL/min/1.73 m
2
; we calculated 
the FRAX predicted fracture risk to be 11.0% and the observed major osteoporotic 
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fracture risk was 5.3%. It may be that adding CKD as a cause of secondary osteoporosis 
does not accurately capture all the complexities of CKD-mineral and bone disorder (12). 
In the future, large prospective studies that incorporate CKD specific fracture risk factors 
(e.g. fibroblast growth factor 23) and include more individuals with advanced CKD are 
needed.  
Our study has several strengths.  The prospective design enabled us to compare 
observed and FRAX predicted fracture risks. Moreover, in accordance with FRAX, 
which includes the death hazard, we accounted for the competing risk of death by using a 
modified Kaplan-Meier method (27). To our knowledge this is the first study to assess 
the discrimination and calibration of FRAX in predicting risk of incident fractures 
comparing individuals with reduced kidney function to individuals with normal kidney 
function. Our study had some limitations. The small number of fractures limited our 
statistical power.  Thus, we were unable to assess the prognostic value of FRAX for hip 
fracture alone, compare different FRAX models (i.e., assess the performance of FRAX 
versus age alone), and we were unable to further stratify kidney function into additional 
eGFR categories.  This last point is of particular clinical relevance because as eGFR 
decreases the fracture rate increases which may be largely attributable to changes in bone 
and mineral metabolism (8, 12); therefore, it may be valuable to assess the performance 
of FRAX at each stage of CKD. However, even given the small number of fracture 
events all of the AUC values for major osteoporotic fracture prediction were statistically 
significant.  The generalizability of our findings may be limited; the majority of our 
sample was white (≥ 99%) and individuals with reduced kidney function were largely 
community dwelling adults who were unaware they had decreased kidney function. 
Therefore, these results may not be generalizable to individuals with more severe stages 
of CKD and diagnosed CKD-mineral and bone disorder. Moreover, we were only able to 
include Canadians which may limit the generalizability of the results to different 
countries; due to the wide variability of fracture rates across countries FRAX needs to be 
calibrated separately for each country (36).  Additionally, a high proportion of individuals 
with normal kidney function had hyperparathyroidism (> 30%) which may limit 
generalizability to other populations; one potential explanation for this is previous 
research has found individuals with moderate declines in kidney function (i.e., eGFR 60-
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69 mL/min/1.73 m
2
) are more likely to have hyperparathyroidism (> 20%) (37); 
moreover, many individuals in our study had low vitamin D levels (approximately 60%); 
as vitamin D levels decrease parathyroid hormone levels increase (38). 
In summary, FRAX was able to accurately predict fracture risk in this cohort of 
individuals with an eGFR <60 mL/min/1.73 m
2
 which was demonstrated by the similar 
observed and FRAX predicted fracture rates. Moreover, FRAX demonstrated major 
osteoporotic fracture predictive discrimination in individuals with an eGFR <60 
mL/min/1.73 m
2
 which was similar to individuals with an eGFR ≥60 mL/min/1.73 m2. 
Therefore, FRAX may be a useful tool for clinicians to use to assess fracture risk in 
patients with reduced kidney function. However, given the limited sample size results 
should be interpreted with caution and large prospective studies are needed before FRAX 
can be recommended to be used routinely for fracture risk assessment in individuals with 
reduced kidney function. 
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4.1 Introduction 
Declining kidney function is associated with changes in mineral metabolism that 
contribute to an increased fracture risk (1). Of note, changes in mineral metabolism can 
persist after a kidney transplant despite improvements in kidney function (1-3) and 
fracture risk may be further increased due to the use of glucocorticoids (4, 5). Moreover, 
kidney transplant recipients may be frail potentially predisposing them to falls, thereby 
increasing fracture risk (6-11).  However, it remains uncertain whether kidney transplant 
recipients are a high risk group for fracture, defined in most clinical guidelines as a 10-
year hip fracture risk ≥ 3% (12, 13). Prior studies suggest recipients may have a higher 
risk of fracture compared to the general population (14-22), with males aged 25-44 years 
experiencing a five-time higher fracture risk compared to their counterparts in the general 
population (18).  
Current data concerning fracture risk post-transplant has several limitations.  First, 
few prior studies included kidney transplant recipients who received a transplant after the 
year 2000 (this is important because characteristics of recipients [e.g. comorbidities] and 
clinical practice patterns [e.g. trend towards decreased steroid use] have changed over 
time (22-25)). Second, many previous studies had a short follow-up time, with median 
follow-up times less than 6 years, which limits our ability to comment on the long term 
risks of fracture post-transplant (26).  Third, these studies did not compare fracture rates 
in transplant recipients to a reference population which limits our ability to understand 
the specific burden of fracture post-transplant. Moreover, large between-study variability 
in fracture rates in recipients is recognized (incidence rates ranging from 3.3 to 99.6 
fractures per 1000 person-years), with studies varying in their fracture locations (26).   
A better understanding of fracture incidence remains important for estimating 
sample size requirements for future fracture prevention trials, obtaining informed 
consent, and clinical prognostication.  Given the variability in fracture incidence across 
the literature, limitations of previous studies, and because fracture rates can widely vary 
across countries (27, 28)  we conducted this study to provide a precise estimate of the 3-
year incidence of non-vertebral fracture according to age and sex in a cohort of adult 
Canadian kidney transplant recipients.  To provide a comprehensive examination of 
fracture in a secondary analysis we examined the following: 3-year incidence of all 
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fractures (excluding skull, toe, and fingers) and falls with hospitalization according to age 
and sex; 5- and 10-year incidence of non-vertebral fracture according to age and sex; 10-
year incidence of hip fracture alone according to age and sex; and non-vertebral fracture 
incidence in adult Canadian kidney recipients compared to several matched non-
transplant reference groups (one group at a low fracture risk; two groups at increased 
fracture risk). 
 
4.2 Methods 
4.2.1 Design and Setting 
We used healthcare databases at the Institute for Clinical Evaluative Sciences in 
Ontario, Canada to conduct a population-based cohort study. All residents of Ontario are 
provided with universal access to physician and hospital services. We conducted this 
study using a protocol approved by the Research Ethics Board at Sunnybrook Health 
Sciences Centre (Ontario, Canada).  
4.2.2. Data Sources 
We used several linked databases to ascertain the study population, patient 
characteristics, and outcome data. The Canadian Organ Replacement Register (CORR) 
provided information on all kidney transplant recipients in Ontario. The Ontario Health 
Insurance Plan reported information on Ontario physicians’ billing claims for inpatient 
and outpatient services. Information on diagnostic and procedural codes for Ontario 
hospitalizations were provided by the Canadian Institute for Health Information. The 
National Ambulatory Care Reporting System provided information on emergency room 
visits. Information on demographics and vital status was obtained from the Ontario 
Registered Persons Database. The Ontario Drug Benefit Plan, a universal drug plan for 
individuals aged ≥ 65 years, provided information on outpatient prescription drug usage. 
Since April 1997 information was also provided for special populations < 65 years. Data 
was complete except for race (10% missing), primary cause of end-stage renal disease 
(11%), and donor type (1%).  
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4.2.3 Primary Cohort 
4.2.3.1 Kidney transplant recipients 
We reviewed the CORR database from July 1
st
, 1994 to December 31
st
, 2009 for 
evidence of a first kidney-only transplant. We excluded recipients who previously 
received another organ transplant (including simultaneous transplants [e.g. kidney-
pancreas]), recipients who were < 18 years of age on the date of transplant, and recipients 
who were non-Ontario residents at the time of transplant (defined by postal code). The 
date of cohort entry (index date) was defined as the date of the kidney transplant.  
4.2.4 Reference Cohorts 
To help put the burden of fracture into context we matched a kidney transplant 
recipient to three different reference cohorts (one group at a low fracture risk; two groups 
at increased fracture risk) on age (± 1 year), sex, and index date (± 1 year). To increase 
statistical power we matched one recipient to four non-transplant persons in two of the 
three reference cohorts, and in the last cohort we matched one recipient to one non-
transplant person due to a smaller sample size. Cohort creation for the reference groups is 
described below.  
4.2.4.1 Healthy segment of the population with no bone disease and no 
kidney disease (low fracture risk) 
We randomly assigned an index date to the entire adult (≥ 18 years) Ontario 
population (n=18,184,929 from 1994 to 2009) based on the index date distribution of the 
recipient cohort. We looked back to the initiation of the databases (July 1, 1991) and 
excluded individuals with chronic kidney disease (including prior receipt of a kidney 
transplant or dialysis), osteoporosis (defined as an osteoporosis diagnostic code within 1 
year after a dual-energy x-ray absorptiometry examination) (29), or a previous non-
vertebral fracture (proximal humerus, forearm, hip).   
4.2.4.2 Healthy segment of the general population with no kidney disease 
and a previous non-vertebral fracture (increased fracture risk) 
As in the previous cohort we randomly assigned an index date based on the index 
date distribution of the recipient cohort; however, in this cohort we only included 
individuals who had a non-vertebral fracture (proximal humerus, forearm, hip) within the 
69 
 
 
5 years prior to index date. We excluded individuals with chronic kidney disease 
(including prior receipt of a kidney transplant or dialysis).  
4.2.4.3 Non-dialysis chronic kidney disease (CKD) (increased fracture 
risk) 
We reviewed the databases from July 1
st
, 1994 to December 31
st
, 2009 for first 
evidence of a CKD diagnostic code (date of the first CKD diagnosis defined as index 
date); a CKD diagnostic code identifies Ontario individuals who have a median estimated 
glomerular filtration rate of 38 mL/min/1.73 m
2
 (30).We excluded individuals who 
received chronic dialysis or a previous transplant.  
4.2.5 Outcomes 
In the primary analysis we followed kidney transplant recipients for 3 years after 
the date of transplant or until evidence of a non-vertebral fracture (including multiple 
fractures on the same day) or death; if an individual had multiple fractures on the same 
day we only counted one fracture as an event. We continued to follow recipients even if 
they experienced graft failure (defined as return to chronic dialysis or re-transplant). The 
last possible date of follow-up was December 31
st
, 2012.  Our primary outcome was non-
vertebral fracture with hospital presentation (emergency room visit or hospital admission) 
which was defined as a composite of proximal humerus, forearm, and hip fracture. We 
selected these locations as they are considered major osteoporotic fracture locations and 
are associated with morbidity and mortality (31-33).  Moreover, fracture codes for these 
sites have been validated and have high accuracy (> 90% sensitivity, ≥ 85% specificity, > 
80% positive predictive value) (34-38). All analyses were performed including fractures 
accompanied by trauma codes; in addition to low-trauma fractures, fractures associated 
with high-trauma are more likely to occur in individuals with reduced bone strength (39). 
Although vertebral fractures are considered a major osteoporotic fracture, they were 
excluded from the primary analysis because merely one-third are clinically detected (40).  
In an additional analysis, we included the following fracture locations along with non-
vertebral fractures: lower leg (ankle, tibia, fibula, patella), femoral shaft, 
rib/sternum/trunk, scapula, clavicle, clinical vertebral, and pelvis fractures. We used the 
9
th
 version of the Canadian Modified International Classification of Disease (ICD) system 
prior to April 1
st
, 2002 and the 10
th
 version thereafter to ascertain fracture events.  
70 
 
 
Diagnosis codes for hip, forearm, and femoral shaft fractures also had to have evidence of 
associated procedural codes to increase fracture definition accuracy (37, 41, 42). We 
identified procedural codes from hospital encounters and physician billing codes. Given 
falls are associated with an increased fracture risk and are associated with significant 
morbidity and economic costs  we also assessed falls with hospital presentation using the 
9
th
 and 10th version of the Canadian Modified International Classification of Disease 
system codes (9, 10, 43-45). 
4.2.6 Statistical Analyses 
We used median (interquartile range) to summarize baseline characteristics for 
continuous data and percentages to summarize categorical data. We defined the 3-year 
cumulative incidence of fracture as the proportion of recipients who sustained a fracture 
in the 3 year follow-up period; no fracture could occur in follow-up if the recipient died 
before fracture. We similarly calculated the 3-year cumulative incidence of falls. We also 
calculated the 3-year incidence rate of fracture (rate per 1000 person-years) and censored 
at death or fracture during the follow-up period. We presented the results for fracture and 
falls by sex (male versus female) and age (< 50 versus ≥ 50 years) at date of transplant.  
The age dichotomization was chosen for several reasons, including: based on previous 
research we expected that the median age of kidney transplant recipients would be 50 
years (46), average age of menopause is roughly 50 years (47, 48) (fracture risk increases 
with menopause) (49, 50), and previous research has found kidney transplant recipients ≥ 
50 years have an increased fracture risk (22). To test the hypothesis that there was no 
difference in non-vertebral fracture incidence between recipients and each reference 
group we used the log-rank test stratifying on matched pairs; we also used Cox 
proportional hazard analysis to assess the effect of transplant status (transplant versus no 
transplant) on the hazard of fracture; we stratified on matched sets and tested for the 
proportional hazard assumption (proportional hazard was met). In addition to matching 
on age (± 1 year), sex, and index date (± 1 year) we performed an analysis adjusting for 
diabetes (given diabetes is a strong risk factor for fracture (51)).  We also examined the 
5- and 10-year cumulative incidence and incidence rate of non-vertebral fracture and the 
10-year incidence of hip fracture alone. We considered a two-tailed p-value < 0.05 as 
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statistically significant for all tests. We conducted all analyses with SAS (Statistical 
Analysis Software), version 9.3 (www.sas.com). 
4.2.7 Additional Analyses 
In a sensitivity analysis we only included kidney transplant recipients who 
received a transplant between April 1
st
, 2002 and December 31
st
, 2009, providing a more 
current representation of fracture rates and accounting for potential changes in coding 
(Ontario switched to ICD-10 coding April 1
st
, 2002). To take into account graft failure we 
performed an additional sensitivity analysis to determine the 3-year cumulative incidence 
of non-vertebral fracture censoring at the time of graft failure (defined as return to 
chronic dialysis or re-transplant).  
 
4.3 Results 
4.3.1 Baseline Characteristics  
We studied 4821 kidney transplant recipients who received a transplant from 
1994 to 2009.  Baseline characteristics for the recipient cohort are described in Tables 4.1 
and 4.2. The median age of recipients was 50 years (interquartile range, 38-59) and 
36.9% were women. When known, the most common cause of end-stage renal disease 
was glomerulonephritis, 74.1% had hypertension, and the median time on dialysis prior 
to transplant was 2.4 years (interquartile range, 1.0-4.5). Baseline characteristics for the 
reference groups (healthy segment of the general population with no previous non-
vertebral fracture [n=19,284]; healthy segment of the general population with a previous 
non-vertebral fracture [n=4821]; and non-dialysis CKD [n=19,284]) are described in 
Table 4.1. 
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Table 4. 1. Baseline characteristics of kidney transplant recipients compared to several 
reference groups 
 Reference Groups 
Characteristic Kidney 
transplant 
recipients 
(n=4821) 
Healthy segment 
of the general 
population with 
no bone disease 
and no kidney 
disease 
(n=19,284) 
Healthy 
segment of the 
general 
population with 
no kidney 
disease and a 
previous non-
vertebral 
fracture 
(n=4821) 
Non-dialysis 
Chronic kidney 
disease  
(n=19,284) 
Age, years 50 (38-59) 50 (38-59) 49 (38-59) 50 (38-59) 
Women 1781 (36.9%) 7124 (36.9%) 1781 (36.9%) 7124 (36.9%) 
 
Era 
1994-1997 
1998-2001 
2002-2005 
2006-2009 
 
 
914 (18.9%) 
1111 (23.1%) 
1182 (24.5%) 
1614 (33.5%) 
 
 
3655 (19.0%) 
4424 (22.9%) 
4776 (24.8%) 
6429 (33.3%) 
 
 
906 (18.8%) 
1083 (22.4%) 
1214 (25.2%) 
1618 (33.6%) 
 
 
3643(18.9%) 
4441 (23.0%) 
4736 (24.6%) 
6464 (33.5%) 
Hypertension 3572 (74.1%) 3829 (19.9%) 1040 (21.5%) 9050 (46.9%) 
Diabetes 1255 (26.0%) 1527 (7.9%) 503 (10.4%) 6371 (33.0%) 
Cardiovascular disease
¶
 2068 (42.9%) 1424 (7.4%) 490 (10.2%) 4486 (23.3%) 
Prior non-vertebral 
fracture
‡ 
106 (2.2%)   296 (1.5%) 
Data are medians (interquartile range) or n(%). 
¶Cardiovascular disease was defined as the presence of peripheral vascular disease, congestive heart failure or 
coronary artery disease. 
‡Prior non-vertebral fracture defined as a composite of proximal humerus, forearm, hip fractures from 1991 to cohort 
entry. The median number of years (interquartile range) of baseline records prior to cohort entry is as follows: kidney 
transplant recipients, 11.9 years (7.5-15.6); non-dialysis chronic kidney disease, 11.9 years (7.6-15.6). 
Note: The reference group general population with no previous non-vertebral osteoporotic fracture has no previous 
fracture as this was a requirement to enter the cohort. The reference group general population with a previous non-
vertebral osteoporotic fracture has 100% sustaining a fracture prior to cohort entry as this was requirement for cohort 
entry. 
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Table 4. 2. Additional characteristics of kidney transplant recipients 
Characteristic Kidney transplant recipients 
(n=4821) 
Race 
White 
Black 
Asian 
Other
‡
  
Missing 
 
3277 (68.0%) 
272 (5.6%) 
309 (6.4%) 
485 (10.1%) 
479 (9.9%) 
 
Cause of end-stage renal disease 
Glomerulonephritis 
Cystic kidney disease 
Diabetes 
Renal vascular disease 
Other 
Unknown/missing 
 
 
1710 (35.4%) 
620 (12.9%) 
843 (17.5%) 
448 (9.3%) 
665 (13.8%) 
535 (11.1%) 
 
Pre-transplant dialysis 
Peritoneal dialysis 
Hemodialysis 
Pre-emptive
†
 
 
 
1441 (29.9%) 
2880 (59.7%) 
500 (10.4%) 
 
Donor Type 
      Living 
      Deceased 
      Missing 
 
 
2007 (41.6%) 
2755 (57.2%) 
59 (1.2%) 
 
Dialysis (years prior to transplant)
‖
 
 
2.4 (1.0-4.5) 
 
Delayed graft function
€
 
 
899 (18.6%) 
 
Primary non-function
β
 
 
Pretransplant Parathyroidectomy 
 
143 (3.0%) 
 
                         257 (5.3%) 
 
Medications
£
  
         Glucocorticoids
¶
 22.5 (12.5-30) 
         Cyclosporine⃰ 
          Tacrolimus
¥
 
367 (13.6%) 
1417 (52.6%)  
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          Bisphosphonates
**
 646 (18.2%) 
Data are median (interquartile range) or n (%). 
‡Other was defined as a composite of: Indian Sub-Continent, Pacific Islander, Aboriginal, Mid East/Arabian, Latin 
American, Other/Multiracial. 
 †If there was no evidence of hemodialysis or peritoneal dialysis prior to transplant the recipient was coded as having 
a pre-emptive transplant. 
‖Includes individuals who received a pre-emptive transplant where the time spent on dialysis was defined as 0 years. 
€ Delayed graft function was defined as presence of one dialysis code contained in administrative databases in the 
first 7 days after transplant. 
β Primary non-function  was defined as  at least three codes for dialysis on three different days with at least one code 
appearing in the first 7 days after the transplant date,  one in the 8- 30 days after the transplant date, and  one in the 
31-60 days after the transplant date. 
£ Medication information was obtained in the first 90 days after transplantation for glucocorticoids, cyclosporine and 
tacrolimus. Medication information was obtained in the first 3 years after transplantation for bisphosphonates. 
¶ Glucocorticoid information was available for 1896 kidney transplant recipients and was presented as the median 
dose in the first 90 days after transplant (mg/day). 
⃰Denominator was n=2695 (number of recipients eligible for prescription drug coverage in the first 90 days after 
transplantation). 
¥ Denominator was n=2695 (number of recipients eligible for prescription drug coverage in the first 90 days after 
transplantation). 
**Denominator was n=3540 (number of recipients eligible for prescription drug coverage in the first 3-years after 
transplantation). 
 
Over 3 years of follow-up (13,850 person-years) 298 (6.2%) recipients died and 
77 (1.6%) sustained a non-vertebral fracture. For the reference groups, during the 3 year 
follow-up, 260 (1.3%) individuals from the healthy segment of the general population 
with no previous non-vertebral fracture died and 98 (0.5%) sustained a non-vertebral 
fracture, 170 (3.5%) from the healthy segment of the general population with a previous 
non-vertebral fracture died and 113 (2.3%) sustained a non-vertebral fracture, and 2637 
(13.7%) individuals with non-dialysis CKD died and 207 (1.1%) sustained a non-
vertebral fracture. 
4.3.2 Fracture Risk 
The 3-year cumulative incidence and incidence rate of non-vertebral fracture 
(proximal humerus, forearm, hip) according to age and sex is presented in Table 4.3.The 
overall 3-year cumulative incidence of non-vertebral fracture in recipients was 1.6% (95% 
CI 1.3-2.0%). In recipients, the number of non-vertebral fracture events increased linearly 
over the 3 years after transplant (Figure 4.1). For hip fracture alone the overall 3-year 
cumulative incidence in recipients was 0.4% (95% CI, 0.3-0.7%).The overall 5- and 10-
year cumulative incidence of non-vertebral fracture in recipients was 2.7% (95% CI, 2.2-
3.2%) and 5.5% (95% CI 4.6-6.5%), respectively (Table 4.4). For hip fracture alone the 
overall 10-year cumulative incidence in recipients was 1.7% (1.2-2.3%) (Table 4.5). For 
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all analyses women recipients aged ≥ 50 years had the highest cumulative incidence of 
fracture (Tables 4.3, 4.4, 4.5). 
 
 
Figure 4. 1. Cumulative incidence of non-vertebral fracture (proximal humerus, forearm, 
or hip) in recipients and non-transplant reference populations. Kidney transplant 
recipients had a significantly higher fracture rate compared to the non-dialysis chronic 
kidney disease population (P=0.03 by the log-rank test) and the healthy segment of the 
general population with no bone disease and no kidney disease (P<0.0001 by the log-rank 
test). Kidney transplant recipients had a significantly lower fracture rate compared to the 
healthy segment of the general population with no kidney disease and a previous non-
vertebral fracture (P=0.007 by the log-rank test). 
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Table 4. 3. 3-year cumulative incidence and incidence rate of non-vertebral fracture 
(proximal humerus, forearm, or hip) stratified by sex and age in kidney transplant 
recipients
¶
 
 3-year cumulative 
incidence, %
 
(95% CI)
 
Incidence rate per 1000 
person years
 
(95% CI) 
Overall  
(n=4821) 
1.6 
(1.3-2.0) 
 
5.6 
(4.4-7.0) 
Women  < 50 
years (n=944) 
0.6 
(0.3-1.4) 
 
2.2 
(0.8-4.7) 
Women ≥ 50 
years (n=837) 
3.1  
(2.1-4.5) 
 
11.1 
(7.3-16.3) 
Men < 50 years 
(n=1463) 
0.7 
(0.4-1.3) 
 
2.3 
(1.1-4.1) 
Men  ≥ 50 years 
(n=1577) 
2.2  
(1.6-3.1) 
7.9 
(5.5-11.0) 
 Abbreviation: CI, confidence interval 
¶ 3-year cumulative incidence defined as the proportion of kidney transplant recipients who sustained a non-vertebral 
fracture within the 3 years of follow-up; no fracture could occur in follow-up if the kidney transplant recipient died 
before fracture. Incidence rate defined as the rate per 1000 person years; censoring occurred at death or at the time of a 
fracture event during the follow-up period. 
 
Table 4. 4. 5- and 10-year cumulative incidence and incidence rate of non-vertebral 
fracture in kidney transplant recipients stratified by sex and age 
 5-year 
cumulative 
incidence, %
 
(95% CI)
 
Incidence rate 
per 1000 
person years
 
(95% CI) 
 10-year 
cumulative 
incidence, % 
(95% CI) 
Incidence rate 
per 1000 
person years
 
(95% CI) 
Overall 
(n=4070) 
2.7 
(2.2-3.2) 
 
5.8 
(4.8-7.0) 
Overall                         
(n=2385) 
5.5 
(4.6-6.5) 
6.4 
(5.3-7.6) 
Women < 50 
years 
(n=817) 
1.5  
(0.8-2.6) 
 
3.1 
(1.6-5.3) 
Women < 50 
years 
(n=536) 
3.7 
(2.4-5.6) 
4.1 
(2.5-6.3) 
 
Women ≥ 50 
years 
(n=682) 
 
5.7  
(4.2-7.7) 
 
 
12.8 
(9.1-17.5) 
 
Women ≥ 50 
years 
(n=354) 
 
13.3 
(10.1-17.2) 
 
17.3 
(12.7-23.0) 
 
Men <50 years 
(n=817) 
 
1.3 
(0.8-2.0) 
 
2.6 
(1.5-4.2) 
 
Men <50 years 
(n=817) 
 
2.6 
(1.7-3.9) 
 
2.7 
(1.7-4.2) 
 
Men ≥ 50 years 
(n=1291) 
 
3.3 
(2.5-4.5) 
 
4.8 
(2.9-7.5) 
 
Men ≥ 50 years 
(n=678) 
 
6.3 
(4.7-8.4) 
 
8.1 
(5.9-10.9) 
Note: For the 5-year cumulative incidence/incidence rate we only included kidney transplant recipients who received 
a transplant before April 1, 2008 and for the 10-year cumulative incidence/incidence rate we only included kidney 
transplant recipients who received a transplant before April 1, 2003. To increase the number of kidney transplant 
recipients for this additional analysis we defined the maximum follow-up as March 31, 2013. 
77 
 
 
Table 4. 5. 10-year cumulative incidence and incidence rate of hip fracture in kidney 
transplant recipients stratified by sex and age 
 10-year 
cumulative 
incidence, % 
(95% CI) 
Incidence rate per 
1000 
person years
 
(95% CI) 
Overall                         
(n=2385) 
 
1.7 
(1.2-2.3) 
1.9 
(1.4-2.6) 
Women ≥ 50 years 
(n=354) 
 
5.6 
(3.7-8.6) 
7.1 
(4.3-10.9) 
Men ≥ 50 years 
(n=678) 
2.5 
(1.6-4.0) 
3.2 
(1.8-5.0) 
Note: For the 10-year cumulative incidence/incidence rate we only included kidney transplant recipients who 
received a transplant before April 1, 2003. To increase the number of kidney transplant recipients for this additional 
analysis we defined the maximum follow-up as March 31, 2013.  
We were not able to report the 10-year cumulative incidence of hip fracture for women and men <50 years for 
reasons of privacy (cell size, 1-5). 
 
Recipients had a higher 3-year cumulative incidence of non-vertebral fracture 
(1.6%, 95% CI 1.3-2.0%) compared to the healthy segment of the general population 
(matched on age, sex, and index date) with no previous non-vertebral fracture (0.5%, 95% 
CI 0.4-0.6%; P<0.0001) and compared to the non-dialysis CKD population (1.1%, 95% CI 
0.9-1.2%; P=0.03) (Table 4.6) (Figure 4.1).  However, recipients had a lower 3-year 
cumulative incidence of non-vertebral fracture compared to the healthy segment of the 
general population with a previous non-vertebral fracture (2.3%, 95% CI 1.9-2.8%; 
P=0.007).  After adjusting for diabetes in addition to matching all results remained 
statistically significant (Table 4.6). 
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Table 4. 6. 3-year cumulative incidence, incidence rate, and hazard ratios of non-
vertebral fracture (proximal humerus, forearm, or hip) in several reference groups 
compared to kidney transplant recipients matched on age, sex, and index date
¥
  
Population 3-year 
cumulative 
incidence, 
%
 
(95% 
CI)
 
Incidence rate 
per 1000 
person years
 
(95% CI)
 
Hazard 
Ratio
¥
 
(95% CI) 
Hazard Ratio
‡ 
(95% CI) 
Kidney transplant 
recipients
 
(n=4821) 
1.6 
(1.3-2.0) 
5.6 
(4.4-6.9) 
1.00 
(reference) 
1.00 
(reference) 
 
Healthy segment of the 
general population
 
with 
no bone disease and no 
kidney disease 
(n=19,284) 
 
 
0.5 
 (0.4-0.6) 
 
 
1.7 
(1.4-2.1) 
 
0.3 
(0.2- 0.4) 
 
 
0.3 
(0.2-0.4) 
Healthy segment of the 
general population with 
no kidney disease and a 
previous non-vertebral 
fracture 
(n=4821) 
 
2.3 
 (2.0-2.8) 
 
8.1 
(6.6-9.7) 
1.4 
(1.1-1.9) 
 
1.6 
(1.1-2.2) 
Non-dialysis chronic 
kidney disease 
(n=19,284) 
1.1  
(0.9-1.2) 
 
4.0 
(3.5-4.6) 
0.8 
(0.6-0.98) 
0.7 
(0.6-0.9) 
¥ Matched on age (±1 year), sex, and index date (±1 year) 
‡Matched on age (±1 year), sex, and index date (±1 year) and adjusting for diabetes. 
 
When including all fracture locations, the overall 3-year cumulative incidence in 
recipients was 3.5% (95% CI 3.0-4.1%); amongst the four age and sex strata, the 3-year 
cumulative incidence was highest in women recipients aged ≥ 50 years (5.7%, 95% CI 
4.3-7.5%) (Table 4.7). The most common location of first clinically diagnosed fracture in 
recipients was the lower leg (defined as a composite of tibia, fibula, patella, and ankle) 
(32.5% of all fractures) and a similar result was found in the healthy segment of the 
general population with a previous non-vertebral fracture (27.9% of all fractures) (Table 
4.8).  
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Table 4. 7. 3-year cumulative incidence and incidence rate of all fracture in kidney 
transplant recipients stratified by sex and age
‡
 
 3-year cumulative incidence, %
 
(95% CI)
 
Incidence rate per 1000 
person years
 
(95% CI) 
Overall 
 (n=4821) 
3.5 
(3.0-4.1) 
 
12.3 
(10.5-14.3) 
 
Women  < 50 years  
(n=944) 
2.1 
(1.4-3.3) 
 
7.3 
(4.5-11.3) 
 
Women ≥ 50 years 
 (n=837) 
5.7 
(4.4- 7.5) 
20.8 
(15.3-27.5) 
 
Men < 50 years 
(n=1463) 
2.4 
(1.7- 3.3) 
 
8.2 
(5.7-11.4) 
 
Men  ≥ 50 years 
(n=1577) 
4.2 
(3.3- 5.3) 
15.0 
(11.6-19.1) 
   ‡ All fracture locations defined as a composite of hip, forearm, proximal humerus, lower leg (ankle, tibia, fibula, 
patella), femoral   shaft, rib/sternum/trunk, scapula, clavicle, vertebral, and pelvis fractures 
Table 4. 8. Location of the first fracture in follow-up‡ 
Fracture location Kidney transplant recipients 
(n=4821) 
Healthy segment of the 
general population with no 
kidney disease and a 
previous non-vertebral 
fracture  
(n=4821) 
Hip 17 (10.6%) 24 (10.6%) 
Forearm 43 (26.9%) 60 (26.6%) 
Proximal humerus 12 (7.5%) 24 (10.6%) 
Lower leg
† 
52 (32.5%) 63 (27.9%) 
Ribs/sternum/trunk 12 (7.5%) 33 (14.6%) 
Pelvis 10 (6.2%) 7 (3.1%) 
Other
¥ 
14 (8.8%) 15 (6.6%) 
‡Multiple fracture events that occurred on the same day were excluded from this table; therefore, for kidney 
transplant recipients there were a total of 160 events (n=9 excluded) and 226 (n=12 excluded) in the general 
population with a previous non-vertebral fracture. 
†Lower leg includes a composite of tibia, fibula, patella and ankle fractures 
¥ Other includes a composite of fracture locations that had ≤5 events including: vertebral, clavicle, femoral shaft, 
scapula fractures 
Note: The most common fracture location for each group is denoted in bold. 
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4.3.3 Additional Analyses 
When we limited the analysis to recipients who received a transplant in recent 
years (transplant received from 2002 to 2009) the overall 3-year cumulative incidence of 
non-vertebral fracture was similar to when we included all transplant years (1.8%, 95% CI 
1.4-2.4%) and again was highest amongst women recipients aged ≥ 50 years (3.0%, 95% 
CI 1.9-4.8%) (Table 4.9). When we censored after graft failure (308 returned to dialysis 
[6.4%] and 14 re-transplanted [0.3%]) the overall 3-year cumulative incidence in 
recipients decreased slightly (1.5%, 95% CI 1.2-1.9%) (Table 4.10). With respect to falls, 
the overall 3-year cumulative incidence in recipients was 7.9% (95% CI 7.1-8.7%); 
amongst the four age and sex strata, women recipients aged ≥50 years had the highest 3-
year cumulative incidence of falls (11.1%, 95% CI 9.1-13.4%) (Table 4.11). 
 
Table 4. 9. 3-year cumulative incidence and incidence rate of fracture stratified by sex 
and age only including kidney transplant recipients who received a transplant from 2002-
2009 
Fracture location 3-year 
cumulative 
incidence, 
%
 
(95% CI)
 
Incidence rate 
per 1000 
person years
 
(95% CI) 
Fracture location 3-year 
cumulative 
incidence, %
 
(95% CI)
 
Incidence 
rate per 1000 
person years
 
(95% CI) 
Proximal humerus, 
forearm, or hip 
  All fracture locations
‡
   
Overall 
(n=2723) 
1.8 
(1.4-2.4) 
 
6.3 
(4.6-8.3) 
Overall 
(n=2723) 
3.9 
(3.2-4.7) 
13.7 
(11.2-16.6) 
Women < 50 years 
(n=461) 
 <1.5%
 
 
3.0 
(0.8-7.6) 
Women < 50 years 
(n=461) 
1.7 
(0.9- 3.4) 
6.0 
(2.6-11.7) 
Women ≥ 50 years 
(n=531) 
3.0 
(1.9-4.8) 
 
10.7 
(6.1-17.4) 
Women ≥ 50 years 
(n=531) 
5.5 
(3.8- 7.6) 
19.6 
(13.2-28.2) 
Men < 50 years 
(n=721) 
<1.5% 
 
 
3.3 
(1.3-6.8) 
Men < 50 years 
(n=721) 
3.2 
(2.1- 4.7) 
11.0 
(6.9-16.4) 
Men  ≥ 50 years 
(n=1010) 
2.2 
(1.4-3.3) 
7.8 
(4.9-11.7) 
Men  ≥ 50 years 
(n=1010) 
4.6 
(3.4- 6.0) 
16.4 
(12.0-21.8) 
‡ All fracture locations defined as a composite of hip, forearm, proximal humerus, lower leg (ankle, tibia, fibula, 
patella), femoral shaft, rib/sternum/trunk, scapula, clavicle, vertebral, and pelvis fractures. 
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Table 4. 10. 3-year cumulative incidence and incidence rate of non-vertebral fracture 
(proximal humerus, forearm, or hip) stratified by sex and age and censoring after graft 
failure 
 3-year cumulative 
incidence,  
%
 
(95% CI)
 
Incidence rate per 1000 
person years
 
 (95% CI)
 
Overall 
 (n=4821) 
1.5 
(1.2-1.9) 
5.4   
(4.2-6.8) 
 
Women  < 50 years  
(n=944) 
0.6 
(0.3-1.4) 
2.3 
(0.8-5.0) 
 
Women ≥ 50 years  
(n=837) 
2.9 
(1.9-4.2) 
10.7 
(6.9-15.9) 
 
Men < 50 years 
(n=1463) 
0.7 
(0.4-1.3) 
2.4 
(1.2-4.5) 
 
Men  ≥ 50 years 
(n=1577) 
2.0 
(1.4-2.9) 
7.5 
(5.1-10.5) 
 
Abbreviation: CI, confidence interval 
¶ 3-year cumulative incidence defined as the proportion of kidney transplant recipients who sustained a non-vertebral 
fracture within the 3 years of follow-up; no fracture could occur in follow-up if the kidney transplant recipients died or 
experienced graft failure before fracture. Incidence rate defined as the rate per 1000 person years of follow-up; 
censoring at the time of death, graft failure, or fracture in follow-up 
 
Table 4. 11. 3-year cumulative incidence, incidence rate of falls stratified by sex and age 
 3-year cumulative 
incidence, %
 
(95% CI)
 
Incidence rate per 1000 
person years
 
(95% CI) 
Overall  
(n=4821) 
7.9 
(7.1- 8.7) 
 
28.3 
(25.5-31.3) 
 
Women < 50 years 
(n=944) 
6.4 
(5.0- 8.1) 
 
22.3 
(17.0-28.7) 
 
Women ≥ 50 years 
(n=837)  
11.1 
(9.2- 13.4) 
 
41.4 
(33.4-50.8) 
 
Men < 50 years 
(n=1463) 
5.2 
(4.2-6.5) 
 
18.1 
(14.2-22.6) 
 
Men  ≥ 50 years 
(n=1577) 
9.5 
(8.2-11.1) 
35.1 
(29.7-41.2) 
Abbreviation: CI, confidence interval 
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4.4 Discussion  
The cumulative incidence of fracture in kidney transplant recipients was lower 
than previously reported with approximately 1 in 50 sustaining a non-vertebral fracture in 
the 3 years after transplant, approximately 1 in 20 sustaining a non-vertebral fracture in 
the 10 years after transplant, and approximately 2% sustaining a hip fracture in the 10-
year follow-up (≥ 3% defines high risk). Among women recipients aged ≥ 50 years only 
1 in 30 sustained a non-vertebral fracture in the 3 years after transplant. Further, 
recipients had a lower fracture incidence compared to the healthy segment of the general 
population with a previous non-vertebral fracture.  Our results suggest that despite the 
changes in mineral metabolism and use of steroids after kidney transplantation, recipients 
may not be a high risk group for fracture. 
The fracture incidence in our study is lower than many prior studies (15-21, 52); 
however, it is important to note that a variety of locations are included across studies 
making comparisons difficult. For example, Ball et al. found an incidence rate of 3.3 hip 
fractures per 1000 person-years in kidney transplant recipients (20); in contrast, we found 
an incidence rate of 1.9 hip fractures per 1000 person-years.  However, not all previous 
studies have found a high fracture incidence. For example, Opelz et al. conducted a study 
including recipients from 32 countries and found a 5-year cumulative incidence of hip 
fracture of 0.85%, similar to our study 3-year cumulative incidence estimate of 0.4% and 
a 10-year cumulative incidence of 1.9% (53). Moreover, a recent Canadian study 
suggests kidney transplant recipients are not a high risk fracture group (10-year major 
osteoporotic fracture risk  6.3%) (54), but follow-up time for this analysis began an 
average of one-year after kidney transplant (54); previous studies have suggested that an 
accelerated loss in bone mineral density happens in the first one-year post-transplant 
therefore early fractures may have been missed (55-57). 
There are several explanations for the lower than expected fracture incidence.  
First, 6 out of the 10 previous studies assessing fracture risk in kidney transplant 
recipients did not include recipients who transplanted after the year 2000 (26). In recent 
years there have been changes in maintenance immunosuppressive regimens. 
Specifically, tacrolimus is now used more commonly than cyclosporine which may result 
in less bone loss (58).  In our study, of recipients eligible for prescription drug coverage, 
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8.7% were on cyclosporine and 63.6% were on tacrolimus. There has also been a trend 
towards decreasing prednisone dose after kidney transplantation; corticosteroids are well 
known to promote bone loss (4, 5). In our study the median steroid dose in the first 90 
days after transplant in 1997 was 27.6 mg/day compared to 20.2 mg/day in 2009.  In 
recent years there may be an increase in the number of recipients prescribed fracture 
prevention therapy (bisphosphonates and vitamin D); the Kidney Disease Improving 
Global Outcomes for Chronic Kidney Disease-Mineral and Bone Disorder guidelines 
recommend that bisphosphonates and vitamin D are prescribed to recipients who have an 
estimated glomerular filtration rate >30 mL/min/1.73 m
2
 and low bone mineral density 
(1). In our study, of recipients eligible for prescription drug use, 5.5% of recipients who 
received their transplant in 1997 were prescribed bisphosphonates in the first three years 
after transplant compared to 11.5% in 2009, but the number of fracture events was too 
small to detect any impacts from these interventions.  Therefore, including recipients who 
more recently transplanted may have decreased the overall incidence rate. Second, to 
increase the accuracy of our fracture definition it was necessary that hip and forearm 
fracture diagnostic codes were accompanied by associated procedural codes (37, 41, 42); 
failure to include procedural codes may lead to over-ascertainment of fractures. 
Therefore, previous transplant studies may have been overestimating fractures at these 
locations. Last, the majority of previous studies have been conducted in the US (26); 
fracture rates and patient characteristics may vary across countries. For example, Leslie et 
al. found that in the general population proximal femoral fracture rates were 30% lower 
in Canadian women compared to women from the US (28). Moreover, differences in 
transplant characteristics have been found between the US and Canada, potentially 
affecting fracture rates (e.g. more obese individuals in the US) (59). 
 The low fracture incidence provides an explanation for why previous clinical 
trials assessing the efficacy of bisphosphonates in kidney transplant recipients have been 
underpowered (60). To conduct a 2-arm parallel randomized control trial (80% power) 
and to obtain a 60% relative risk reduction we would need a total of 9900 recipients 
(based on 1.6% of recipients sustaining a non-vertebral fracture). However, we did not 
include vertebral fractures; smaller sample sizes would likely be required if these fracture 
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locations were included. Nevertheless, to conduct a fracture prevention trial with 
adequate statistical power there would still need to be participation of multiple centres. 
We found recipients had a significantly lower 3-year cumulative incidence of 
non-vertebral fracture compared to the healthy segment of the general population with a 
previous non-vertebral fracture, matching on age, sex, and index date. Although one of 
the strongest risk factors for a future fracture is a previous fracture (61), we expected that 
recipients would have a higher fracture incidence due to bone mineral metabolism 
changes associated with CKD and steroid administration (1). Despite these factors, based 
on clinical practice guidelines recipients would not be considered a high risk fracture 
group with only 1.7% sustaining a hip fracture in the 10 years after transplant (high risk 
defined as ≥ 3%). Only women recipients ≥ 50 years would be defined as a high risk 
fracture group with 5.6% sustaining a hip fracture in the 10-years after transplant. 
However, recipients did have a 3 time higher fracture risk compared to a healthy segment 
of the general population (no kidney disease and no bone disease); previous studies 
comparing recipients to the general population have found an even higher relative 
fracture risk (14, 18, 19). For example, Ramsey-Goldman et al. found female recipients 
between the ages of 45-64 years had almost a 35 times higher fracture risk compared to 
similarly aged individuals from the general population (18).  However, previous studies 
comparing recipients to the general population did not include recipients who received a 
transplant more recently (after the year 2000), therefore, potentially overestimating 
fracture risk in more contemporary recipients.  
Several strengths of our study deserve mention. No other study, to our knowledge, 
has compared fracture rates in recipients to several matched reference groups to better 
quantify incremental fracture risk. Moreover, our study’s large sample size and long-term 
follow-up allowed us to meaningfully examine long-term fracture risk (10-year follow-
up).  We are also the first study to report the incidence of falls stratifying by age and sex. 
Finally, to account for changes in recipient characteristics and changes in clinical practice, 
we performed an additional analysis restricted to recipients who received a transplant after 
the year 2002.  
Limitations of this study should be recognized. First, we may not have captured all 
fracture events; we did not include vertebral fracture in our primary fracture definition 
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with merely one-third of these fractures being recognized in a clinical setting (40); this 
may have underestimated fracture risk. However, using only hip fracture codes kidney 
transplant recipients were not considered to have a high fracture risk (10-year risk <3%); 
all hip fractures should be treated in the hospital and therefore will not be missed using 
administrative databases. Moreover, even the upper bound of the 95% confidence interval 
for non-vertebral fracture was low with only 2.0% of recipients fracturing. Second, we 
were only able to capture fractures and falls that presented at the hospital or in the 
emergency room. However, the majority of fractures are managed through the emergency 
room or hospital; additionally, we used the same databases and codes to capture fracture 
events in recipients and the reference groups. Third, we were not able to compare fracture 
incidence in recipients to individuals on the transplant waitlist; our administrative 
databases do not provide information on individuals on dialysis who were on the 
transplant waitlist; therefore, we did not think individuals on dialysis would make an 
accurate comparison given many of these individuals would have greater comorbidities 
and not qualify for transplantation. However, one previous study has compared fracture 
rates in waitlist patients to transplant recipients finding hip fracture risk was higher in the 
first 600 days after transplant, however, it decreased after this time point (20).  Fourth, 
these results may not readily generalize to all races; 68% of recipients in our study were 
white (whites have a higher fracture risk compared to blacks) (62). Moreover, these results 
may not generalize to other countries given the large global variation in fracture rates (27). 
Fifth, due to the small number of non-vertebral fracture events (n=77) we were not able to 
assess trends in fracture incidence over time and delineate reasons for changes in fracture 
rates. Sixth, we were only able to obtain drug information for a subset of recipients 
eligible for prescription drug coverage. Finally, we were unable to obtain serum creatinine 
values to define CKD and as a result some individuals with CKD may have been 
misclassified; however, the specificity for the CKD codes was high (>90%) (30).  
In conclusion, although kidney transplant recipients had a higher relative fracture 
risk compared to other populations they had a low absolute fracture risk with few 
recipients sustaining a fracture after transplantation. Further research is needed to identify 
reasons for this lower than expected fracture risk. 
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5.1 Introduction 
Kidney transplant recipients have an increased risk of fracture compared to the 
general population (1-3). Reasons for the increased fracture risk are multifactorial, and  
may include perturbations in bone and mineral metabolism  that occur in renal bone 
disease, and the administration of  glucocorticoids after transplantation (4). However, we 
remain uncertain of the risk factors for fracture after transplant; in a recent systematic 
review many classical risk factors for fracture in the general population (e.g. older age, 
female sex) were inconsistently associated with fractures in kidney transplant recipients  
(5). Unlike the transplant population, risk factors for fracture in the general population 
are well-established and are included in the World Health Organization’s (WHO) 
Fracture Risk Assessment tool (FRAX). FRAX is used to guide treatment decisions in the 
general population through incorporating age, sex, clinical risk factors (body mass index, 
parental hip fracture, glucocorticoid use, rheumatoid arthritis, smoking, high alcohol 
intake [≥ 3 units of alcohol a day]), and bone mineral density (optional) to predict the 10-
year hip fracture or major osteoporotic fracture probability (proximal humerus, forearm, 
hip, or clinical vertebral) (6-8). However, kidney transplant recipients may have different 
risk factors for fracture given the unique pathophysiology that underlies their bone 
disease (9). For example, in a recent cohort study the only classical risk factor for fracture 
that reached statistical significance in kidney transplant recipients was high alcohol use 
(10); however, this study had only 21 fracture events and may have had inadequate 
statistical power to identify other risk factors (10).  The same study also found that FRAX 
may be a useful tool to predict fracture in kidney transplant recipients (area under the 
receiver operating characteristic curve 0.62); however, the authors hypothesized that 
incorporating transplant-specific risk factors for fracture may improve the accuracy of 
FRAX (10). FRAX currently does not incorporate kidney transplantation or chronic 
kidney disease into its algorithm. 
The WHO has called for a global strategy on fracture prevention and management 
(11). Such strategies require an understanding of well-validated fracture risk factors and 
prediction tools so populations at high risk can be targeted for diagnosis, treatment, and 
therapeutic trials. Given that risk factors for fracture in kidney transplant recipients have 
not been well-established, in a modern cohort of Canadian adult kidney transplant 
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recipients we conducted this study to determine transplant-specific risk factors (e.g. 
length of time on dialysis prior to transplant) and general risk factors (e.g. age, sex, 
previous fracture, previous fall) associated with major fractures (proximal humerus, 
forearm, hip, and clinical vertebral). In a secondary analysis we assessed risk factors for 
other fracture locations (excluding major fractures, and those of the skull, fingers, and 
toes). 
 
5.2 Methods 
5.2.1 Design and Setting 
This was a population-based cohort study using the Institute for Clinical 
Evaluative Sciences (ICES) healthcare databases in Ontario, Canada. Ontario residents 
are given universal access to hospital and physician services. Study approval was 
obtained from Sunnybrook Health Sciences Centre’s Research Ethics Board (Toronto, 
Ontario, Canada). 
5.2.2 Data Sources 
We utilized several databases to establish our study cohort, patient characteristics, 
risk factors, and outcome data. Information on all kidney transplant recipients who 
received their transplant in Ontario was provided by the Canadian Organ Replacement 
Register (CORR). Information on provincial physicians’ billing claims was provided by 
the Ontario Health Insurance Plan. The Canadian Institute for Health Information  
database provided information on diagnostic and procedural codes during Ontario 
hospitalizations and information on emergency room visits was provided by the National 
Ambulatory Care Reporting System. The Ontario Registered Persons Database provided 
information on vital status and demographics. 
5.2.3 Cohort 
We utilized the CORR database from April 1
st
, 2002 to December 31
st
, 2009 to 
identify individuals from Ontario with a first kidney-only transplant who had not 
previously received another organ transplant and were ≥ 18 years of age at the transplant 
date. We selected April 1
st
, 2002 as our cohort entry date as this was when the Canadian 
International Classification of Disease (ICD) system changed from version 9 to 10. The 
cohort entry date (index date) was the date an individual received their kidney transplant.  
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5.2.4 Risk Factors 
We assessed several general risk factors for fracture (age, sex, and prior major 
fracture) which are incorporated in the WHO FRAX algorithm.  We also assessed other 
general risk factors found to increase fracture risk in the non-transplant population, 
including: a fall with hospitalization in the year prior to transplantation, race/ethnicity, 
and diabetes (only type 1 diabetes is included in FRAX) (12-14). We assessed several 
transplant-specific risk factors including: length of time on dialysis prior to transplant 
(years), type of donor (living vs. deceased), cause of end-stage renal disease (ESRD, e.g., 
diabetes mellitus, glomerulonephritis, renal vascular disease, cystic kidney disease, or 
other [i.e., any cause of ESRD not included in the aforementioned categories such as 
pyelonephritis]), pre-transplant dialysis modality (peritoneal, hemodialysis, or pre-
emptive), and donor characteristics (age and sex). 
5.2.5 Outcomes 
We followed kidney transplant recipients from the date of transplant until 
fracture, death, or end of follow-up (March 31
st
, 2013). We did not censor kidney 
transplant recipients if they returned to chronic dialysis or if they had another transplant 
(graft failure) during follow-up. Our primary outcome was major fractures which were 
defined as a composite of hip, forearm, proximal humerus, and clinical vertebral 
fractures. We chose to assess risk factors for major fractures with hospital presentation 
(emergency room visit or hospital admission) as these fracture locations are associated 
with excess morbidity and mortality in the general population (15-17).  In an additional 
analysis we assessed other fracture locations, defined as: lower leg (ankle, tibia, fibula, 
patella), femoral shaft, rib/sternum/trunk, scapula, clavicle, and pelvis fractures.  We 
assessed these fractures as a secondary outcome as they may be  more common in kidney 
transplant recipients (9). For example, in prior studies ankle fractures were common in 
kidney transplant recipients (1, 18). We included both high and low trauma fractures 
because, similar to low-trauma fractures, high-trauma fractures occur more commonly 
when an individual has compromised bone strength (19).  We identified fracture events 
using the 10
th
 version of the ICD system.  To increase accuracy, diagnosis codes for hip, 
forearm, and femoral shaft fractures were accompanied by procedural codes identified 
from hospital encounters and physician billing codes (20).  
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5.2.6 Statistical Analysis 
We compared differences in baseline characteristics of recipients with a fracture 
and without a fracture using the Mann Whitney U test for continuous variables and the 
chi-square test for categorical variables. We calculated the incidence rate of fracture (per 
1000 person-years) censoring the observation period on the date of death, first fracture, or 
end of follow-up (March 31, 2013). We used the Cox proportional hazards model to 
relate the hazard of the first fracture to risk factors. Prior to obtaining the adjusted hazard 
ratio (aHR) to quantify the effect of each risk factor model assumptions such as the 
proportional hazards assumption and linearity of continuous factors (martingale 
residuals) were assessed with a P-value <0.05  used as criteria for a violation (21-23). We 
used the backward elimination strategy to select risk factors that would be entered into 
the final model, with recipient age and sex forced into the model. A priori we chose a p-
value of ≤0.2 to determine variables that would be included in the final model (24). We 
chose this p-value to decrease the possibility of missing important risk factors for fracture 
post-transplant. We assessed multicollinearity among variables prior to entering variables 
into the backward elimination model. We found limited concern for multicollinearity, 
since all variance inflation factors were less than 2 (25).  We were missing data for the 
following variables: donor age (2.2%), donor sex (0.9%), cause of ESRD (11.6%), race 
(10.7%), and donor type (0.8%). We handled missing data by randomly assigning values 
based on the distribution of variables that were not missing with the exception of donor 
age for which we supplemented missing values with the median age. We performed all 
analyses using SAS (Statistical Analysis Software), version 9.4 (www.sas.com). 
 
5.3 Results 
5.3.1 Incidence of Fracture 
Of the 2723 kidney transplant recipients the total follow-up was 16,274 person-
years (average 6 years). Over this time, there were 402 (14.8%) deaths in follow-up and 
132 (4.8%) sustained a major fracture (8.1 fractures per 1000 person-years, 95% 
confidence interval [CI] 6.8-9.6). 
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5.3.2 Baseline Characteristics 
Recipients who sustained a major fracture in follow-up compared to recipients 
with no major fracture had a significantly higher median age (57 vs 51 years), were more 
likely to be women (48.5% vs 35.8%), and were less likely to have glomerulonephritis as 
their cause of ESRD (29.6% vs 36.7%) (Table 5.1).  
 
Table 5. 1. Characteristics of kidney transplant recipients classified by major fracture 
status
†
 
 No fracture 
(n=2591) 
Major Fracture 
(n=132) 
P-value 
General risk factors 
Age, years 50.5 (41-61) 56.5 (45-63) 0.01 
Women 928 (35.8%) 66 (48.5%) 0.004 
Race   0.40 
    White           1845 (71.2%) 103 (78%)  
     Asian  208 (8.0%) 8 (6.1%)  
      Black  198 (7.6%) 7 (5.3%)  
      Other
€
 340 (13.1%) 14 (10.6%)  
Diabetes 673 (25.6%) 40 (30.3%) 0.27 
Fall with hospitalization in the year 
prior to the transplant date   
92 (3.6%) 8 (6.1%) 0.15 
Major  fracture prior to the 
transplant date
‡
 
   
Transplant specific risk factors 
 Length of time on dialysis prior to 
transplant (measured in years)
¶
 
2.8 (1.2-5.4) 2.7 (0.92-5.1) 0.56 
Type of donor    0.47 
        Deceased (vs. Living) 1458 (56.3%) 70 (53.0%)  
Cause of end-stage renal disease
¥
   0.004 
         Glomerulonephritis 951 (36.7%) 39 (29.6%)  
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         Cystic kidney disease 385 (14.9%) 31 (23.5%)  
          Diabetes 560 (21.6%) 37 (28.0%)  
          Other 695 (26.8%) 25 (18.9%)  
 
Pre-transplant dialysis modality
‖
 
   
0.99 
        Peritoneal dialysis 701 (27.1%) 35 (26.5%)  
        Hemodialysis 1622 (62.6%) 83 (62.9%)  
         Pre-emptive 268 (10.3%) 14 (11.6%)  
Donor age, years 46 (36-54) 47.5 (41-55) 0.16 
Donor sex 
        Women 
 
1295 (50.0%) 
 
68 (51.5%) 
0.73 
Data are median (interquartile range) or n (%). 
†Major fracture events were comprised of forearm (n=81), hip (n=22), proximal humerus (n=18), and clinical vertebral 
fractures (n=13).  
€Other was defined as a composite of: Indian Sub-Continent, Pacific Islander, Aboriginal, Mid East/Arabian, Latin 
American, Other/Multiracial. 
‡Due to the small number of recipients with a prior major fracture this risk factor was not able to be assessed. 
 ¶ Includes individuals who received a pre-emptive transplant where the time spent on dialysis was defined as 0 years. 
¥ Due to the small number of recipients with a major fracture who had renal vascular disease as the cause of their ESRD 
this category was combined into the other category. 
‖We defined hemodialysis and peritoneal dialysis based on the modality the recipient first received. We defined pre-
emptive transplant as no evidence of hemodialysis or peritoneal dialysis prior to transplant. 
 
5.3.3 Univariable Analysis 
We found older recipient age and female recipient sex were the general risk 
factors associated with an increased risk of major fracture (Table 5.2). For example, 
female recipients had almost a two-fold greater risk of major fracture (hazard ratio [HR] 
1.65, 95% CI 1.18-2.33). Regarding transplant-specific risk factors, cystic kidney disease 
(HR 1.93, 95% CI 1.20-3.08) and diabetes (HR 1.80, 95% CI 1.15-2.82) as the cause of 
ESRD (compared to glomerulonephritis as the reference cause) were both associated with 
a higher risk of major fracture. Each 5-year increase in donor age was also associated 
with a greater risk of major fracture (HR 1.11, 95% CI 1.04-1.18). 
5.3.4 Multivariable Analysis 
In the multivariable model, older recipient age (5-year increase) (aHR 1.11, 95% 
CI 1.03-1.19) and female recipient sex (aHR 1.81, 95% CI 1.28-2.57) were the general 
risk factors associated with a greater risk of major fracture (Table 5.2). Regarding 
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transplant-specific risk factors diabetes (aHR 1.72, 95% CI 1.09-2.72) and cystic kidney 
disease (aHR 1.73, 95% CI 1.08-2.78) as the cause of ESRD (compared to 
glomerulonephritis as the reference cause), and older donor age (5-year increase) (aHR 
1.09, 95% CI 1.02-1.17) were associated with a greater risk of major fracture. 
 
Table 5. 2.  Univariable and multivariable analysis of risk factors for major fracture in 
kidney transplant recipients 
 Univariable analysis Multivariable analysis 
Risk Factors Hazard ratio
 
(95% CI) 
Hazard ratio
 
(95% CI) 
Age (per 5 year increase) 1.13 (1.06-1.21) 1.11 (1.03-1.19) 
Sex 
Men  
Women 
 
Reference 
1.65 (1.18-2.33) 
 
 
1.81 (1.28-2.57) 
Race   
White Reference  
Asian 0.72 (0.35-1.47)  
Black 0.65 (0.30-1.39)  
Other
€
 0.78 (0.44-1.36)  
Diabetes (vs. none) 1.40 (0.96-2.02)  
Fall with hospitalization in the year prior to 
the transplant date  (vs. none) 
2.00 (0.98-4.09) 1.72 (0.84-3.50) 
Major  fracture prior to the transplant 
date
‡
(vs. none) 
  
Length of time on dialysis prior to 
transplant (measured in years)
¶
 
1.06 (0.61-1.84)  
Type of donor    
Living 0.99 (0.70-1.39)  
Deceased Reference  
Cause of end-stage renal disease
¥
   
100 
 
 
Glomerulonephritis Reference Reference 
Cystic kidney disease 1.93  (1.20-3.08) 1.73 (1.08-2.78) 
Diabetes 1.80 (1.15-2.82) 1.72 (1.09-2.72) 
Other 0.92 (0.56-1.53) 0.88 (0.53-1.46) 
 
Pre-transplant dialysis modality
‖
 
  
Hemodialysis Reference  
Peritoneal dialysis 0.99 (0.67-1.47)  
Pre-emptive 0.96 (0.54-1.68)  
Donor age (per 5 year increase) 1.11 (1.04-1.18) 1.09 (1.02-1.17) 
Donor sex 
Men 
Women 
 
Reference 
1.03 (0.73-1.44) 
 
 
 
‡ Due to the small number of recipients with a prior major fracture this risk factor was not able to be assessed. 
€Other was defined as a composite of: Indian Sub-Continent, Pacific Islander, Aboriginal, Mid East/Arabian, Latin 
American, Other/Multiracial. 
¥ Due to the small number of recipients with a major fracture who had renal vascular disease as the cause of their ESRD 
this category was combined into the other category. 
¶Includes individuals who received a pre-emptive transplant where the time spent on dialysis was defined as 0 years. 
‖We defined hemodialysis and peritoneal dialysis based on the modality the recipient first received. We defined pre-
emptive transplant as no evidence of hemodialysis or peritoneal dialysis prior to transplant. 
 
5.3.5 Other Fractures 
When we assessed other fracture events (excluding the major fractures, and the 
skull, fingers, and toes) kidney transplant recipients had 141 fractures (8.7 fractures per 
1000 person-years, 95% CI 7.3-10.2). Recipients with such fractures compared to those 
without such fractures were significantly more likely to have diabetes (40.4% vs 25.4%) 
and were more likely to have had a fall with hospitalization in the year prior to transplant 
(7.1% vs 3.5%) (Table 5.3).   In the multivariable model we found diabetes and a fall 
with hospitalization prior to transplantation were the general risk factors associated with 
an increased risk of fracture, while length of time on dialysis, and renal vascular disease 
and other causes of ESRD were the transplant-specific risk factors associated with a 
greater risk of other fractures (Table 5.4). 
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 Table 5. 3. Characteristics of kidney transplant recipients classified by other fractures 
status
¥
  
 No fracture 
(n=2582) 
Other fracture 
(n=141) 
P-value 
General risk factors 
Age, years 52 (42-61) 54 (44-61) 0.18 
Women 944 (36.6%) 48 (34.0%) 0.55 
Race   0.33 
    White 1838 (71.2%) 110 (78.0%)  
    Asian  208 (8.1%) 8 (5.7%)  
    Black  198 (7.8%) 7 (5.0%)  
   Other
€
 338 (13.1%) 16 (11.4%)  
Diabetes 656 (25.4%) 57 (40.4%) <0.001 
Fall with hospitalization in the 
year prior to the transplant  index  
90 (3.5%) 10 (7.1%) 0.03 
Major  fracture prior to the 
transplant date
β 
 
69 (2.7%) 13 (9.2%) <0.001 
Transplant specific risk factors 
 Length of time on dialysis prior 
to transplant (measured in years)
¶
 
2.7 (1.1-5.4) 3.0 (1.7-5.3) 0.068 
Type of donor     
Deceased 1439 (55.7%) 89 (63.1%) 0.09 
Cause of end-stage renal 
disease 
  0.003 
Glomerulonephritis 958 (37.1%) 32 (22.7%)  
Cystic kidney disease 397 (15.4%) 19 (13.5%)  
Diabetes 555 (21.5%) 42 (29.8%)  
Renal Vascular Disease 294 (11.4%) 23 (16.3%)  
Other 378 (14.6%) 25 (17.7%)  
Pre-transplant dialysis 
modality
‖
 
  0.09 
Peritoneal dialysis 694 (26.7%) 42 (29.8%)  
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Hemodialysis 1613 (62.5%) 92 (65.3%)  
Pre-emptive 275 (10.7%) 7 (5.0%)  
Donor age, years 46 (36-54) 48 (40-54) 0.13 
Donor sex 
Women 
1298 (50.3%) 65 (46.1%) 0.33 
Data are median (interquartile range) or n (%). 
¥ Other fracture events were comprised of pelvis (n=15), ankle (n=37), patella (n=8), tibia/fibula (n=37), rib/sternum 
(n=34), and other (femoral shaft, scapula, clavicle; n=16). 
€Other was defined as a composite of: Indian Sub-Continent, Pacific Islander, Aboriginal, Mid East/Arabian, Latin 
American, Other/Multiracial. 
βPrior major fracture had to occur from 1991 to cohort entry (date of transplant). 
¶Includes individuals who received a pre-emptive transplant where the time spent on dialysis was defined as 0 years. 
‖We defined hemodialysis and peritoneal dialysis based on the modality the recipient first received. We defined pre-
emptive transplant as no evidence of hemodialysis or peritoneal dialysis prior to transplant. 
 
 
Table 5. 4. Univariable and multivariable analysis of risk factors for other fracture in 
kidney transplant recipients 
 Univariable analysis Multivariable analysis 
Risk Factor Hazard ratio 
(95% CI) 
Hazard ratio 
(95% CI) 
Age (per 5 year increase) 1.09 (1.02-1.17) 1.03 (0.96-1.10) 
Sex 
Men  
Women 
 
Reference 
0.99 (0.63-1.26) 
 
 
0.97 (0.68-1.39) 
Race   
White Reference  
Asian 0.67 (0.33-1.37) 0.67 (0.32-1.39) 
Black 0.59 (0.27-1.26) 0.47 (0.21-1.02) 
Other
€
 0.82 (0.49-1.39) 0.73 (0.43-1.26) 
Diabetes (vs. none) 2.2 (1.57-3.08) 2.19 (1.38-3.49) 
Fall with hospitalization in the year prior 
to the transplant date   (vs. none) 
2.37 (1.25-4.52) 2.05 (1.07-3.93) 
Length of time on dialysis prior to 
transplant (measured in years)
¶
 
1.06 (1.00-1.12) 1.07 (1.01-1.14) 
Type of donor    
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Living Reference  
Deceased 0.67 (0.47-0.92)  
Cause of end-stage renal disease   
Glomerulonephritis Reference Reference 
Cystic kidney disease 1.4 (0.8-2.47) 1.35 (0.76-2.39) 
Diabetes 2.47 (1.56-3.91) 1.40 (0.78-2.49) 
Renal vascular disease 2.40 (1.41-4.10) 2.11 (1.22-3.65) 
Other 2.04 (1.21-3.44) 2.03 (1.20-3.45) 
Pre-transplant dialysis modality
‖
   
Hemodialysis Reference  
Peritoneal dialysis 1.06 (0.74-1.53)  
Pre-emptive 0.43 (0.2-0.92)  
Donor age (per 5 year increase) 1.07 (1.01-1.14) 1.06 (0.99-1.12) 
Donor sex 
Men 
Women 
 
Reference 
0.83 (0.6-1.16) 
 
 
€Other was defined as a composite of: Indian Sub-Continent, Pacific Islander, Aboriginal, Mid East/Arabian, Latin 
American, Other/Multiracial. 
¶Includes individuals who received a pre-emptive transplant where the time spent on dialysis was defined as 0 years. 
‖We defined hemodialysis and peritoneal dialysis based on the modality they first received. We defined pre-emptive 
transplant as no evidence of hemodialysis or peritoneal dialysis prior to transplant. 
 
5.4 Discussion 
Of the transplant-specific risk factors available to us in this study, we found only 
diabetes or cystic kidney disease as the cause of ESRD and increasing age of the kidney 
donor were associated with a significantly increased major fracture risk; however, the 
strength of the association for the hazard ratios was only modest. Our results suggest that 
fracture prediction tools used in the general population may also be suitable to use in the 
transplant population given few transplant-specific risk factors predicted major fractures.  
We previously published a study of 321 kidney transplant recipients from 
Manitoba, Canada and found that FRAX was able to predict fracture risk; the area under 
the receiver operating characteristic curve value was 0.62; FRAX also seemed to be 
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reasonably calibrated with a similar observed and 10-year FRAX predicted major 
osteoporotic fracture probability (6.3% versus  5.6%) (10). However, the number of 
major osteoporotic fracture events was small (n=21), with correspondingly wide 95% 
confidence intervals (10). We hypothesized that a fracture prediction tool incorporating 
both general and transplant-specific risk factors may improve fracture prediction (10). In 
the current study only the cause of ESRD (diabetes and cystic kidney disease) and 
increasing age of the kidney donor reached statistical significance suggesting that a 
modified fracture prediction tool which includes transplant-specific risk factors may not 
be needed. Moreover, the low absolute fracture rate, the moderate strength of the 
transplant-specific risk factors, the large sample size needed to update a model, and the 
reasonable performance of the original FRAX model in kidney transplant recipients 
further suggests model updating may not be needed. However, diabetes may be important 
for clinicians to consider as an independent risk factor for fracture in kidney transplant 
recipients; similar to our study, previous studies have consistently found diabetes to be 
associated with an increased fracture risk in kidney transplant recipients (2, 18, 26). 
Future research should assess other potential transplant-specific risk factors (unavailable 
in our current analyses), including: change in body mass index after transplantation 
(weight changes found to increase fracture risk in the general population) and fibroblast 
growth factor 23 (suppresses mineralization of the bone matrix) (27, 28).  
Of concern, several of the risk factors for fracture identified in this study are 
becoming more common in recent eras of kidney transplant recipients. For example, we 
found diabetes as the cause of ESRD and older recipient age were significant risk factors 
for major fractures. The number of recipients with diabetes and the average recipient age 
has been increasing (29). Similar to results found in a previous study (30), increasing 
donor age was also associated with an increased risk of major fracture. This is concerning 
as there has been an increase in the number of recipients receiving a kidney from older 
donors (31, 32). It is important to note that donor age may only be a surrogate measure 
for recipient age, with kidneys from older donors often being allocated to older 
recipients; however, we found that the correlation between these two variables was weak. 
Nevertheless, the increase in the aforementioned risk factors may have important 
implications for fracture risk in future recipients.  
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Unfortunately, none of the risk factors for major fractures found in this study are 
easily modifiable. However,  a hospitalized fall in the year prior to transplant was a 
significant risk factor for other fractures; falls are  potentially  modifiable through the use 
of fall prevention programs (33-35). The paucity of modifiable risk factors is concerning 
as one of the best ways to prevent fractures in the general population is to provide therapy 
(e.g. bisphosphonates); the efficacy of these therapies in kidney transplant recipients is 
unclear (36). However, given that not many recipients sustained a fracture the lack of 
modifiable risk factors may be less of a concern. 
We found that risk factors for fracture may vary across fracture locations. For 
example, there were different risk factors for fracture between our two fracture 
classifications (major fracture locations versus other fracture locations). A possible 
explanation for this finding is that in the kidney transplant population risk factors for 
fractures are site specific. For example, similar to what some studies have found in the 
general population, in our study increasing recipient age and female recipient sex were 
both associated with an increased major fracture risk (37-39). However, increasing age 
and female recipient sex were not associated with an increased risk of other fractures. 
This provides a potential explanation for the results of a previous systematic review 
which found risk factors for fracture in kidney transplant recipients were inconsistent; 
studies in the review included different fracture locations (5). However, we cannot 
discount the possibility that the differences in risk factors across fracture locations found 
in this study were the result of a type II error. 
Strengths of this research deserve discussion. First, we are the first study to assess 
transplant-specific and general risk factors for major fractures. Given these fractures are 
associated with mortality and morbidity it is important to understand their risk factors 
(15-17). Second, to our knowledge, this is the first study to look at a previous fall with 
hospitalization as a risk factor for fracture in kidney transplant recipients. Limitations of 
the study are noted.  First, we were unable to assess drug use (e.g. glucocorticoids) as a 
potential risk factor for fracture; drug information in our databases was only available for 
a sub-cohort of kidney transplant recipients; therefore, our sample size would have been 
decreased, limiting statistical power. Second, we were unable to assess several risk 
factors, such as body mass index, due to a high proportion of missingness (>50%). Third, 
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the small number of fracture events may have limited statistical power and increased 
concerns about the validity of the model.  However, we selected a liberal p-value in our 
backward elimination analysis to ensure we were not excluding potentially important 
variables. Additionally, for risk factors that did not reach statistical significance the 
confidence intervals were narrow  with values gathered around the null value, decreasing 
our concerns about type II errors (40). Moreover, there were at least 10 events per 
variable with previous research suggesting type I errors and relative bias are uncommon 
when there are 5 or more events per variable (41). Finally, due to the small number of 
fracture events we were also not able to assess several of the other risk factors included in 
the FRAX algorithm (e.g. rheumatoid arthritis). Last, the generalizability of these results 
to other races/ethnic groups may be limited as the majority (72%) of our sample was 
white. 
In conclusion, these results provide further support for the use of prediction tools 
used in the general population to guide prognostication and treatment decisions in kidney 
transplant recipients. However, future studies with a larger sample size should assess the 
ability of other transplant-specific risk factors to predict fracture. 
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6.1 Introduction 
Kidney transplant recipients have a higher risk of fracture compared to the general 
population (1-3), although recent observations suggest that the absolute incidence is still 
low (4).  The reasons for this higher risk are multifactorial and include pre-existing 
chronic kidney disease-mineral and bone disorder (CKD-MBD) and glucocorticoid 
administration after transplantation (5). In the general population Osteoporosis Canada 
guidelines recommend bone mineral density (BMD) testing be done in individuals at a 
high risk of fracture, as a decreased BMD can help risk stratify those individuals at a 
higher risk of fracture (6-8). However, in the kidney transplant population the ability of 
BMD to predict fracture is unclear (9-11). Limited evidence can lead to substantial 
practice variability. Therefore, we conducted a population-based study to determine the 
frequency, total cost, and the variability in BMD testing across all six transplant centres 
in Ontario, Canada.  We also compared the frequency of BMD testing in transplant 
recipients to non-transplant reference groups (matching on age, sex, and date of cohort 
entry). 
 
6.2 Methods 
6.2.1 Design and Setting 
We used healthcare databases form Ontario, Canada contained at the Institute for 
Clinical Evaluative Sciences (ICES). These data sets were held securely in linkable files 
without direct personal identifiers, and were analyzed at ICES. In Ontario residents have 
universal healthcare. Ethics approval was obtained from Sunnybrook Health Sciences 
Centre (Toronto, Ontario, Canada).  
6.2.2 Data Sources 
Information on Ontario kidney transplant recipients is provided by the Canadian 
Organ Replacement Register. Information on Ontario physicians’ billing claims for 
inpatient and outpatient services is reported by the Ontario Health Insurance Plan 
(OHIP). The Ontario Registered Persons Database provides information on demographics 
and vital status. Prescription drug utilization data is provided from the Ontario Drug 
Benefit Plan (individuals who are ≥ 65 years are provided with drug coverage). It also 
provides information since April 1997 on special populations aged < 65 years who are 
113 
 
 
eligible for the program. The ICES Physician Database provides information on 
physician specialty. Emigration from the province was the only reason for loss to follow-
up (0.5% per year) (12).  
6.2.3 Primary Cohort 
6.2.3.1 Kidney Transplant Recipients 
We included all Ontario adults (age ≥ 18 years) with a first kidney transplant from 
July 1
st
, 1994 to December 31
st
, 2009 (excluding individuals with a previous transplant). 
We defined the date of the kidney transplant as the date of cohort entry (also referred to 
as the index date).  
6.2.4 Reference Cohorts 
We matched recipients on age (± 1 year), sex, and index date (± 1 year) to two 
non-transplant reference cohorts (healthy segment of the general population with no 
previous non-vertebral fracture [defined as proximal humerus, forearm, hip]; and healthy 
segment of the general population with a previous non-vertebral fracture). When 
permitted by the available sample, we matched one recipient to four persons from the 
non-transplant reference cohort.  
           6.2.4.1 Healthy Segment of the General Population with No Previous Non-
vertebral Fracture 
Using the index date distribution of the recipient cohort we randomly assigned an 
index date to the Ontario population (≥ 18 years). We excluded individuals with chronic 
kidney disease (including evidence of kidney transplantation or dialysis), osteoporosis 
(defined as a dual-energy x-ray absorptiometry examination followed by an osteoporosis 
diagnostic code within 1 year) (13), or a previous non-vertebral fracture (proximal 
humerus, forearm, hip) prior to index date (looked back to July 1, 1991).   
          6.2.4.2 Healthy Segment of the General Population with a History of Non-
vertebral Fracture 
As described above, using the index date distribution of the recipient cohort we 
randomly assigned an index date to the Ontario population; however, to enter the cohort 
the individual had to have sustained a non-vertebral fracture (proximal humerus, forearm, 
hip) in the 5 years prior to entering the cohort. Our cohort excluded chronic kidney 
disease patients (including evidence of kidney transplantation or dialysis).  
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6.2.5 Outcomes 
We used physician fee-for-service billings to identify BMD by dual energy x-ray 
absorptiometry and, prior to April 1998,  dual-photon absorptiometry tests (14). In 
Ontario, these data are largely complete with approximately 94% of physicians 
submitting such billing (15). These BMD billing codes have been successfully used in 
several prior studies (Table 6.1 describes codes utilized) (13, 16). We tabulated the 
number of BMD tests in the three years following kidney transplantation; multiple 
billings for a BMD test for a given person on the same day were counted as one test.  To 
calculate the total cost of the BMD tests we included all associated billings, even if there 
were multiple billings on the same day, and accounted for inflation. We included fee 
suffixes A, B, and C in the OHIP fee schedule. Fee suffix A was used prior to April 1, 
2001 to describe both the technical and physical component of the exam (17). After  
April 1, 2001 fee suffixes B (technical component of the exam) and C  (professional 
component) were required to be billed  separately (17).  
 
Table 6. 1. Database codes for bone mineral density tests 
 OHIP Fee Codes 
Dual-photon 
absorptiometry 
 
 
 
J654 Bone mineral density by single proton method 
J655 Total boday calcium proton actiation 
J656 Bone min. content dual-photon absorbtiomet. 2 or more sites 
J688 Bone mineral content by dual photon single site 
J854 Bone mineral density by single photon method 
J855 Total body calcium - neutron activation 
J856 Bone min. content dual-photon absorbtiomet. 2 or more sites 
J888 Bone mineral content by dual photon absorb 
Dual energy x-ray 
absorptiometry  
X145  Bmd - baseline test, one site 
X146 Bmd - baseline test, two or more sites 
X149 Bone mineral density high risk 1 site 
X152 Bone mineral density low risk 1 site 
X153 Bone mineral density low risk 2+ sites 
X155 Bone mineral density high risk 2+sites 
X157 Diag. rad. bone density (mineral content) measurement 
Abbreviations: OHIP, Ontario Health Insurance Plan 
 
6.2.6 Statistical Analysis 
To describe baseline characteristics for continuous data we used medians 
(interquartile range [IQR]) or means (standard deviation) and we used proportions to 
describe categorical data. To compare baseline characteristics between recipients with at 
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least one BMD test to those without a BMD test we used the chi-square test, Mann-
Whitney U test, or Student’s t-test as appropriate. We stratified the frequency of BMD 
testing by sex (men versus women) and age at the time of transplantation (< 50 versus ≥ 
50 years). We used logistic regression to determine if there was a statistically significant 
difference across transplant centres in the decision to perform at least one BMD test after 
transplantation. We adjusted for covariates that may influence a physician’s decision to 
order a BMD test (age, sex, previous fracture,  and comorbidities [as measured by the 
Charlson comorbidity index(18)]). To determine if there were changes over time in the 
number of BMD tests performed we used the Cochran-Armitage test for trend. To 
compare the number of recipients who had at least one BMD test to the matched non-
transplant reference groups we used the McNemar’s test. We considered a two-sided p-
value < 0.05 as statistically significant.  We conducted the analyses using the Statistical 
Analysis Software (SAS version 9.3). 
 
6.3 Results 
6.3.1 Baseline Characteristics 
We included 4821 kidney transplant recipients with a total observation time of 
13,943 person-years; 304 (6.3%) recipients died within three years.  Comparing 
recipients who had at least one BMD (n=2786) to recipients who did not (n=2035), 
recipients with at least one BMD were significantly more likely to be women (66.4 
versus 33.6%; P<0.001), to have received a transplant in the later years of cohort entry 
(2006-2009 versus 1994-1997) (67.9 vs. 32.1%; P<0.001), and were older (50 versus 49 
years; P=0.04); there was no significant difference in history of a previous non-vertebral 
fracture prior to transplant (2.4% vs. 2.0%) (Table 6.2). Matching characteristics were 
similar between recipients and the non-transplant reference groups (Table 6.3).  
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Table 6. 2. Characteristics of kidney transplant recipients classified by presence of at 
least one bone mineral density (BMD) test in the 3 years after transplantation
 
 Bone Mineral Density Test  
Characteristic 
Yes 
(n=2786) 
No 
(n=2035) 
      P-value 
Age, years 50 (39-59) 
 
49 (38-59) 
 
0.04 
 
Women 1182 (66.4%) 
 
599 (33.6%) 
 
<0.001 
 
Transplant era 
   1994-1997 
   1998-2001 
   2002-2005 
   2006-2009 
 
 
290 (31.7%) 
 
631 (56.8%) 
 
769 (65.1%) 
 
1096 (67.9%) 
 
 
 
624 (68.3%) 
 
480 (43.2%) 
 
413 (34.9%) 
 
518 (32.1%) 
 
 
Diabetes 690 (24.8%) 
 
565 (27.8%) 
 
0.02 
 
Previous non-vertebral 
fracture
‡
 
68 (2.4%) 
 
41 (2.0%) 
 
0.33 
 
 
Charlson Comorbidity 
Index
¥
 
 
2.6 ± 1.0 
 
2.7 ± 1.2 
 
0.002 
Data are median (interquartile range), mean (± SD) or n (%)  
Abbreviation: BMD, bone mineral density; SD, standard deviation 
‡Prior non-vertebral fracture was defined as a composite of proximal humerus, forearm, hip fractures from 1991 to 
transplant date (cohort entry).  
¥All recipients with a Charlson Comorbidity Index (CCI) of 0 were given a score of 2 and those with a score of 1 were 
given a score of 3; one of the variables in the CCI is presence of end-stage renal disease which automatically results in 
recipients receiving a score of 2. 
 
 
 
 
 
 
 
 
 
 
 
<0.001 
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Table 6. 3. Baseline characteristics of reference groups
¥ 
Characteristic 
 
Kidney transplant 
recipients 
(n=4821) 
Healthy segment of the 
general population 
with no previous non-
vertebral fracture 
(n=19,284) 
Healthy segment of the 
general population 
with a previous non-
vertebral fracture 
(n=4821) 
Age, years 50 (38-59) 50 (38-59) 49 (38-59) 
Women 1781 (36.9%) 7124 (36.9%) 1781 (36.9%) 
Era 
1994-1997 
1998-2001 
2002-2005 
2006-2009 
 
914 (18.9%) 
1111 (23.1%) 
1182 (24.5%) 
1614 (33.5%) 
 
 
3655 (19.0%) 
 
4424 (22.9%) 
 
4776 (24.8%) 
 
6429 (33.3%) 
 
 
906 (18.8%) 
 
1083 (22.4%) 
 
1214 (25.2%) 
 
1618 (33.6%) 
Diabetes 1255 (26.0%) 1527 (7.9%) 503 (10.4%) 
Prior non-vertebral 
fracture
‡ 
109 (2.3%)   
Data are median (interquartile range) or n (%)  
¥ Matched on age (±1 year), sex, and index date (±1 year) 
‡ Prior non-vertebral fracture defined as a composite of proximal humerus, forearm, hip fractures from 1991 to 
cohort entry.  
Note: The reference group healthy segment of the general population with no previous non-vertebral fracture has no 
previous fracture as this was a requirement to enter the cohort. The reference group healthy segment of the general 
population with a previous non-vertebral fracture has 100% sustaining a fracture prior to cohort entry as this was a 
requirement for cohort entry. 
 
 
 
6.3.2 Bone Mineral Density (BMD) 
Approximately 58% (n=2786) of kidney transplant recipients had at least one 
BMD test within three years of receiving their transplant and 22% (n=1047) of recipients 
had received a BMD test in the three months following transplant. Among those with at 
least one BMD test, the median time after transplant to first BMD was 133 days 
(interquartile range 62-372 days). A total of 68.1% of female recipients aged ≥ 50 years 
received a BMD test, a higher proportion than the other three age and sex strata 
(P<0.005) (Table 6.4). There were a total of 4802 BMD tests (median 1, range 0-6 tests 
per recipient) and almost one-third (31.7%) of recipients received more than one BMD 
test in the three years after transplant (Table 6.5). The total cost of these tests was 
$614,997 (CAD 2014 equivalent dollars) (approximately $128 per recipient) across the 
18-year study period.  
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Table 6. 4. Number (proportion) of kidney transplant recipients with at least one bone 
mineral density test in the 3 years after transplantation by age and sex 
 Kidney transplant recipients 
(n=4821) 
Overall 
 
2786 (57.8%) 
 
Women < 50 years 
(n=944) 
 
612 (64.8%) 
 
Women ≥ 50 years 
(n=837) 
 
570 (68.1%) 
 
Men < 50 years 
(n=1463) 
 
741 (50.7%) 
 
Men  ≥ 50 years 
(n=1577) 
 
863 (54.7%) 
 
 
Table 6. 5. Frequency of bone mineral density tests performed in kidney transplant 
recipients (n=4821) 
Number of BMD 
tests per recipient 
N (%) 
0 2035 (42.2%) 
1 1259 (26.1%) 
2 1081 (22.4%) 
3 412 (8.5%) 
4 27 (0.6%) 
≥5 7 (0.1%) 
Abbreviation: BMD, bone mineral density 
 
The proportion of recipients who received at least one BMD test in follow-up 
varied from 15.6 to 92.1% (P<0.001) across the six Ontario transplant centres. The 
variation across transplant centres persisted after adjustment for recipient age, sex, 
history of a previous non-vertebral fracture, and comorbidities (logistic regression model, 
P<0.001). When information on the ordering physician was available (96% of tests), 
BMD tests for recipients were most commonly ordered by nephrologists (67.8%) and 
family physicians (16.5%), followed by general internists (5.0%), rheumatologists 
(3.4%),  and endocrinologists (2.4%).  
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6.3.3 Non-transplant Reference Groups 
In the healthy segment of the general population with a previous non-vertebral 
fracture (n=4821), there were 863 BMD tests (range 0-4) in the three years after the index 
date compared to 4802 BMD tests in the recipient population. In the healthy segment of 
the general population with no previous non-vertebral fracture (n=19,284), there were 
1936 BMD tests (range 0-4). There were a significantly higher number of kidney 
transplant recipients with at least one BMD (58%) in the three year follow-up versus both 
matched reference groups (13.8 % healthy segment of the general population with a 
previous non-vertebral fracture and 8.5% healthy segment of the general population with 
no previous non-vertebral fracture, respectively, P value < 0.001 for each paired 
comparison) (Table 6.6). The proportion of individuals who received at least one BMD 
test in follow-up significantly increased over time in all three groups (recipients, 20.9% 
in 1994 and 66.4% in 2009; healthy segment of the general population with a previous 
non-vertebral fracture, 3.5% in 1994 and 15.6% in 2009; healthy segment of the general 
population with no previous non-vertebral fracture, 2.6% in 1994 and 8.5% in 2009; P for 
trend < 0.001) (Figure 6.1). 
 
Table 6. 6. Number (proportion) of kidney transplant recipients with at least one bone 
mineral density test in the 3 years of follow-up compared to reference groups matched on 
age, sex, and index date
¥
  
Population        N 
      (%) 
    P-value
‡
 
Kidney transplant recipients 
(n=4821) 
 
2786 
(57.8%) 
 
Reference 
Healthy segment of the general population 
with no previous non-vertebral fracture 
(n=19,284) 
1645 
(8.5%) 
<0.001 
 
Healthy segment of the general population 
with a previous non-vertebral fracture 
(n=4821) 
 
665 
(13.8%) 
 
<0.001 
¥ Matched on age (±1 year), sex, and index date (±1 year) 
‡Paired P-value 
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Figure 6. 1. Kidney transplant recipients, individuals from the healthy segment of the 
general population with a previous non-vertebral fracture (GPPF), and individuals from 
the healthy segment of the general population with no previous non-vertebral fracture 
(GPNPF) with at least one bone mineral density test in the 3 years after cohort entry, 
presented by year of cohort entry (P for trend <0.001 for all 3 cohorts). 
6.3.4 Bisphosphonates 
  Of the 3540 recipients who had prescription drug coverage through universal 
healthcare benefits, 646 (18.2%) were prescribed bisphosphonates in the first 3 years 
after transplant. Of recipients prescribed bisphosphonates, 548 (84.8%) of these 
prescriptions were filled at a median of 57 days (IQR 21 to 175 days) after the BMD test, 
with 417 receiving a bisphosphonate prescription in the first six months after a BMD test.   
 
6.4 Discussion 
In Ontario, Canada we found that over half of the kidney transplant recipients 
received at least one BMD test in the subsequent three years after transplant and many 
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recipients received multiple tests. The frequency of BMD testing varied widely by centre 
– from as few as 15% of recipients receiving a BMD test to as many as 92%, and this 
variability was not explained by recipient characteristics. Kidney transplant recipients 
were significantly more likely to receive a BMD compared to two matched non-transplant 
reference groups. Our results suggest that BMD testing is commonly performed in kidney 
transplant recipients despite conflicting evidence in the literature supporting its 
widespread use.  
The results of our population-based multicentre study extend the findings of two 
prior single centre reports with smaller sample sizes. In the first study of kidney transplant 
recipients (n=326) from Manitoba, Canada,  almost 60% of  recipients were found to have 
had at least two BMD tests within approximately eight years of their transplant (19). The 
second study from Akaberi et al. found that 670 BMD tests were performed in 238 kidney 
transplant recipients (75% had at least two BMD tests) from Sweden over 12 years (9).   
The centres in these two prior studies had protocols in place for routine BMD testing, and 
so the frequency of BMD testing would be expected to be high. In contrast, in our study 
only a few of the transplant programs had a protocol for BMD testing (information 
provided by the six Ontario transplant centres, personal communication). 
Particularly striking are the high number of kidney transplant recipients who had 
multiple BMD tests in the three years after transplantation, at a high cost to the healthcare 
system. For example, almost one-third of kidney transplant recipients received two or 
more BMD tests within three years of their transplant;  in the non-transplant population 
the benefits of performing multiple BMD tests over several years has been questioned 
(20, 21), especially given the increasing knowledge of unwarranted screening harms (22, 
23).  
The variability in BMD testing we observed across transplant centres was in the 
setting of universal healthcare benefits. It is possible BMD testing variability across 
transplant centres might be even greater in jurisdictions without such healthcare benefits, 
as economic factors may also influence testing.  
The benefit of BMD tests in kidney transplant recipients remains uncertain. First, 
the utility of BMD in predicting fracture in kidney transplant recipients is unclear (9-11). 
For example, the Kidney Disease Improving Global Outcomes (KDIGO) guidelines for 
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Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) suggest that patients 
with an estimated glomerular filtration rate > 30 mL/min/1.73 m
2
 have their BMD 
assessed in the first three months after kidney transplant if they received glucocorticoids 
or have other risk factors for osteoporosis (5); given the limited evidence, this suggestion 
was given the weakest grade of evidence (5). It is important to note that this 
recommendation is being reassessed in the revised version of the guidelines in light of 
recent evidence finding that BMD may be predictive of fracture in individuals with CKD, 
including dialysis (24-26); however, there is still conflicting evidence in kidney 
transplant recipients (9-11).  Second, given the high incidence of adynamic bone disease 
(i.e., low turnover) in kidney transplant recipients, the KDIGO guidelines suggest that a 
bone biopsy may be needed to guide treatment decisions; this limits the clinical 
usefulness of BMD testing post-transplant (5). Last, and perhaps most relevant, recent 
research suggests in contrast to what has been previously reported, most kidney 
transplant recipients will not fracture and have an average mean BMD for age and sex (4, 
9, 19, 27). Note, however, that the lower than expected fracture incidence and normal 
BMD may be the result of increased monitoring of bone health after transplant.  Taken 
together this suggests there may be little need to perform BMD tests routinely. New high-
quality information from prospective observational studies and clinical trials is needed to 
guide the optimal recommended timing and frequency of BMD testing. Such studies 
should also assess the ability of BMD to predict fracture and its cost-effectiveness.  
It is important to note that BMD testing may alter clinical practice.  Many kidney 
transplant recipients were prescribed a bisphosphonate in the first six months after 
receiving a BMD test. However, the efficacy of this and other fracture prevention 
strategies in kidney transplant recipients remains uncertain (28).  
Strengths of this study should be recognized. To our knowledge we are the first 
multicentre study and largest study (n=4821) to assess BMD testing practices across 
several kidney transplant centres. Moreover, to help put the frequency of BMD testing into 
context we are the first study to compare BMD frequency in recipients to matched non-
transplant reference groups.  
Study limitations are worth noting. We did not have drug dispensing information 
for the entire transplant cohort (only those who were covered by provincial drug 
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benefits). While we were unable to characterize immunosuppression use at the patient 
level, during the time frame of this study steroids were nearly universally prescribed at 
the Ontario transplant centres. Additionally, we only knew if a BMD was done, without 
information on the BMD value. However, the former supported the primary objective of 
this study - to determine the frequency of BMD testing in the first three years after 
transplant across several kidney transplant centres. Finally, we did not assess the impact 
of the KDIGO CKD-MBD guidelines on BMD testing. However, this guideline received 
the weakest grade of evidence; therefore, its uptake would likely be variable across 
transplant centres as demonstrated in this study. 
  In conclusion, many kidney transplant recipients receive a BMD test in the three 
years after transplantation but there was wide practice pattern variation. These results 
highlight the need for further studies to investigate the utility, frequency, timing, and 
cost-effectiveness of BMD testing in kidney transplant recipients. 
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CHAPTER 7: Discussion and Conclusions 
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7.1 Introduction 
The overall goal of this thesis was to better understand the epidemiology of 
fracture in adults with kidney disease and to use this information in the care of this 
unique patient population.  The specific objectives were 1) to summarize the incidence 
and risk factors for fracture in kidney transplant recipients; 2) to determine the predictive 
ability of FRAX in individuals with reduced kidney function compared to individuals 
with normal kidney function; 3) to estimate the incidence of fracture in kidney transplant 
recipients; 4) to determine risk factors for fracture in kidney transplant recipients; and 5) 
to examine the frequency, total cost, and the variability in bone mineral density (BMD) 
testing in kidney transplant recipients across Ontario transplant centres. Data sources 
utilized in this thesis allowed for a comprehensive examination of the epidemiology of 
fracture in a Canadian context, addressing many limitations of previous research. 
 
7.2 Summary of Key Findings 
7.2.1 Systematic Review of Fracture Risk in Kidney Transplant Recipients  
 Chapter 2 systematically summarized cohort studies that provided information on 
fracture incidence and risk factors in kidney transplant recipients.  
 The incidence and risk factors for fracture in kidney transplant recipients were 
variable across studies. Potential reasons for this variability across studies included 
differences in study methodological quality, inclusion of different fracture locations, and 
differences in recipient characteristics. The results of this study allowed for the 
identification of several knowledge gaps in the literature. Specifically, previous studies 
had a short follow-up time;  given recipients are surviving longer there is a need for 
studies with an increased follow-up time (1). Moreover, few previous studies included 
recipients who recently received a transplant; given changes in clinical practice (2-4) and 
changes in recipient characteristics there was a need for studies that included recently 
transplanted kidney transplant recipients (4, 5). With respect to risk factors there was a 
need to assess other potentially relevant risk factors (e.g. falls) and a need to assess risk 
factors specific to different fracture locations.   Therefore, these results provided the 
information required to design high quality studies in chapters 4 and 5 of this thesis. 
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7.2.2 Comparison of Fracture Prediction among Individuals with Reduced and          
Normal Kidney Function 
Chapter 3 examined the predictive ability of FRAX in individuals with reduced 
kidney function (estimated glomerular filtration rate [eGFR] <60 mL/min/1.73 m
2
) 
compared to individuals with normal kidney function (eGFR ≥ 60 mL/min/1.73 m2) using 
data from the Canadian Multicentre Osteoporosis Study (CaMos).   
 FRAX was able to predict major osteoporotic fractures in individuals with 
reduced kidney function with similar accuracy to individuals with normal kidney 
function. Specifically, the 5-year observed major osteoporotic fracture risk in individuals 
with reduced kidney function was comparable to the FRAX predicted fracture risk.  
Moreover, there were no significant differences in the area under the curve (AUC) values 
for FRAX when comparing individuals with reduced and normal kidney function. These 
results paralleled findings from a study conducted by Jamal et al. which found FRAX 
may be an accurate tool for clinicians to use to predict fractures in individuals with 
reduced kidney function (6). Similarly, these results are consistent with findings from a 
study conducted by Naylor et al. in kidney transplant recipients (a group that experiences 
similar changes in bone mineral metabolism to those with non-transplant chronic kidney 
disease [CKD]) which found observed and FRAX predicted fracture risks were 
concordant and  AUC values were statistically significant (7).  
              Taken together the results of chapter 3 suggest that FRAX may be a useful tool 
for clinicians to use to predict fracture and help guide treatment decisions in individuals 
with reduced kidney function.  However, validation of FRAX with a different data source 
is needed before it can be routinely used in clinical practice. In particular, the 
discrimination and calibration of FRAX should be assessed across different levels of 
kidney dysfunction (i.e., stage 3a, stage 3b, stage 4 and stage 5 CKD). Moreover, given 
the limited sample size in this study, larger studies are also needed before its use is 
implemented into routine clinical practice. 
 7.2.3 Fracture Incidence in Kidney Transplant Recipients 
Chapter 4 used several of Ontario’s large healthcare databases held at the Institute 
for Clinical Evaluative Sciences (ICES) to examine the incidence of fracture and falls in 
kidney transplant recipients. 
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In contrast to previous studies which found kidney transplant recipients have a 
high fracture risk (3, 8-15) in this study the 10-year cumulative incidence of hip fracture 
was 1.7% (where a high risk is defined as ≥ 3% in clinical guidelines) (16, 17). These 
findings are consistent with a previous Canadian study conducted by Naylor et al. where 
the 10-year incidence of major osteoporotic fracture in kidney transplant recipients from 
Manitoba, Canada was approximately 6% (where a low risk is defined as <10%) (7, 17, 
18); however, cohort entry was an average of 1-year post-transplant preventing an 
accurate estimation of fracture (7). These findings are also consistent with another study 
conducted by Naylor et al. which found  that bone mineral density (BMD) in kidney 
transplant recipients from Manitoba, Canada was not below the average for age and sex 
(19).  
Kidney transplant recipients had a significantly higher incidence of non-vertebral 
fracture compared to a healthy segment of the general population (no kidney disease and 
no bone disease; low fracture risk group) and the non-dialysis CKD population (group 
with an increased fracture risk), but had a significantly lower incidence of non-vertebral 
fracture compared to a healthy segment of the general population with no kidney disease 
and a previous non-vertebral fracture (group with an increased fracture risk). Therefore, 
although kidney transplant recipients had a low absolute fracture risk they still had a high 
relative fracture risk. 
Many kidney transplant recipients experienced a fall with hospitalization with a 3-
year cumulative incidence of 11.1% in women aged ≥ 50 years. These findings are 
comparable to a Canadian study conducted by Naylor et al. where the 3-year cumulative 
incidence of falls with hospitalization in the non-transplant CKD population was  9.1% in 
women aged ≥65 years with stage 4 CKD and 13.1% in individuals with stage 5 CKD 
(end-stage renal disease) (20).  The high incidence of falls highlights the need for further 
study assessing the effectiveness of interventions to prevent falls in kidney transplant 
recipients. 
Despite bone mineral metabolism changes and administration of steroids after 
transplantation results from chapter 4 suggest that bone health in kidney transplant 
recipients is better than previous research has suggested. However, it is important to 
emphasize that these encouraging results may be unique to Canadian recipients due to 
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variability in fracture rates across countries (21, 22), differences in recipient 
comorbidities (23), and potential practice pattern differences. Moreover, it is important to 
note that even though a low absolute fracture risk was observed in this study, fracture 
rates in this population should be continually monitored due to several factors which 
could potentially increase fracture rates, including: an increasing average recipient age 
(5), an increase in recipients with comorbidities (e.g. diabetes) (5), and an increase in 
suboptimal quality kidneys (24, 25). 
     7.2.4 Risk Factors for Fracture in Kidney Transplant Recipients 
                Chapter 5 used healthcare administrative databases to examine transplant 
specific (e.g. donor age) and general (e.g. sex) risk factors for major fractures (hip, 
forearm, proximal humerus, and clinical vertebral) and other fractures (excluding the 
major fractures, and the skull, fingers, and toes). 
The multivariable analysis revealed that the general risk factors associated with a 
greater risk of major fracture were older recipient age and female sex. Transplant-specific 
risk factors associated with a greater risk of major fracture included diabetes or cystic 
kidney disease as the cause of end-stage renal disease (ESRD) (compared to 
glomerulonephritis as the reference cause) and older donor age. General risk factors 
associated with a greater risk of other fractures were diabetes and a prior fall with 
hospitalization. The transplant-specific risk factors associated with an increased risk of 
other fractures were length of time on dialysis prior to transplant and renal vascular 
disease or other as the cause of ESRD (compared to glomerulonephritis as the reference 
cause).  
            Few of the transplant-specific risk factors that were available to assess in chapter 
5 predicted major fractures in the post-transplant period with any significance. Therefore, 
there may not be a need to create a modified FRAX tool that incorporates transplant-
specific risk factors; as previously discussed, Naylor et al. found FRAX may be a useful 
tool for fracture prediction in kidney transplant recipients with an area under the receiver 
operating characteristic curve value of 0.62 and a comparable observed and FRAX 
predicted fracture risk (7). Rather, fracture prediction tools used in the general population 
in combination with the use of a few independent transplant-specific risk factors could be 
used for prognostication. For example, clinicians could use the FRAX score in 
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combination with information on whether the recipient had diabetes as the cause of their 
ESRD to guide treatment decisions. Unfortunately, risk factors for fracture identified in 
chapter 5 are not easy to modify; this is concerning given that the efficacy of fracture 
prevention therapy (e.g. bisphosphonates) in kidney transplant recipients is uncertain 
(26). 
7.2.5 Bone Mineral Density Testing in Kidney Transplant Recipients 
Chapter 6 examined the frequency, total cost, and variability in bone mineral 
density (BMD) testing in kidney transplant recipients across the six transplant centres in 
Ontario, Canada, from 1994 to 2009 using ICES databases.  
 There were a total of 4802 BMD tests performed in 4821 kidney transplant 
recipients in the first three years after transplant (range 0 to 6), costing approximately 
$600,000 (2014 CAD equivalent dollars). The proportion of recipients who received at 
least one BMD test varied widely across the six transplant centres (15.6 to 92.1%). This 
finding is similar to a study conducted in the general population which examined BMD 
testing patterns in Ontario from 1992-1998, a time period when there was a lack of 
consensus on BMD guidelines, finding there was significant regional variation across 
Ontario in the number of BMD tests performed (range 0.2 to 47.1 tests per 1000 women) 
(27).    
Overall the results of chapter 6 demonstrate that a large number of BMD tests 
were performed in kidney transplant recipients with many recipients receiving multiple 
tests, despite conflicting evidence to support their ability to predict fracture (28-30). Even 
in the general population, where the utility of BMD has been well established, the 
frequency and timing of BMD tests has been questioned with recent studies finding there 
is little benefit of repeating BMD tests within several years (31, 32). This is an important 
finding as the harms of unwarranted screening have become increasingly recognized, and 
many guidelines now recommend less frequent screening (33, 34). Given how frequently 
these tests are being performed, prospective studies are needed to determine the optimal 
timing and frequency of BMD testing and the ability of BMD to predict fracture. 
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7.3 Implications 
7.3.1 Clinical Practice Guidelines 
           Currently kidney disease patients are not discussed in the Osteoporosis Canada 
Clinical Practice guidelines and are minimally discussed in the United States National 
Osteoporosis Foundation guidelines (35, 36). Given greater than 30% of adults over the 
age of 60 years have CKD these guidelines are failing to provide advice for a large 
segment of the population who are at an increased fracture risk (37). The results in 
chapter 3 combined with results from a study conducted by Jamal et al. (6) provide some 
evidence to support the use of FRAX in the non-transplant CKD population; currently, 
Osteoporosis Canada and the National Osteoporosis Foundation only support the use of 
FRAX in the non-kidney disease general population (35, 38). Results from chapter 4 
suggest guidelines should highlight that kidney transplant recipients have a significantly 
higher relative fracture risk compared to the healthy general population; therefore, these 
individuals should be monitored more closely by clinicians and counseled on potential 
preventative actions for fracture (e.g. weight bearing exercise, bisphosphonates).  
The results of this thesis also indicate that a discussion on falls is needed in the 
Kidney Disease Improving Global Outcomes (KDIGO) guidelines for Chronic Kidney 
Disease-Mineral and Bone Disorder (CKD-MBD) (43). Chapter 4 found falls were 
common in recipients and chapter 5 found falls were a significant risk factor for other 
fractures (excluding the major fractures, and the skull, fingers, and toes). However, 
currently the guidelines provide no discussion of falls in the context of kidney transplant 
recipients. Regarding the non-transplant CKD population falls were minimally discussed 
with the guidelines simply stating that these individuals may experience more falls which 
may impact fracture risk (43). In chapter 3 a previous fall in combination with T-scores 
was found to discriminate between individuals who did and did not fracture providing 
support that kidney disease patients who fall should be given a fracture risk assessment. 
Recognizing the important relationship between falls and fractures (39), in the general 
population Osteoporosis Canada guidelines provide an in-depth discussion of falls and 
strategies to prevent falls (e.g. exercise programs); the guidelines also state that 
management of falls is integral to reducing the number of fracture events in Canada (18).  
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7.3.2 Clinical Prognostication  
Accurately identifying kidney disease patients who are at a high fracture risk is 
important to appropriately target high risk groups for fracture prevention, diagnosis, and 
therapeutic trials. Chapter 3 revealed FRAX may be an accurate tool to predict fractures 
in individuals with reduced kidney function and guide treatment decisions. Given 
concerns about the safety and efficacy of bisphosphonates in individuals with more 
severe decrements in kidney function applying early therapeutic intervention could 
conceivably prevent fractures later on when bisphosphonates are contraindicated (40, 41); 
research in the general population has found that due to bisphosphonates long half-life 
(40) residual effects of the drug may occur years after discontinuation (42-44). With 1 in 
10 women > 65 years of age with ESRD sustaining a fracture over three years (20) and 
over 60% of dialysis patients dying after sustaining a hip fracture, early preventative 
therapy could be particularly important (45). Regarding kidney transplant recipients, 
Naylor et al. previously concluded that the discrimination and calibration of FRAX in 
kidney transplant recipients may be improved by adding transplant specific risk factors 
(7). However, chapter 5 found few transplant-specific risk factors reached statistical 
significance suggesting a modified version of FRAX may not need to be developed for 
kidney transplant recipients. However, diabetes might be an additional risk factor for 
clinicians to use to help identify recipients who have a high fracture risk, and who may 
benefit from fracture prevention strategies such as a lower dose of steroids. 
7.3.3 Clinical Trials 
Therapies are needed to safely prevent fractures in individuals with advanced 
kidney disease (26, 46, 47). Clinical trials that assess these therapies need to enroll 
individuals who have a high risk of the outcome to ensure adequate power (48). The 
results of chapter 3 demonstrate that FRAX may be useful to identify non-transplant 
CKD patients who have a high fracture risk and would benefit from the inclusion in 
clinical trials. Regarding kidney transplant recipients, chapter 4 found that due to the low 
number of fracture events thousands of recipients would need to be enrolled in clinical 
trials to ensure adequate power. As a result, multicentre collaboration would be required 
to obtain an adequate sample size. However, given the low absolute fracture risk in 
kidney transplant recipients there may not be a need for these trials. 
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7.3.4 Informed Consent 
Previous research suggests that in the early post-transplant period recipients have 
a higher fracture risk compared to individuals on dialysis (14); however, chapter 4 
revealed that post-transplant the absolute fracture risk is low. This is reassuring as 
individuals who receive a transplant not only have improved survival and quality of life 
compared to dialysis patients but also have a low absolute fracture risk (1, 49, 50). Given 
fractures are associated with morbidity, mortality, and a decreased quality of life this 
information is important to provide to potential kidney transplant recipients as part of the 
informed consent process (51-53).  
  
7.4 Strengths and Limitations 
7.4.1 Study Strengths 
Strengths of this thesis have been highlighted in the discussion section of each 
chapter; however, several key strengths of this thesis deserve mention. First, this thesis 
provided a comprehensive examination of fracture in Canadian kidney disease patients. It 
was crucial that Canadian studies were conducted as several factors may result in 
differential fracture rates across countries, including: Canadians have lower vitamin D 
levels (low vitamin D is a risk factor for fracture) (54, 55); universal healthcare access 
(Americans less likely to regularly see a doctor and be on needed medications) (56); 
different patient population (e.g. different racial distribution in the US) (23); and potential 
differences in immunosuppressant protocols. Indeed, the results of chapter 4 confirmed 
that fracture rates in recipients were lower than fracture rates found in the United States.  
Second, in this thesis several methods were employed to ensure fracture events 
were accurately captured. In chapter 3 self-reported fractures were required to be verified 
by structured interviews to obtain more detailed information about the fracture event 
and/or by the treating physician or hospital (57). The fracture codes used in chapters 4 
and 5 were valid (>90% sensitivity, ≥ 85% specificity, > 80% positive predictive value) 
(58-65). Moreover, procedural codes were required to accompany hip, forearm, and 
femoral shaft diagnostic codes to increase their accuracy (58, 64, 66); previous literature 
has found this combination increases accuracy compared to diagnostic or procedural 
codes alone (58, 64, 66) . For example, Hudson et al., conducted a systematic review and 
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found that when using diagnostic codes alone the positive predictive value for hip 
fracture was 63-96% but increased to 86-98% when including both diagnostic and 
procedural codes (58); therefore, previous studies may have been overestimating the 
number of fractures in recipients.  
Third, loss to follow-up was minimal. In chapter 3 multiple methods were 
employed to retain over 96% of participants, including: sending a yearly birthday card,  
sending a yearly non-denominational Christmas card (67), and obtaining contact 
information from next of kin (57). For chapters 4, 5, and 6 loss to follow-up was also 
minimal as data from Ontario healthcare administrative databases was utilized where all 
residents of Ontario are provided with universal access to physician and hospital services. 
We also only included permanent residents from Ontario with less than 0.5% emigrating 
from the province each year (68).      
Last, the studies in this thesis were the first to understand the epidemiology of 
fracture in kidney disease patients in the context of several reference groups. In chapter 3 
the utility of FRAX in individuals with reduced kidney function was compared to 
individuals with normal kidney function to determine if kidney function affected FRAX’s 
performance. Similarly, in chapters 4 and 6 fracture risk and the number of BMD tests 
performed in recipients were compared to several reference groups.   
7.4.2 Study Limitations 
Limitations of this thesis are recognized and described in the discussion section of 
each chapter. Overall this research had some limitations. First, some data was missing 
from both data sources used in this thesis. In chapter 3 many individuals were excluded 
due to a missing eGFR measurement in the CaMos database. However, in an additional 
analysis multiple imputation was used to handle missing eGFR values and similar results 
to the complete case analysis were found (Appendix C). Although many of the data 
sources contained at ICES are robust, there was a considerable amount of missingness for 
several transplant variables that would have been of interest to assess as potential risk 
factors for fracture (e.g. body mass index). Moreover, drug information was missing for 
individuals who were <65 years and were not covered under the Ontario Special Drug 
Benefits Plan. However, the many benefits of secondary datasets (large sample size; 
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generalizability; feasibility) made using ICES datasets the most appropriate option to 
study kidney transplant recipients in this thesis. 
Second, the studies contained in this thesis may have under-captured fracture 
events.  Using ICES databases vertebral fractures were not able to be included in the 
primary analysis of fracture incidence  with only one-third coming to clinical attention 
(69). To increase the reliability of capturing vertebral fractures a prospective study design 
that utilizes x-rays (e.g. CaMos) would need to be utilized. However, prospective studies 
are costly and would take several years to complete. In the CaMos database fracture 
events were self-reported and therefore, some events may have been missed. However, 
previous studies comparing self-reported fractures to hospital records have found that the 
number of false negatives is low (<3%) and self-report of fractures is more accurate 
compared to many other self-reported items (e.g. myocardial infarction) (70-73). 
Additionally, CaMos requires individuals to complete a fracture questionnaire each year 
and if individuals failed to return the questionnaire they were censored at the time of the 
last questionnaire. Although this could potentially introduce selection bias (individuals 
who left the study could be sicker and thus might be more likely to fracture), as 
previously discussed loss to follow-up was minimal. 
          Third, the low number of fracture events prevented the conduction of some 
meaningful analyses and decreased statistical power. In chapter 3 it would have been of 
value to assess the discrimination and calibration of FRAX for hip fracture alone given 
the significant morbidity and mortality associated with these fractures (74, 75). The small 
number of fracture events also limited statistical power and as a result it was emphasized 
in chapter 3 that further studies with larger sample sizes are needed before FRAX should 
be used regularly in clinical practice.  In chapter 4 it would have been of value to stratify 
the incidence of non-vertebral fracture in kidney transplant recipients by presence of a 
previous non-vertebral fracture, given a previous fracture is a strong risk factor for a 
future fracture in the general population (76). Moreover, assessing secular trends in 
fractures would have provided insight about potential reasons for the low absolute 
fracture risk in kidney transplant recipients. To account for the small number of fracture 
events in chapter 4 each recipient was matched to a minimum of one individual from the 
reference groups to increase statistical power (77, 78). For chapter 5 the small number of 
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fracture events prevented several risk factors for fracture from being assessed and risk 
factors were not able to be stratified by sex (risk factors for fracture differ by sex in the 
general population) (79, 80).  Given the low number of fracture events in chapter 5 the 
issue of power was discussed as a limitation and a recommendation for the conduction of 
future studies with larger sample sizes was provided. 
Lastly, the external generalizability of these results may be limited. The majority 
of individuals in this thesis were of white race; therefore, results may not be generalizable 
to non-white races. Fracture rates have been found to be variable across races; for 
example, white individuals have been found to have a higher fracture risk compared to 
black individuals (81).  Risk factors for fracture have also been found to vary across races 
(82). Moreover, given the variation in fracture rates across countries these results may 
only generalize to the Canadian population (83).  
 
7.5 Future Directions 
This thesis addressed numerous limitations of previous studies done in the field; 
however, there are still many unanswered questions regarding the epidemiology of 
fracture in kidney disease patients which require further research. These knowledge gaps 
are reflected in the minimal number of recommendations from the KDIGO CKD-MBD 
guidelines which are currently being reassessed for updating (84).  
First, future research should determine reasons for the low observed fracture rate 
in kidney transplant recipients.  Specifically, secular trends in fracture preventative 
therapy (e.g. bisphosphonates and vitamin D) need to be studied to determine if an 
increase in bisphosphonate use has decreased fracture rates.  Additionally, research needs 
to examine the effects of increased BMD monitoring, decreased steroid dose, and 
changes in recipient characteristics (e.g. increasing age, body mass index, and diabetics) 
on fracture rates.  
 Second, studies that assess fracture prevention strategies are needed, particularly 
in individuals with more severe declines in kidney function. For example, the efficacy of 
fracture prevention therapies, fall prevention programs, and the utility of BMD to predict 
fracture need to be better understood.   
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Third, although FRAX may be an accurate tool to use in kidney disease patients, 
given the complex pathophysiology of bone disease, other risk factors that are unique to 
the kidney disease population and were not assessed in this thesis may also be useful to 
use as markers for fracture (6, 7). For example, risk factors that may be unique to the 
kidney disease population, such as fibroblast growth factor 23, may play an accurate role 
in fracture prediction (85, 86). Moreover, in the general population a relatively new 
method to assess bone texture (bone microarchitecture) called the trabecular bone score 
has been found to accurately predict fracture (87-89) and could be useful at predicting 
fracture in the kidney disease population.  
Fourth, improvements in the data quality of kidney disease information contained 
in administrative healthcare databases are needed. As previously discussed, drug 
information for only a sub-cohort of kidney transplant recipients was available in ICES 
databases and some important kidney transplant recipient variables (e.g. body mass 
index) had considerable missingness. One method to obtain more detailed information on 
Ontario kidney transplant recipients is to perform a medical chart abstraction as was done 
for living kidney donor studies at ICES (90, 91); however, this takes a considerable 
amount of time and funding. Chart abstraction could also be used to ensure the accuracy 
of information contained in the recipient database through conducting validation studies. 
Last, family physicians are often the primary care providers for individuals with 
mild to moderate reductions in kidney function (92) and once an individual receives a 
kidney transplant they are often managed by a family physician in tandem with a 
nephrologist. Therefore, family physicians can play a critical role in preventing fractures 
in the kidney disease population. The Canadian Society of Nephrologists recognizes this 
stating that it is important that fracture prevention guidelines specific to CKD patients be 
provided to family physicians (93). Survey research should be conducted to determine 
family physicians’ knowledge of bone disease in kidney disease patients and their 
fracture prevention practices. The results would assist with determining areas for 
improvement in the medical school curriculum and in determining how to better 
disseminate this information to family physicians.  
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7.6 Conclusions 
As improvements in survival have been achieved in kidney disease patients (5, 
94), associated long-term complications have become an increasing concern. This thesis 
examined one important complication of kidney disease, fracture. The knowledge gained 
from this thesis provided information to improve prognostication, advance osteoporosis 
and transplant guidelines, guide the allocation of healthcare resources, assist with sample 
size estimations for future fracture prevention trials, clarify fracture incidence, and guide 
informed consent.  
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A.1 Additional Methods 
For objectives 3 and 4 a systematic review was performed as part of the literature 
review. Detailed methods for this systematic review are described below. 
A.1.1 Design and Study Selection 
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) guidelines were used in the reporting of this systematic review (1). Inclusion 
and exclusion criteria were developed a priori. Studies were included if they met the 
following criteria:1) full-text English articles, 2) cohort study, 3) more than 50 kidney 
transplant recipients, 4) mean age ≥ 18 years (the mechanisms underlying fracture in 
children are different than in adults) (2), 5) reported any type of fracture (including low 
or high trauma), 6) earliest accrual period after 1984 (1984 was the year cyclosporine was 
introduced into clinical practice) (3), 7) time zero (start of follow-up) the day of kidney 
transplant or thereafter, and 8) mean follow-up greater than one year. The following 
studies were excluded from the review: 1) no incidence of fracture reported (i.e., only 
bone mineral density, which is controversial in kidney transplant recipients) (4, 5), and 2) 
insufficient information on when the fracture occurred (see Figure A.1 for final study 
selection). 
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Figure A. 1. Study selection 
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A.1.2 Identifying Relevant Studies 
Both MEDLINE (1984 to November, 2012) and EMBASE (1984 to December, 
2012) were searched.  For both databases, the search strategies were pilot tested and 
modified to ensure known relevant articles were identified. The final search strategy 
consisted of keywords such as kidney transplantation, renal transplant, fracture, bone, and 
falls (Tables A.1 and A.2).  The search strategy was modified for each database used. The 
related articles option was also used in Google Scholar to search for additional articles.  
 
Table A. 1. Search strategies: Embase search strategy <1984 to 2012 Week 50> 
1 exp kidney transplantation/ 
2 kidney transplant$.tw. 
3 renal transplant$.tw. 
4 kidney graft$.tw. 
5 renal graft$.tw. 
6 kidney allograft$.tw. 
7 renal allograft$.tw. 
8 1 or 2 or 3 or 4 or 5 or 6 or 7 
9 exp fracture/ 
10 exp bone/ 
11 posttraumatic osteoporosis/ or primary osteoporosis/ or senile osteoporosis/ or 
involutional 
osteoporosis/ or secondary osteoporosis/ or idiopathic osteoporosis/ or osteoporosis/ or 
corticosteroid 
induced osteoporosis/ or osteoporosis.mp. orpostmenopause osteoporosis/ 
12 osteoporosis$.tw. 
13 fracture$.tw. 
14 (mineral$ adj2 bone$ adj2 disease$).tw. 
15 exp falling/ 
16 fall$.tw. 
17 BMD.tw. 
18 exp renal osteodystrophy/co, di, dm, dr, dt, ep, et, pc, si, su, thYOU 
19 renal osteodystrophy$.tw. 
20 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 
21 8 and 20 
22 limit 21 to yr="1984 -Current" 
23 limit 22 to english language 
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Table A. 2. Search strategies: Medline search strategy (1946 to November Week 3 2012) 
1. exp Kidney Transplantation/ 
2. kidney transplant$.tw. 
3. renal transplant$.tw. 
4. kidney graft$.tw. 
5. renal graft$.tw. 
6. kidney allograft$.tw. 
7. renal allograft$.tw. 
8. 1 or 2 or 3 or 4 or 5 or 6 or 7 
9. exp Fractures, Bone/ 
10. fracture$.tw. 
11. exp Osteoporosis/ 
12. osteoporosis$.tw. 
13. exp Renal Osteodystrophy/ 
14. exp Accidental Falls/ 
15. fall$.tw. 
16. 9 or 10 or 11 or 12 or 13 or 14 or 15 
17. 8 and 16 
18 limit 17 to yr="1984 -Current" 
19 limit 18 to English 
 
A.1.3 Article Eligibility Criteria 
Two reviewers (K.N. and A.L.) independently screened each citation’s title and/or 
abstract to determine eligibility. Full-text articles were retrieved for citations that were 
identified by either reviewer as potentially relevant. Both reviewers independently 
assessed the eligibility of full-text articles. Discrepancies among the two reviewers were 
resolved through re-evaluation and discussion. 
A.1.4 Data Abstraction 
The data abstraction form was designed and pilot tested. The following data was 
abstracted independently by paired reviewers: study design, patient characteristics, 
fracture incidence, and fracture risk factors. Differences in abstracted data were discussed 
by two reviewers and were resolved. 
The methodological quality was assessed using a modified version of the Downs 
and Black checklist for nonrandomized studies (Table A.3) (6). The completeness and 
clarity of reporting, bias, and external validity was assessed. On the modified scale, all 
included studies were given a score from 0 to 17, with a higher score indicative of greater 
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quality. Attempts were made to obtain additional study information by contacting 
corresponding authors. 
 
Table A. 3.  Modified Downs and Black checklist for non-randomized studies 
(Prospective and Retrospective Studies) r 
ALL 
CRITERIA 
DESCRIPTION OF CRITERIA (with additional explanation as 
required, determined by consensus raters) 
POSSIBLE  
ANSWERS 
1 Is the hypothesis/aim/objective of the study clearly described? Must 
be explicit  
 
Yes/No 
2 Are the main outcomes to be measured clearly described in the 
Introduction or Methods section? If the main outcomes are first 
mentioned in the Results section, the question should be answered no. 
ALL primary outcomes should be described for YES  
 
Yes/No 
3 Are the characteristics of the patients included in the study clearly 
described? In cohort studies and trials, inclusion and/or exclusion criteria 
should be given. In case-control studies, a case-definition and the source 
for controls should be given. Single case studies must state source of 
patient. *Are baseline characteristics of individuals clearly described. 
 
Yes/No 
 
4 Are the main findings of the study clearly described? Simple outcome 
data (including denominators and numerators) should be reported for all 
major findings so that the reader can check the major analyses and 
conclusions. 
 
Yes/No 
 
5 Does the study provide estimates of the random variability in the 
data for the main outcomes? In nonnormally distributed data the inter-
quartile range of results should be reported. In normally distributed data 
the standard error, standard deviation or confidence intervals should be 
reported 
 
Yes/No 
 
6 Have the characteristics of patients lost to follow-up been described? 
If not explicit = NO. RETROSPECTIVE – 
if not described = UTD; if not explicit re: numbers agreeing to participate 
= NO. Needs to be >85% 
 
Yes/No 
 
7 Have actual probability values been reported (e.g. 0.035 rather than 
<0.05) for the main outcomes except where the probability value is 
less than 0.001? 
 
Yes/No 
 
8 Were the subjects asked to participate in the study representative of 
the entire population from which they were recruited? The study must 
identify the source population for patients and describe how the patients 
were selected. 
 
Yes/No/UTD 
 
9 Were those subjects who were prepared to participate representative 
of the entire population from which they were recruited? The 
proportion of those asked who agreed should be stated. 
 
Yes/No/UTD 
10 Were the staff, places, and facilities where the patients were treated, 
representative of the treatment the majority of patients receive? For 
Yes/No/UTD 
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the question to be answered yes the study should demonstrate that the 
intervention was representative of that in use in the source population. 
Must state type of hospital and country for YES. 
 
11 If any of the results of the study were based on “data dredging”, was 
this made clear? Any analyses that had not been planned at the outset of 
the study should be clearly indicated. Retrospective = NO. Prospective= 
YES 
 
Yes/No/UTD 
 
12 In trials and cohort studies, do the analyses adjust for different 
lengths of follow-up of patients, or in case-control studies, is the time 
period between the intervention and outcome the same for cases and 
controls? Where follow-up was the same for all study patients the answer 
should yes. Studies where differences in follow-up are ignored should be 
answered no. Acceptable range 1 yr follow up = 1 month each way; 2 
years follow up = 2 months; 3 years follow up = 3months........10years 
follow up = 10 months 
 
Yes/No/UTD 
13 Were the statistical tests used to assess the main outcomes 
appropriate? The statistical techniques used must be appropriate to the 
data. If no tests done, but would have been appropriate to do = NO 
 
Yes/No/UTD 
 
14  *Were the main outcome measures used accurate (valid and 
reliable)? YES=used radiographs, codes, patient records or multiple 
methods (i.e. questionnaires verified by codes). NO=questionnaires only 
used to determine if patient fractured. UTD=no method was reported 
 
Yes/No/UTD 
15 *Was a case definition of fracture provided? YES=stated that a 
fracture was a fall from standing height or less and/or stated that they 
excluded/included high trauma fractures NO=not reported 
 
YES/NO 
16 Was there adequate adjustment for confounding in the analyses from 
which the main findings were drawn? In nonrandomised studies if the 
effect of the main confounders was not investigated or no 
adjustment was made in the final analyses the question should be 
answered as NO. If no significant difference between groups shown then 
YES 
 
Yes/No/UTD 
 
17 Were losses of patients to follow-up taken into account? If the 
numbers of patients lost to follow-up are not reported = unable to 
determine. 
Yes/No/UTD 
 
YES=1 
NO=0 
UTD (unable to determine)=0                                             Total Score:____/17 
*Items that have been added. 
Source: Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality 
both of randomized and non-randomised studies of health care interventions. J Epidemiol Community Health 1998; 52: 
377. 
 
A.1.5 Data Analysis 
Where possible, incidence rates were normalized to 1000 person-years, although 
in some studies only cumulative incidence was reported. Risk factors were summarized if 
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they were determined by multivariable analysis and were statistically significant in at 
least one study. A meta-analysis was not performed because the studies were too 
heterogeneous. 
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APPENDIX B: Ethics Approval, Consent Form, and Questionnaire for the 
Canadian Multicentre Osteoporosis Study (Chapter 3)
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C.1 Detailed Methods 
C.1.1 FRAX Development and Validation Cohorts 
To develop the original FRAX model nine prospective population-based cohorts 
were used, including populations from around the world (1).   Detailed information on the 
aforementioned studies has been previously described (2-12). In the validation cohort 
eleven independent cohorts were used, including populations from around the world (1). 
The validation cohort was comprised of randomized control trials, prospective and 
retrospective cohorts, and case-control studies (1). Detailed information on the 
aforementioned cohorts has been previously described (13-23). The major differences 
between the development and validation cohorts and the cohort used in chapter 3, 
include: the mean age of individuals is higher in chapter 3, the time frame is in a later 
calendar period, and the percentage of females is lower (compared to the validation 
cohort) (Table C.1). 
 
Table C. 1. Comparison of the FRAX development cohort, internal validation cohort and 
the CaMos cohort  
 Development Cohort 
(n=46,340) 
Internal 
Validation 
Cohort 
(n=230,486) 
CaMos cohort (eGFR 
<60 mL/min/1.73 m
2
) 
(n=320) 
Predictors    
Women 68% 100% 71% 
Age (yr) 65 63 75 
Body mass index kg/m
2
 26.2 26.7 27.6% 
Maternal history of 
fracture
†
 
7% 12% 10.9% 
Glucocorticoids 
4% 2% 3.4% 
Prior fracture 29% 16% 25.3% 
Ever smoked 20% 27% 7.5% 
High alcohol use 11% 21% 0 
Rheumatoid arthritis 5% 3% 0.94% 
Outcome -Self-report and/or 
verified by hospital or 
databases 
-Locations: differed by 
cohort (two cohorts: hip, 
forearm, spine, humerus; 
one cohort: spine, pelvis, 
-Self-report and/or 
verified by 
hospital, imaging 
databases, family 
physician  
-Locations: not 
specified 
-Self-report and /or 
verified by hospital 
-Locations: hip, forearm, 
clinical spine, humerus 
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ribs, distal forearm, 
forearm, and hip; other 
cohorts osteoporotic 
fracture sites) 
Cohort eligibility years 1980s-late 1990s
¥
 1970s-2000s
¥ 
2006-2011 
Abbreviation: eGFR, estimated glomerular filtration rate 
†The CaMos cohort used in this study looked at parent fracture hip not just maternal. 
¥ Years were not clearly described 
Source: Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J, et al. The use of clinical risk factors enhances 
the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 
2007;18:1033-1046. 
 
To develop the FRAX prediction model Poisson regression was used and 
predictors were selected into the model using stepwise regression (1). Risk factors for 
fracture and interaction terms to potentially be included in the final predictive model 
were determined through meta-analyses (1). To evaluate the performance of the model 
gradients of risk (risk ratios) per standard deviation increase in FRAX score were used 
(1). 
C.1.2 Data Source Details 
To determine the prognostic value of the Fracture Risk Assessment tool (FRAX) 
in individuals with reduced kidney function data from the Canadian Multicentre 
Osteoporosis Study (CaMos) was utilized. CaMos is an ongoing prospective cohort study 
which includes non-institutionalized adults aged ≥ 25 years and began in 1996 (2). The 
original objective of CaMos was to determine the incidence of fracture and the impact 
that osteoporosis has on adults across Canada to aid in the development of fracture and 
osteoporosis prevention programs (2). Adult Canadians were selected to participate in 
CaMos through identifying a region-,sex-, and age- stratified random sample of 
individuals who lived  within 50 kilometers of the following Canadian cities: St.John’s, 
Halifax, Quebec City, Toronto, Hamilton, Kingston, Saskatoon, and Calgary (2). This 
criteria covered approximately 40% of Canadians (2). The only major group that was 
excluded were individuals living in northern Canada (2).  Based on postal codes from the 
pre-specified geographic regions a random sample of telephone numbers was generated 
(2).  At baseline approximately 72% (n=9423) of contacted individuals participated (fully 
42%; partially 30%) (24). Partial participation was defined as individuals who refused to 
participate in the study but agreed to complete a refusal questionnaire; the refusal 
211 
 
 
questionnaire obtained information on key risk factors for osteoporosis (e.g. sex, previous 
fracture) (24). Starting at baseline, standardized interviewer-administered questionnaires 
were given every 5 years (2). For this chapter data was utilized from years 10-15 of the 
CaMos study; however, baseline information, such as sex, that was collected at year 1 
was also utilized. At year 1 of CaMos an in-person interviewer-administered 
questionnaire (Appendix B), two questionnaires that focused on health status (SF-36 (25) 
and  McMaster University’s health status assessment  [Health Utilities Index Mark 2 and 
3] (26, 27)), Mini-Mental State exam (28), and a variety of physical measurements  
(height, weight, dual energy x-ray absorptiometry, ultrasound assessment of the 
calcaneus, and x-ray of lateral thoracic and lumbar spine for individuals aged ≥ 50 years) 
were given (2). Follow-up was maintained through the following mechanisms: greeting 
cards, birthday cards, and a yearly questionnaire was mailed to obtain information on 
fractures and other new diagnoses that may have occurred within the last year (2). 
Moreover, contact information for next of kin was obtained to help contact individuals 
who may have moved (24). 
The questionnaire used in the study was developed specifically for CaMos.  No 
previously validated questionnaires covered the scope of information that the CaMos 
questionnaire wanted to capture and therefore a new questionnaire was developed. 
Nadalin et al. assessed the test-retest reliability of a section of the CaMos questionnaire 
through first collecting information by personal interview then three to five months later 
the participants were administered the same questions by telephone interview (29). 
Employment status, height, weight, and female reproductive history had a high reliability 
(kappa >0.80 or intra-class correlation coefficient >0.80) (29). However, physical 
activity, sun exposure, and previous weight loss demonstrated lower reliability (kappa 
ranged from 0.30 to 0.58).   Kmetic et al. evaluated nonresponse bias for the CaMos 
questionnaire through using multiple imputation to adjust for nonresponse bias  (30). 
Individuals who did not agree to participate in the study were asked to complete a brief 
questionnaire which assessed major risk factors for osteoporosis (30).  Multiple 
imputation then used osteoporotic risk factors to estimate the osteoporosis status for 
individuals who did not agree to participate (30). The results found that selection bias  is 
of most concern in elderly individuals (>80 years) (30). 
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C.1.3 Data Cleaning 
Data cleaning and data checking for the CaMos data was performed at McGill 
University (CaMos coordinating centre) by a biostatistician. Kyla Naylor performed 
additional data checking through the use of histograms and minimum and maximum 
values for categorical variables. Means (standard deviations), medians (interquartile 
range), and minimum and maximum values were assessed for continuous variables. All 
fracture dates were also checked by Kyla Naylor. Any concerns about potentially 
implausible values were brought to the coordinating centre’s attention. For example, 
several fracture dates were brought to the coordinating centre’s attention and were 
checked by contacting the hospital in which the fracture occurred to confirm the date of 
the fracture; if there were any discrepancies the date was then corrected using the date 
recorded at the hospital as the gold-standard. 
C.1.4 Sample Size Calculations 
Based on data from a Jamal et al. study which used CaMos data to examine 
fracture risk in individuals with reduced kidney function it was estimated that 7% of 
individuals with reduced kidney function would fracture over 5-years of follow-up (31). 
Sample size was calculated using the area under the receiver operating characteristic 
curve sample size method proposed by Hanley et al. (32). An alpha of 0.05, 80% power, 
and a null area under the curve (AUC) value of 0.5 were used (Table C.2).  Based on 
2251 individuals with a serum creatinine measurement at year 10 of CaMos it was 
expected that 20% of individuals would have CKD (n=450) (based on results from the 
Jamal et al. study using CaMos data) (31).  Therefore, based on our sample size estimates 
it was expected that we would have 80% power to detect an AUC of 0.65 (Table C.2). 
Based on a study conducted by Jamal et al. assessing the predictive ability of FRAX in 
patients with CKD it was hypothesized that an AUC of approximately 0.7 would be 
found (33).  In chapter 3 there were only 16 major osteoporotic fracture events in 
individuals with CKD; as a result of the low number of fracture events and corresponding 
wide 95% confidence intervals, conclusions from chapter 3 were very cautious. 
Specifically, it was emphasized in the conclusion of chapter 3 and the overall discussion 
section in chapter 7 of this thesis that further study is needed with larger samples before 
FRAX should be routinely used in clinical practice. 
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Table C. 2. Estimated sample size requirements for individuals with CKD 
Number of Individuals with a 
Fracture 
Number of Individuals without 
a Fracture 
Area Under the Curve Value 
286 3718 0.55 
32 416 0.65 
18 234 0.7 
12 156 0.75 
Sources: Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) 
curve. Radiology 1982; 143: 29-36. Obuchowski NA. Sample size calculations in studies of test accuracy. Statistical 
Methods in Medical Research 1998; 7: 371-392. 
 
C.2 Additional Analyses 
C.2.1 Missing Data  
For this chapter the main analyses were all done with a complete case analysis. A 
large number of individuals were excluded (n=2520) due to missing an estimated 
glomerular filtration rate (eGFR). The reason for missing data was the refusal to 
participate in blood collection. Those who did not participate may be systematically 
different than those who consented and exclusion of these people could bias estimates. 
Therefore, in a secondary analysis multiple imputation was performed to impute missing 
eGFR values for individuals who refused to participate to determine the robustness of the 
results on the basis of all available data. Multiple imputation was not performed in the 
primary analysis as previous research has suggested that caution should be exercised 
when imputing exposures (eGFR), particularly when the missingness is high (excluded 
n=2520, 45.3% of individuals due to missing eGFR) (34, 35); additionally the benefits of 
imputing the exposure have been found to be low (35). Individuals who did not have a 
BMD measurement at year 10 were also excluded from the study (n=52, 0.9%); previous 
research has found that when the missingness is <10% minimal differences exist between 
complete case analysis and multiple imputation (36). Individuals were missing a BMD 
measurement if they did not consent to getting the test done.  
Multiple imputation deals with missing data through imputing each missing value 
multiple times while accounting for the uncertainty of the data through creating numerous 
imputed data sets (37); the results of the imputed data sets are then combined to provide a 
single estimate (37). Multiple imputation was also used to handle missing FRAX with 
BMD (approximately 19% of individuals with a missing eGFR were missing FRAX with 
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BMD) in addition to missing eGFR.  Given that only approximately 10% (n=269) of 
individuals with a missing eGFR were missing a body mass index (BMI) measurement, 
single mean imputation was used to impute the missing BMI value for these individuals. 
Previous research has found that when approximately 10% of the data is missing single 
mean imputation produces similar results to multiple imputation (38, 39).    
Missing data can be described as missing completely at random (MCAR), missing 
at random (MAR), or missing not at random (MNAR). MCAR is often considered an 
unrealistic assumption and only occurs when the pattern of missingness is not related to 
any of the variables under study (40). MAR is more realistic, although you are not able to 
test for this assumption; it assumes that missingness does not depend on unobserved 
values but rather on observed values (40). NMAR assumes that observed and unobserved 
values determine missingness. In this analysis it was assumed the data was MAR as 
previous literature has stated it is reasonable to assume this pattern of missingness unless 
previous knowledge about the data indicates missing values are dependent on unobserved 
values (40).  
Multiple imputation requires several steps. To determine which covariates to 
include in the imputation model an extensive literature search was performed to 
determine which variables were associated with the imputed variables (FRAX with BMD 
and eGFR). Associations between eGFR and the other variables were assessed using 
Pearson correlation for two continuous variables or the two-sample t-test for a continuous 
and binary variable. Variables were also included in the imputation model that were 
possibly related to the missingness of the variable based on comparing baseline 
characteristics between individuals with an eGFR (or FRAX with BMD) and individuals 
who were missing an eGFR (Tables C.3 and C.4). The dependent variable of interest was 
also included in the model (major osteoporotic fracture).  The literature suggests that the 
imputation model should include the following variables: all variables included in the 
complete case analysis model (including the dependent variable), variables related to the 
missingness of the imputed variable, and variables associated with the imputed variable 
(41).  The pattern of missingness was explored using PROC MI in SAS. The data did not 
demonstrate a monotone pattern of missingness; therefore, the fully conditional 
specification method was used to handle the arbitrary pattern of the data (42). The models 
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were then created and imputation was applied. FRAX with BMD was imputed first 
(variable with the least missingness is imputed first). The variables that were included in 
the model to predict FRAX with BMD were: major osteoporotic fracture, FRAX without 
BMD, age, sex, BMI, previous fracture, high alcohol use, corticosteroid use, rheumatoid 
arthritis, secondary osteoporosis, smoking, femoral neck BMD,  and parental hip fracture. 
The variables that were included in the model to predict eGFR were: major osteoporotic 
fracture, FRAX without BMD, FRAX with BMD, diabetes, hypertension, health, age, 
sex, prior fracture, smoking and femoral neck BMD.    Ten imputations were performed 
to ensure the efficiency of the model was ≥ 95% (36).  SAS PROC LOGISTIC was used 
to analyze each imputed dataset.  Finally, the average AUC values were calculated after 
imputing the missing eGFR and FRAX with BMD values. To calculate the Kaplan-Meier 
estimates 12 imputations were performed to ensure the efficiency was ≥ 95% for all 
imputed variables. To ensure all terms that were in the survival model were included in 
the imputation model total follow-up was included in addition to the variables described 
above. All imputation was performed using Statistical Analysis System (SAS version 9.3, 
SAS Institute, Cary, NC, USA). 
 
Table C. 3. Comparison of characteristics in individuals with and without a missing 
estimated glomerular filtration rate measurement  
Characteristic Missing eGFR 
(n=2520) 
No Missing eGFR 
(n=2107) 
p-value 
Age 70.6 ± 11.8 67 ± 10  <0.0001 
Women 1857 (73.7%) 1485 (70.5%) 0.02 
Kidney Disease 44 (1.7%) 30 (1.4%) 0.38 
Body Mass Index (kg/m
2
) 27.3 ± 4.9 27.2 ± 4.7 0.53 
Previous fracture 537 (21.3%) 387 (18.4%) 0.013 
Parent fractured hip 296 (11.8%) 267 (12.7%) 0.34 
Current smoking 279 (11.1%) 180 (8.5%) 0.004 
Corticosteroid use for >3 
months 
59 (2.3%) 33 (1.6%) 0.06 
Rheumatoid arthritis 27 (1.1%) 16 (0.8%) 0.27 
Secondary osteoporosis 105 (4.2%) 88 (4.2%) 0.99 
≥ 3 alcoholic beverages per 
day 
28 (1.1%) 21(1.0%) 0.70 
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Femoral neck BMD 
Missing 
0.71± 0.12 
477 (18.9%) 
0.73 ± 0.12 <0.0001 
FRAX without BMD 
FRAX with BMD 
Missing                                  
7.2 (95% CI 7.0-7.4) 
5.9 (95% CI 5.7-6.1)           
477 (18.9%) 
5.7 (95% CI 5.5-5.9) 
4.9 (95% CI 4.8-5.1) 
<0.0001 
<0.0001 
Fall in the past 12 months 670 (26.6%) 542 (25.7%) 0.51 
Bisphosphonate use
€
 667 (26.5%) 506 (24.0%) 0.06 
Type 2 Diabetes 262 (10.4%) 159 (7.5%) 0.0008 
Excellent, very good or 
good self-reported current 
health 
2250 (89.3%) 1953 (92.7%) <0.0001 
Outcome Variable    
Major osteoporotic 
fracture
¶
 
121 (4.8%) 64 (3.0%) 0.0023 
Data are Mean ± SD, mean (95% CI), or n (%)   
Abbreviations: BMD, bone mineral density; FRAX, Fracture Risk Assessment tool 
¶ Major osteoporotic fracture events occurred between years 11-15 of the study 
 
Table C. 4. Comparison of characteristics in individuals with and without a missing 
FRAX with BMD 
Characteristic Missing FRAX with 
BMD 
(n=477) 
No Missing FRAX with 
BMD 
(n=4150) 
p-value 
Age 74.9 ± 11.8 68.4 ± 11.0 <0.0001 
Women 370 (77.6%) 2972 (71.6%) 0.006 
Kidney Disease 10 (2.1%) 64 (1.5%) 0.36 
Body Mass Index (kg/m
2
) 27.2 ± 4.8 27.2 ± 4.8 0.9 
Previous fracture 113 (23.7%) 811 (19.5%) 0.03 
Parent fractured hip 61 (12.8%) 502 (12.1%) 0.66 
Current smoking 50 (10.5%) 409 (9.9%) 0.66 
Corticosteroid use for >3 
months 
12 (2.5%) 80 (1.9%) 0.38 
Rheumatoid arthritis 4 (0.84%) 39 (0.94%) 1.00 
Secondary osteoporosis 25 (5.2%) 168 (4.1%) 0.22 
≥ 3 alcoholic beverages per 
day 
0 (0%) 49 (1.2%) 0.008 
FRAX without BMD 9.1 (8.6-9.7) 6.2 (6.0-6.3) <0.0001 
Fall in the past 12 months 138 (28.9%) 1074 (25.9%) 0.15 
Bisphosphonate use
€
 124 (26.0%) 1049 (25.3%) 0.73 
Type 2 Diabetes 56 (11.7%) 365 (8.8%) 0.03 
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Excellent, very good or 
good self-reported current 
health 
406 (85.1%) 3797 (91.5%) <0.0001 
Outcome Variable    
Major osteoporotic 
fracture
¶
 
34 (7.1%) 151 (3.6%) 0.0002 
Data are Mean ± SD, mean (95% CI), or n (%)   
Abbreviations: BMD, bone mineral density; FRAX, Fracture Risk Assessment tool 
¶ Major osteoporotic fracture events occurred between years 11-15 of the study 
 
To determine if the results from multiple imputation were different from when 
complete case analysis was used, AUC values from the complete case analysis were 
compared to values obtained from multiple imputation (AUC values for FRAX and 
FRAX without BMD) (Table C.5). The results were similar to the complete case analysis 
with all AUC values still reaching statistical significance for individuals with reduced 
kidney function (eGFR <60 mL/min/1.73 m
2
); however, the AUC confidence intervals 
were narrower reflecting increased precision. Similar to what was found in the complete 
case analysis, the 5-year observed major osteoporotic fracture risk (7.4%, 95% 
confidence interval [CI] 5.7 to 9.4%) was comparable to the FRAX predicted fracture 
risk (7.4%, 95% CI 7.1-7.7% with BMD; 9.4%, 95% CI 9.0%-9.7% without BMD) in 
individuals with an eGFR <60 mL/min/1.73 m
2
; the fracture risk predicted by FRAX was 
within the observed fracture risks 95% CI. The observed fracture risk was higher than 
what was observed in the complete case analysis; however, this would be expected as 
individuals with a missing eGFR had more comorbidities. 
 
Table C. 5. Comparison of area under the curve values for incident major osteoporotic 
fracture prediction according to complete case analysis versus multiple imputation 
Complete Case Analysis 
 <60 mL/min/1.73 m
2
 ≥60 mL/min/1.73 m2 
 
Risk Factor  
 
AUC 
 
95% CI 
 
 
AUC 
 
95% CI 
 
FRAX with BMD 0.69 0.54- 0.83 0.76 0.70- 0.82 
FRAX without BMD 0.65 0.52 - 0.79 0.74 0.67- 0.81 
Multiple Imputation   
 <60 mL/min/1.73 m
2
 ≥60 mL/min/1.73 m2 
 
Risk Factor  
 
AUC 
 
95% CI 
 
 
AUC 
 
95% CI 
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Abbreviations: AUC, area under the curve; BMD, bone mineral density; CI, confidence interval; FRAX, Fracture Risk 
Assessment tool 
 
C.2.2 Loss to follow-up  
Loss to follow-up is a concern as losses can bias results, decrease statistical 
power, and decrease generalizability (43, 44). Specifically, loss to follow-up can result in 
attrition bias (defined as systematic differences in the characteristics of individuals who 
are lost to follow-up resulting in selection bias) (45). The external and internal validity of 
results can be affected by attrition bias (46). In the literature there is a lack of consensus 
on acceptable levels of loss to follow-up, however, some journals require that a minimum 
of 80%  follow-up is achieved (47). In this study there were a total of 81 (3.8%) 
individuals lost to follow-up (8.4% [n=27] with an eGFR <60 and 3.0% [n=54] with an 
eGFR ≥60 mL/min/ 1.73 m2). Table C.6 (eGFR <60 mL/min/1.73 m2) and Table C.7 
(eGFR ≥60 mL/min/1.73 m2) demonstrate differences in baseline characteristics between 
individuals with complete follow-up and individuals who were lost to follow-up. 
 
Table C. 6. Comparison of baseline characteristics for individuals with complete follow-
up versus lost to follow-up (eGFR <60 mL/min/1.73 m
2
) 
Characteristic Complete follow-up 
(n=293) 
Loss to follow-up 
(n=27) 
p-value 
FRAX Variables 
Age 75.4 ± 7.1 81.6 ± 4.8 <0.0001 
Women 205 (70.0%) 22 (81.5%) 0.21 
Body Mass Index (kg/m
2
) 27.5 ± 4.6 28.1 ± 4.3 0.53 
Previous fracture 72 (24.6%) 9 (33.3%) 0.32 
Parent fractured hip 34 (11.6%) 1 (3.7%) 0.33 
Current smoking 21 (7.2%) 3 (11.1%) 0.44 
Corticosteroid use for >3 months 10 (3.4%) 1 (3.7%) 1.00 
Rheumatoid arthritis 2 (0.7%) 1 (3.7%) 0.23 
Secondary osteoporosis
¶
 22 (7.5%) 0 0.24 
≥ 3 alcoholic beverages per day 0 0 _____ 
FRAX with BMD 
 
FRAX without BMD 
0.70  
 
0.67                       
0.62-0.77 
 
0.60-0.74 
0.76 
 
0.74 
0.72-0.80 
 
0.70-0.78 
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Femoral neck T-score -1.2 ± 0.96 -1.6 ± 0.95 0.05 
FRAX Score    
FRAX without BMD 8.0  (7.4-8.5) 10.6 (8.7-12.5) 0.01 
FRAX with BMD 6.2 (5.7-6.7) 8.6 (6.9-10.3) 0.01 
Comorbidities 
eGFR 49.6 ± 9.1 47.5 ± 8.3 0.23 
Fall in the past 12 months 68 (23.2%) 9 (33.3%) 0.24 
Bisphosphonate use
€
 75 (25.6%) 11 (40.7%) 0.09 
Type 2 Diabetes 35 (12.0%) 
7 (25.9%) 
0.07 
Excellent, very good or good self-
reported current health 
261 (89.1%) 19 (70.4%) 0.01 
Note: Bolded p-values denote statistical significance 
¶Defined as any of the following: chronic liver disease, type I diabetes, hyperthyroidism, hypogonadism, premature 
menopause (<45 years), chronic malnutrition/malabsorption and osteogenesis imperfecta. Source: World Health 
Organization: FRAX World Health Organization Fracture Risk Assessment Tool, 2011. Available at: 
http://www.shef.ac.uk/FRAX/index.aspx. Accessed May 20, 2014. 
€ Defined as a composite of alendronate, clodronate, etidronate, risedronate, ibandronate, pamidronate, zoledronate at 
cohort entry 
 
Table C. 7. Comparison of baseline characteristics for individuals with complete follow-
up versus lost to follow-up (eGFR ≥60 mL/min/1.73 m2) 
Characteristic Complete follow-up 
(n=1733) 
Loss to follow-up 
(n=54) 
p-value 
FRAX Variables 
Age 65.5 ± 9.9 70.8 ± 10.9 0.0001 
Women 1218 (70.3%) 40 (74.1%) 0.55 
Body Mass Index (kg/m
2
) 27.1 ± 4.7 25.9 ± 4.5 0.06 
Previous fracture 293 (16.9%) 13 (24.1%) 0.17 
Parent fractured hip 223 (12.9%) 9 (16.7%) 0.41 
Current smoking 153 (8.8%) 3 (5.6%) 0.62 
Corticosteroid use for >3 months 22 (1.3%) 0 ________ 
Rheumatoid arthritis 13 (0.8%) 0 ________ 
Secondary osteoporosis
¶
 65 (3.8%) 1 (1.9%) 0.72 
≥ 3 alcoholic beverages per day 21 (1.2%) 0 ________ 
Femoral neck T-score -0.99 ± 1.0 -1.3 ± 0.9 0.03 
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FRAX Score    
FRAX without BMD                    5.1 (4.9-5.3)                  7.6 (6.1-9.1) <0.0001 
FRAX with BMD 4.6 (4.4-4.7) 6.0 (4.9-7.1) 0.01 
Comorbidities 
eGFR 81.4 ± 11.4 77.9 ± 12.3 0.03 
Fall in the past 12 months 451 (26.0%) 14 (25.9%) 0.99 
Bisphosphonate use
€
 407 (23.5%) 13 (24.1%) 0.87 
Type 2 Diabetes 112 (6.5%) 5 (9.3%) 0.40 
Excellent, very good or good self-
reported current health 
 
1626 (93.8%) 47 (87.0%) 0.08 
Note: Bolded p-values denote statistical significance 
¶Defined as any of the following: chronic liver disease, type I diabetes, hyperthyroidism, hypogonadism, premature 
menopause (<45 years), chronic malnutrition/malabsorption and osteogenesis imperfecta. Source: World Health 
Organization: FRAX World Health Organization Fracture Risk Assessment Tool, 2011. Available at: 
http://www.shef.ac.uk/FRAX/index.aspx. Accessed May 20, 2014. 
€ Defined as a composite of alendronate, clodronate, etidronate, risedronate, ibandronate, pamidronate, zoledronate at 
cohort entry 
 
For individuals with an eGFR <60 mL/min/1.73 m
2
 individuals who were lost to 
follow-up were significantly older (81.6 versus 75.4 years; P<0.0001), significantly less 
likely to report excellent, very good or good health (87.0% versus 93.8%; P=0.001), and 
had a significantly higher FRAX with and without BMD score compared to individuals 
with complete follow-up.  For individuals with an eGFR ≥ 60 mL/min/1.73 m2 
individuals who were lost to follow-up were significantly older (70.8 versus 65.5 years; 
P=0.0001), had a significantly lower mean eGFR (77.9 versus 81.4 mL/min/1.73 m
2
; 
P=0.03), a significantly lower mean femoral neck T-score (-1.3 versus -0.99; P=0.03), 
and had a significantly higher FRAX with and without BMD score compared to 
individuals with complete follow-up. Bias due to loss to follow-up could potentially 
affect the external generalizability of the results; the results may not be generalizable to 
older and sicker individuals.  
C.2.3 Competing Risk 
A competing risk can be defined as an event (e.g. death) that eliminates an 
individual from being at risk for the event of interest (e.g. fracture) (45). If competing 
risks are not accounted for the outcome may be overestimated (44). In this study death 
was a potential competing risk with fracture. For example, if an individual dies before 
they fracture then death is considered a competing event. The traditional Kaplan-Meier 
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method would simply censor individuals at death; however, this is not the best method as 
after death a fracture can no longer occur (48). The competing risk of death is particularly 
important to consider when assessing fracture risk as many of the fracture risk factors 
(e.g. older age) are also risk factors for death (48). Therefore, the risk of fracture may be 
particularly overestimated in groups of individuals with higher mortality (e.g., older 
individuals) (48). FRAX already accounts for the competing risk of death when 
estimating the 10-year fracture probability (1). Therefore, when the observed probability 
of fracture is calculated the competing risk of death should also be taken into account 
particularly given the older mean age in this study (75.9 years in individuals with an 
eGFR <60 mL/min/1.73 m
2
).  To account for the competing risk of death a modified 
Kaplan-Meier method was used. Leslie et al. developed this modified Kaplan-Meier 
method and assessed it on a cohort of older men and women (aged ≥ 50 years) (48). They 
found that in subgroups that had a high risk of mortality (e.g. men) not accounting for the 
competing risk of death resulted in overestimating fracture risk using the  traditional 
Kaplan-Meier method by 16-56% (48). This modified Kaplan-Meier method produced 
fracture estimates that were within 2% of the estimates produced by the cumulative 
incidence function (method that also takes into account competing risks) (48).  The 
modified Kaplan-Meier method does not censor individuals when they die; individuals 
who die are instead followed until the end of follow-up and considered to remain fracture 
free (48); therefore, the only censoring event that was considered was loss to follow-up 
(48).  In this chapter only 3.3% (n=69) died (5.9% [n=19] with an eGFR <60 and 2.8% 
[n=50] with an eGFR ≥60 mL/min/ 1.73 m2), therefore, the competing risk of death was 
less of a concern. Table C.8 demonstrates that the traditional Kaplan-Meier method and 
the modified Kaplan-Meier method produced estimates that were similar. 
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Table C. 8. Kaplan-Meier estimates (traditional and modified) of fracture risk by 
estimated glomerular filtration rate 
 <60  mL/min/1.73 m
2
 
(n=320) 
≥60  mL/min/1.73 m2 
(n=1787) 
 Traditional 
Kaplan-Meier, 
95% CI 
Kaplan-Meier 
taking into 
account 
competing risk of 
death, 
95% CI 
Traditional Kaplan-
Meier, 
95% CI 
Kaplan-Meier 
taking into 
account competing 
risk of death, 
95% CI 
Major 
osteoporotic 
fracture 
5.6 
(3.4-9.0) 
5.3 
(3.3-8.6) 
2.7 
(2.0-3.6) 
2.7 
(2.1-3.6) 
 
C.2.4 Observed and FRAX Predicted Fracture Estimates 
In this chapter only information on years 10-15 of the CaMos data was able to be 
utilized; therefore, the 10-year FRAX predicted fracture risk was divided by two to get 
the 5-year FRAX predicted fracture risk. To ensure that this method was accurate the 
observed 5- and 10-year fracture risks of the entire CaMos cohort was analysed by sex 
and age group (Table C.9). It was found that the relationship between the 5-year and 10-
year estimates was consistent. Specifically, the 5-year risk was close to half the 10-year 
risk even in older age groups. 
 
Table C. 9. 5- and 10-year observed fracture risks in the entire CaMos cohort  
10-year risks 
Men  Women  
 Fracture 95% CI  Fracture 95% CI 
Age      Age     
45-54 8.0% (5.9%-10.6%) 45-54 8.2% (6.6%-10.0%) 
55-64 7.6% (5.6%-9.9%) 55-64 13.5% (11.8%-15.3%) 
65-74 11.1% (9.0%-13.6%) 65-74 19.9% (18.1%-21.7%) 
75-84 16.7% (12.8%-21.1%) 75-84 27.2% (24.2%-30.3%) 
5-year risks 
Men Women 
 Fracture 95% CI  Fracture 95% CI 
Age      Age     
45-54 4.5% (3.0%-6.5%) 45-54 3.5% (2.5%-4.7%) 
55-64 4.7% (3.2%-6.6%) 55-64 6.9% (5.8%-8.3%) 
65-74 6.3% (4.8%-8.2%) 65-74 10.1% (8.8%-11.4%) 
223 
 
 
75-84 8.3% (5.8%-11.5%) 75-84 16.1% (13.8%-18.5%) 
Ratios comparing the 5- and 10-year risks of fracture 
Men Women 
Age Ratio Age Ratio 
45-54 0.56 45-54 0.43 
55-64 0.62 55-64 0.51 
65-74 0.57 65-74 0.51 
75-84 0.50 75-84 0.59 
*Unreliable estimates for age <45 because of the low number of fracture events.  
 
C.2.5 Hazard Ratio per Standard Deviation for Incident Fracture Prediction 
To further examine the discriminative ability of FRAX hazard ratios per standard 
deviation were also assessed to provide information on the gradient of risk for fracture 
prediction. Cox proportional hazard regression was used to model time to first major 
osteoporotic fracture event. The proportional hazard assumption was assessed using the 
time-dependent covariate approach (e.g. FRAX*log(time)) and the ASSESS option in the 
SAS PROC PHREG command which plots the follow-up time against the observed score 
process (49). A p-value <0.05 was assumed to have violated the proportional hazard 
assumption. To ensure  there were no departures from linearity martingale residuals were 
assessed for each continuous variable using SAS's PROC PHREG ASSESS statement 
which plots the cumulative martingale residuals against the continuous covariate; a p-
value <0.05 was considered a violation of linearity (50).  The proportional hazard 
assumption was met and there were no departures from linearity for all variables. Similar 
results to the area under the receiver operating characteristic curve analysis were found 
with all hazard ratios for incident major osteoporotic fracture prediction reaching 
statistical significance. These results (hazard ratio [HR] per standard deviation increase in 
FRAX with BMD 1.6, 95% CI 1.2-2.3; without BMD 1.5, 95% CI 1.02-2.2) were also 
comparable to the average hazard ratios found in the original FRAX validation study that 
included 11 international cohorts (HR FRAX with BMD 1.6; without BMD 1.5) (Table 
C.10) (1). 
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Table C. 10. Hazard ratio (HR) for incident major osteoporotic fracture prediction* 
 <60 mL/min/1.73 m
2
 ≥60 mL/min/1.73 m2 
 
Risk Factor  
 
HR 
 
95% CI 
 
 
HR 
 
95% CI 
 
FRAX with BMD 1.6 1.2-2.3 1.6   1.4-1.8 
FRAX without BMD 1.5 1.02-2.2 1.65     1.4-1.9 
FRAX without BMD and with secondary 
osteoporosis 
1.6     1.05-2.3   
Femoral neck T-score 2.1 1.2-3.7        2.4 1.7-3.3 
Femoral neck T-score and prior history of fall 2.0 1.1-3.6        2.5 1.8-3.5 
Age 2.5 1.4-4.6        2.0 1.5-2.8 
⃰ All hazard ratios are presented by standard deviation increase except for femoral neck T-score which is presented by 
standard deviation decrease. 
 
 C.2.6 Fracture Discrimination for All Fractures 
A separate analysis was performed to assess the discrimination of FRAX 
including all fracture sites (excluding fingers, toes, and skull) resulting from low or high 
trauma (Table C.11). The rationale for assessing all fracture sites is that in contrast to the 
general population where major osteoporotic fractures are common fracture sites, 
individuals with reduced kidney function may have other fracture sites that are common 
(51). For example, in kidney transplant recipients, who have similar changes in bone 
mineral metabolism as chronic kidney disease patients, ankle fractures have been found 
to be common (52-54). Therefore, it would be useful to know if FRAX could also be used 
to accurately predict all fracture locations. There were a total of 202 (9.6%) all fracture 
events (46 [14.4%] with an eGFR <60 mL/min/1.73 m
2
 and 156 [8.7%] with an eGFR 
≥60 mL/min/1.73 m2). There were no statistically significant differences in the predictive 
discrimination of T-scores alone, age alone, and T-scores with previous falls between 
individuals with an eGFR <60 versus ≥60 mL/min/1.73 m2 for any fracture similar to 
when major osteoporotic fractures was assessed (P>0.05).  Moreover, all AUC values 
were statistically significant (Table C.12) 
 
Table C. 11. Fracture locations included for all fracture locations 
Locations 
Back             
Hip 
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Ribs 
Forearm/wrist 
Pelvis 
Arm/shoulder 
Elbow 
Hands 
Knee 
Ankle 
Foot 
Leg        
Shoulder         
Clavicle        
Scapula 
Neck    
Sacrum        
Coccyx 
 
Table C. 12. Area under the curve for incident fracture prediction according to estimated 
glomerular filtration rate for any fracture 
 <60 mL/min/1.73 m
2
 ≥60 mL/min/1.73 m2   
 
Risk Factor  
 
AUC 
 
95% CI 
 
 
AUC 
 
95% CI 
 
 
AUC Difference, 
95% CI 
 
p- 
Value 
FRAX with BMD 0.71 0.62 to 0.80 0.64 0.59 to 0.68 0.07 
(-0.03 to 0.17) 
0.16 
FRAX without BMD 0.67 0.59 to 0.76 0.63 0.58 to 0.67 0.04  
(-0.06 to 0.14) 
0.42 
FRAX without BMD 
and with secondary 
osteoporosis 
 
0.68 0.59 to 0.76     
Femoral neck T-score 0.66 0.57 to 0.74 0.61 0.56 to 0.66 0.05  
(-0.05 to 0.15) 
0.31 
Femoral neck T-score 
and prior history of 
fall 
0.67 0.59 to 0.76 0.61 0.56 to 0.66 0.06  
(-0.04 to 0.16) 
0.23 
 
Age 
 
0.60 
 
0.51 to 0.69 
 
0.57 
 
0.53 to 0.62 
 
0.03  
(-0.07 to 0.13) 
 
0.56 
Abbreviations: AUC, area under the curve; BMD, bone mineral density; FRAX, Fracture Risk Assessment tool 
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D.1 Detailed Methods 
D.1.1 Database Codes and Data Sources 
Database codes used for cohort creation, baseline characteristics, and censoring 
events are detailed in Table D.1. Databases codes used to identify fracture and fall events 
are detailed in Tables D.2 and D.3. A detailed summary of validation studies and the 
accuracy of database codes used to define fracture events are described in Tables D.4 and 
D.5 (1-8). A detailed description of Ontario’s large healthcare databases used to 
investigate fracture in kidney transplant recipients (Chapters 4, 5, and 6) is provided 
below. 
i)  Canadian Organ Replacement Register (CORR): CORR is an information system that 
provides data on transplant recipients. CORR has excellent coverage with 98.5% of 
transplants recorded in CORR also being recorded in the Canadian Institutes for Health 
Information Discharge Abstract Database (9). A previous study assessing the validity of 
the CORR database found that there was >95% agreement for sex, date of birth, and 
health card number between CORR and the medical chart (10). 
 
ii) The Canadian Institute for Health Information Discharge Abstract Database, Same 
Day Surgery, and National Ambulatory Care Reporting System (CIHI-DAD, SDS, 
NACRS): NACRS provides information on outpatient hospital visits, emergency 
department visits, and dialysis clinic visits (11). CIHI-DAD and SDS provide information 
on Ontario’s acute, rehab, chronic, and day surgery institutions (11). Diagnostics are 
provided using the International Classification of Disease codes (ICD). These codes were 
used to identify fracture events, morbidities, and exclusion criteria. In a study 
determining the agreement between the CIHI databases and data collected from 
abstractors both the femoral fracture and ankle fracture code had a high (≥ 95)  kappa, 
sensitivity, and positive predictive value (5). 
iii) The Ontario Health Insurance Plan (OHIP): OHIP provides information on billing 
claims from Ontario physicians and laboratories. OHIP has good population coverage 
with approximately 94% of physician services billed through OHIP (12). Chart 
abstraction studies have found that agreement between abstracted fee codes and physician 
recorded codes on the chart was high; agreement for the most responsible diagnosis was 
over 90% and over 88% for procedural codes (13).  
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iv)The Registered Persons Database (RPDB): The RPDB provides information on 
demographics such as sex, age, and vital status (14). Information in the RPBD 
corresponds with information on population characteristics held at Statistics Canada (15). 
v) The Ontario Drug Benefit Plan (ODB): ODB is a universal drug plan for individuals 
aged ≥ 65 years, which includes a wide range of routine outpatient medication 
prescriptions. Since April 1997 information is provided for individuals < 65 years of age 
who are eligible for the Trillium Drug Program or the Special Drugs Program, individuals 
with social assistance or individuals residing in long-term care facilities. The error rate in 
this database is minimal (~0.7%, 95% CI: 0.5 to 0.9%) (16).  
vi) Institute for Clinical Evaluative Sciences Physician Database (IPDB): This database 
contains information on all Ontario physicians, including information on physician 
speciality, physician demographics, and physician activity (i.e., workload) (17). This 
database was used to determine physician speciality.
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Table D. 1. Database codes used to define cohorts, baseline characteristics, and censoring events for chapters 4, 5, and 6  
Characteristic Database Database Codes 
Inclusion criteria for kidney 
transplant recipients 
  
Kidney transplant recipients CORR Treatment_code 
 171, 181 
Transplanted_organ_type_code [1-3] 
 10, 11, 12, 18, 19 
Exclusion criteria for kidney 
transplant recipients 
  
Non-Ontario resident RPDB Prcddablk 
Not equal to province code 35 
Previous transplant CORR 
CIHI-DAD 
OHIP 
 
GRAFT_NUM  
2 
ICD-9 
V420, 99681 
ICD-10 
T861, N165, Z940 
CCP 
6743, 675 
CCI 
1PC85 
OHIP Feecode 
E762, S435, E769, S434, E771, Z631, G347, G348, G412, G408, G409 
Evidence of combination transplant 
(e.g. kidney pancreas) 
CORR Transplanted_organ_type_code [1-3] 
Baseline characteristics   
Age RPDB  
Sex RPDB  
Year of Transplant CORR Treatment_date 
Hypertension CIHI-DAD 
OHIP 
ICD-9 
401, 402, 403, 404, 405 
ICD-10 
 I10, I11, I12, I13, I15 
OHIP DX 
401, 402, 403 
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Diabetes CIHI-DAD 
OHIP 
ICD-9 
250 
ICD-10 Codes 
 E10,  E11,  E13, E14 
OHIP DX 
 250 
OHIP Feecode 
 Q040, K029,K030 
Peripheral Vascular Disease CIHI-DAD 
OHIP 
ICD 9 
 4402,  4403, 4408, 4409, 5571, 4439, 444 
ICD 10 
 I700, I702, I708, I709, I731, I738, I739, K551 
CCP 
5125, 5129, 5014, 5016, 5018, 5028, 5038 
CCI 
 1KA76, 1KA50, 1KE76, 1KG26, 1KG50, 1KG57, 1KG76MI, 1KG87 
OHIP Feecode 
R787, R780, R797, R804, R809, R875, R815, R936, R783, R784,R785, 
E626, R814, R786, R937, R860, R861, R855, R856, R933, R934, R791, 
E672, R794, E672, R813, R867,E649 
Congestive heart failure CIHI-DAD 
OHIP 
ICD9 
 425, 5184, 514, 428 
ICD10 
I500, I501, I509, I255, J81 
CCP 
4961, 4962, 4963, 4964 
CCI 
 1HP53, 1HP55, 1HZ53GRFR, 1HZ53LAFR, 1HZ53SYFR 
OHIP Feecode 
 R701, R702, Z429 
OHIP DX 
 428 
Coronary artery disease CIHI-DAD 
OHIP 
 
ICD9 
 412, 410, 413, 414, 4292, 4295, 4296, 4297 
ICD10 
 I20, I21, I22, I23, I24, I25, Z955, Z958, Z959, R931, T822 
CCI 
 1IJ26, 1IJ27, 1IJ54, 1IJ57, 1IJ50, 1IJ76 
CCP 
 4801, 4802, "4803, 4804, 4805, 481, 482, 483 
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OHIP Feecode 
 R741, R742, R743, G298, E646, E651, E652, E654, E655, G262, Z434, 
Z448 
OHIP DX 
 410, 412, 413 
Prior non-vertebral fracture CIHI-DAD 
OHIP 
NACRS 
Please refer to Table D.2. 
Race CORR Racial_Origin_Code 
Caucasian: 01 
Asian: 02 
Black: 03 
Unknown: 98 
Other/Multiracial:11, 99, 10, 08,  05,  09 
Cause of end-stage renal disease CORR Primary_Diagnosis_Kidney 
Glomerulonephritis: 05, 06, 07,  08, 09, 10,  12,  13,  14,  15, 16, 19, 73, 74, 
84, 85, 86, 88  
Cystic Kidney Disease: 40, 41, 42, 43, 49   
Diabetes: 80,  81  
Renal Vascular Disease: 70, 71, 72, 79  
Other: 20, 21, 22, 23, 24, 25,29, 30, 31, 32, 33, 39, 50, 51, 52, 53, 54, 55, 56, 
57, 58, 59, 60, 61, 62, 63, 66, 78, 82, 83, 87, 89, 90, 91, 92, 93, 94, 95, 96, 
97, 99 
Donor type CORR Donor_Type_Code 
Living: 02,  03,  04, 05, 06, 07, 10, 12, 13, 14, 15 
Deceased: 01 
Unknown/Missing: 98 
Dialysis Modality
‖
 CORR Treatment_Code 
Hemodialysis: 060,111, 112, 113, 121, 122, 123, 131, 132, 133, 211, 221, 
231, 311, 312,313,321, 322, 323, 331, 332, 333, 413,423, 433 
Peritoneal: 141,151, 152, 241, 242, 251, 252, 443, 453 
Dialysis
¶ 
(years prior to transplant) CORR Dialysis: Treatment_Date & Treatment_Code: 060, 111, 112, 113, 121, 
122, 123, 131, 132, 133, 141, 151, 152, 211, 221, 231, 241, 242, 251, 252, 
311,312, 313, 321, 322, 323, 331, 332, 333, 413, 423, 433, 443, 453 
Transplant: Treatment_Date & Treatment_Code: 171 
Delayed graft function CIHI-DAD 
OHIP 
At least one code for dialysis appearing in the first 7 days after the 
transplant date. 
CCP 
 5195, 6698 
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CCI 
1PZ21 
OHIP Feecode 
 R849, G323, G325, G326, G860, G863, G866, G330, G331, G332, G861, 
G082, G083, G085, G090, G091, G092, G093, G094, G095, G096, G294, 
G295 
Primary non-function CIHI-DAD 
OHIP 
At least three codes for dialysis on three different days with at least one code 
appearing in the first 7 days after the transplant date, in the 8- 30 days after 
the transplant date, and in the 31-60 days after the transplant date. 
CCP 
 5195, 6698 
CCI 
1PZ21 
OHIP Feecode 
 R849, G323, G325, G326, G860, G863, G866, G330, G331, G332, G861, 
G082, G083, G085, G090, G091, G092, G093, G094, G095, G096, G294, 
G295 
Pretransplant parathyroidectomy CIHI-DAD 
OHIP 
CCP 
1FV59HAX7, 1FV83NZ, 1FV83NZAG, 1FV83PZ, 1FV83PZAG, 
1FV87NZ, 1FV87NZAG,  1FV87PZ, 1FV87PZAG, 1FV89NZ, 
1FV89NZAG, 1FV89PZ, 1FV89PZAG 
CCI 
197, 1971, 1972, 1996 
OHIP Feecodes 
S795, S796, E880, E885 , S792, E882, E883, E884 
Charles Comorbidity Index
*
 CIHI-DAD ICD-9 and ICD-10 codes 
Glucocorticoids ODB Prednisone 
Cyclosporine ODB Cyclosporine 
Tacrolimus ODB Tacrolimus 
Bisphosphonates ODB Etidronic acid disodium, Clodronic acid disodium, Pamidronic acid 
disodium, Etidronic acid disodium, Calcium carbonate & etidronic acid 
sodium, Alendronate sodium, Risedronate sodium, Zoledronic acid, 
Alendronate, Alendronate sodium & cholecalciferol, Pamidronate disodium 
Reference Groups Inclusion and Exclusion criteria 
Osteoporosis CIHI-DAD 
NACRS 
OHIP 
ICD-9 Codes  
Osteoporosis unspecified: 733.00  
Senile osteoporosis: 733.01  
Idiopathic osteoporosis: 733.02  
Disuse osteoporosis: 733.03  
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Other osteoporosis :733.09  
ICD-10 Codes 
Osteoporosis with pathological fracture:M80  
Osteoporosis without pathological fracture: M81:  
Osteoporosis in diseases classified elsewhere: M82 
OHIP DX  
Osteoporosis:733 
Dual energy x-ray absorptiometry OHIP OHIP Feecode 
Bone mineral density by single proton method: J654  
Total boday calcium proton actiation: J655  
Bone min. content dual-photon absorbtiomet. 2 or more sites: J656  
Bone mineral content by dual photon single site: J688  
Bone mineral density by single photon method: J854  
Total body calcium - neutron activation: J855  
Bone min. content dual-photon absorbtiomet. 2 or more sites: J856  
Bone mineral content by dual photon absorb: J888  
BMD - baseline test, one site: X145   
BMD - baseline test, two or more sites: X146  
Bone mineral density high risk 1 site: X149 
Bone mineral density low risk 1 site: X152  
Bone mineral density low risk 2+ sites: X153  
Bone mineral density high risk 2+sites: X155 
Diag. rad. bone density (mineral content) measurement: X157 
Chronic kidney disease CIHI-DAD 
NACRS 
OHIP 
ICD-9 Codes 
Hypertensive chronic kidney disease, malignant, with chronic kidney disease 
stage i through stage iv, or unspecified: 403.00 
Hypertensive chronic kidney disease, malignant, with chronic kidney disease 
stage v or end stage renal disease:403.01 
 Hypertensive chronic kidney disease, benign, with chronic kidney disease 
stage i through stage iv, or unspecified: 403.10 
Hypertensive chronic kidney disease, benign, with chronic kidney disease 
stage v or end stage renal disease: 403.11 
Hypertensive chronic kidney disease, unspecified, with chronic kidney 
disease stage i through stage iv, or unspecified: 403.9 
Hypertensive heart and chronic kidney disease, malignant, without heart 
failure and with chronic kidney disease stage i through stage iv, or 
unspecified 404.00 
Hypertensive heart and chronic kidney disease, malignant, with heart failure 
and with chronic kidney disease stage i through stage iv, or unspecified: 
404.01 
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Hypertensive heart and chronic kidney disease, malignant, without heart 
failure and with chronic kidney disease stage v or end stage renal disease: 
404.02 
Hypertensive heart and chronic kidney disease, malignant, with heart failure 
and with chronic kidney disease stage v or end stage renal disease: 404.03 
Hypertensive heart and chronic kidney disease, benign, with heart failure 
and with chronic kidney disease stage i through stage iv, or unspecified: 
404.11 
Hypertensive heart and chronic kidney disease, benign, without heart failure 
and with chronic kidney disease stage v or end stage renal disease: 404.12   
Hypertensive heart and chronic kidney disease, benign, with heart failure 
and chronic kidney disease stage v or end stage renal disease: 404.13  
Hypertensive heart and chronic kidney disease, unspecified, without heart 
failure and with chronic kidney disease stage i through stage iv, or 
unspecified: 404.90 
Hypertensive heart and chronic kidney disease, unspecified, with heart 
failure and with chronic kidney disease stage i through stage iv, or 
unspecified: 404.91   
Hypertensive heart and chronic kidney disease, unspecified, without heart 
failure and with chronic kidney disease stage v or end stage renal disease: 
404.92   
Hypertensive heart and chronic kidney disease, unspecified, with heart 
failure and chronic kidney disease stage v or end stage renal disease: 
404.93 
Chronic kidney disease, stage i: 585.1 
Chronic kidney disease, stage ii (mild): 585.2 
Chronic kidney disease, stage iii (moderate): 585.3 
Chronic kidney disease, stage iv (severe): 585.4 
Chronic kidney disease, stage v: 585.5 
End stage renal disease: 585.6 
Chronic kidney disease, unspecified: 585.9 
 Renal failure unspecified:586 
Secondary hyperparathyroidism (of renal origin):588.81  
Other specified disorders resulting from impaired renal function : 588.9 
Diabetes with renal manifestations, type ii or unspecified type, not stated as 
uncontrolled: 250.40   
Diabetes with renal manifestations, type i [juvenile type], not stated as 
uncontrolled: 250.41   
Diabetes with renal manifestations, type ii or unspecified type, uncontrolled: 
250.42 
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Diabetes with renal manifestations, type i, uncontrolled: 250.43 
ICD-10 Codes  
Type 1 diabetes mellitus with incipient diabetic nephropathy adequately or 
inadequately controlled with insulin, diet, oral agents: E10.2 
Type 2 diabetes mellitus with incipient diabetic nephropathy adequately or 
inadequately controlled with insulin, diet, oral agents: E11.2 
Other specified diabetes mellitus with incipient diabetic nephropathy 
adequately or inadequately controlled with insulin, diet, oral agents: E13.2 
Unspecified diabetes mellitus with incipient diabetic nephropathy 
adequately or inadequately controlled with insulin, diet, oral agents: E14.2 
Hypertensive renal disease: I12 
Hypertensive renal and heart disease: I13 
Glomerular disorders in diseases classified elsewhere: N08 
Chronic renal failure: N18 
Unspecified renal failure: N19 
OHIP DX 
Hypertensive renal disease: 403  
 Chronic renal failure, uremia: 585  
Dialysis (exclusion criteria) CORR Please refer to CORR codes for dialysis above. 
Dialysis (reference group) CORR Please refer to CORR codes for dialysis above. 
Censoring events   
Non-vertebral fracture  Please refer to Table D.2. 
Death RPDB  
Additional censoring events   
Receipt of another kidney transplant
‡
 CORR Please refer to codes previously defined above. 
Dialysis
¥
 CORR  
Abbreviations: CCI=Canadian Classification of Health Interventions; CCP=Canadian Classification of Diagnostic, Therapeutic and Surgical Procedures; CIHI-
DAD=Canadian Institutes for Health Information-Discharge Abstract Database; CORR= Canadian Organ Replacement Registry; DXA= dual-energy x-ray 
absorptiometry; DX, diagnostic code; ICD=International Classification of Diseases; OHIP=Ontario Health Insurance Plan; RPDB=Registered Persons Database. 
‖We defined hemodialysis and peritoneal dialysis based on the modality they first received. We defined pre-emptive transplant as no evidence of hemodialysis or 
peritoneal dialysis prior to transplant. 
¶Years on dialysis prior to transplant was calculated by (transplant date-dialysis start date)/365.25. Individuals who received a pre-emptive transplant were given 0 
years as the time spent on dialysis. 
* All recipients with a Charlson Comorbidity Index of 0 were given a score of 2 and recipients with a score of 1 were given a score of 3; one of the variables in the CCI 
is presence of end-stage renal disease which automatically gives individuals a score of 2. The Charlson comorbidity index includes the following variables: acute 
myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic obstructive pulmonary disease, rehuamtic-like 
diseases, digestive system ulcers, mild liver disease, diabetes (with and without complications), hemiplegia or paraplegia, renal disease, cancer (with and without 
secondary), liver disease (moderate/severe),  and HIV/AIDS.  Source: Quan, H., V. Sundararajan, et al.. Coding algorithms for defining comorbidities in ICD-9-CM 
and ICD-10 administrative data. Med Care 2005; 43: 1130-1139 
‡ Defined as receipt of another transplant day 1 to 3 years after the initial transplant. 
¥ Defined as chronic dialysis in the 31 days to 3 years after the initial transplant.
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Table D. 2. Database codes used to identify non-vertebral fracture events 
 Diagnostic  codes 
Fracture 
Location
‡
 
ICD-9 Codes ICD-10 Codes 
 Hip  Neck of femur: 8200, 8201, 
8208, 8209 
Trochanteric/subtrochanteric: 
8202, 8203 
Neck of femur: S720 
Trochanteric: S721 
Subtrochanteric: S722 
Forearm  813  
 
S52 
Proximal 
Humerus  
812  
 
S422 
 Procedural codes
†
 
Fracture Location CCP Codes CCI Codes OHIP Fee Codes 
Hip  Reduction: 9104, 9124 
Reduction with fixation: 9054, 
9114, 9134 
Arthroplasty: 935x, 936x 
Reduction: 1VA73, 
1VC73 
Fixation: 1VA74,  
1VA53, 1VC74 
Arthroplasty: 1VA80 
Not applicable 
Forearm  Reduction: 9101, 9121, 
9141 
Reduction with fixation: 9111, 
9131, 9052 
Reduction: 1TV73 
Fixation: 1TV74  
Immobilization: 1TV03 
Reduction:  F014, 
F022, F023, F025, 
F026, F028, F030, 
F032, F033, F046 
Immobilization: 
F024, F027, F031, 
Z203 
Abbreviations: CCI, Canadian Classification of Health Interventions; CCP, Canadian Classification of Diagnostic, 
Therapeutic, and Surgical Procedures; ICD-9 CA, International Classification of Disease, Ninth Revision; ICD-10-CA, 
International Classification of Disease, Tenth Revision; OHIP, Ontario Health Insurance Plan 
‡Fracture diagnoses accompanied by trauma codes were included. 
†Procedural codes were required to accompany hip and forearm fractures for the diagnosis to be included as a fracture 
event. These procedural codes appeared within +/- 30 days of fracture diagnosis, using the respective hospital 
admission dates. We found that the proportion of diagnosis and procedural codes that had identical admission dates was 
very high (Hip, Canadian Institute of Health Research (CIHI) database, 99.4%; Forearm, CIHI, 98%; Forearm, OHIP, 
83%).
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Table D. 3. Database codes used to identify additional fracture events and fall events 
 Diagnostic  codes 
Fracture Location
‡
 ICD-9 Codes ICD-10 Codes 
Pelvis  Sacrum/coccyx: 8056, 8057 
Acetabulum/pubis/ilium/ischium 
/unspecified: 808x 
Sacrum/coccyx: S321, S322 
Acetabulum: S324 
Pubis/ilium/ischium: S323, S325  
Unspecified: S327, S328 
 
Vertebral  Thoracic: 8052, 8053  
Lumbar: 8054, 8055  
 
Thoracic: S220, S221  
Lumbar: S320x  
 
Femoral Shaft  Shaft or unspecified part, closed: 8210 
Shaft or unspecified part, open: 8211  
 
Shaft of femur: S723 
 
Lower leg Fracture of ankle: 824  
Fracture of tibia and fibula: 823  
Fracture of patella: 822 
Fracture of lower leg, including ankle: S82  
 
Rib/sternum/trunk  Fracture of rib(s), sternum, larynx, and 
trachea:807 
Fractures of bones of trunk:809 
 
Fracture of rib(s), sternum and thoracic spine: S22  
 
Other Fracture of clavicle: 810 
S820 
Fracture of scapula: 811 
Fracture of clavicle: S420 
S820 
Fracture of scapula: S421 
Falls with Hospital 
Presentation 
Accidental fall on or from escalator:E880.0  
Accidental fall on or from sidewalk curb: 
E880.1  
Accidental fall on or from other stairs or steps: 
E880.9  
Accidental fall from ladder: E881.0  
Accidental fall from scaffolding: E881.1 
Accidental fall from or out of building or other 
structure: E882  
Accident from diving or jumping into water 
(swimming pool): E883.0  
Accidental fall into well: E883.1  
Accidental fall into storm drain: E883.2  
Accidental fall into other hole or other opening 
Fall on same level involving ice and snow: W00  
Fall on same level from slipping, tripping and stumbling: W01 W02  
Fall involving ice-skates, skis, roller-skates or skateboards: W02 W03  
Other fall on same level due to collision with, or pushing by, another 
person:W03 
Fall while being carried or supported by other persons: W04  
Fall involving wheelchair: W05 
Fall involving bed: W06  
Fall involving chair: W07  
Fall involving other furniture: W08  
Fall involving playground equipment: W09  
Fall on and from stairs and steps: W10  
Fall on and from ladder: W11 
Fall on and from scaffolding: W12  
 
243 
 
 
 
in surface: E883.9  
Accidental fall from playground: E884.0  
Accidental fall from cliff: E884.1  
Accidental fall from chair: E884.2  
Accidental fall from wheelchair: E884.3  
Accidental fall from bed: E884.4  
Accidental fall from other furniture: E884.5  
Accidental fall from commode: E884.6  
Other accidental fall from one level: E884.9  
Accidental fall from (nonmotorized) scooter: 
E885.0  
Accidental fall from roller skates: E885.1  
Accidental fall from skateboard: E885.2  
Accidental fall from skis: E885.3  
Accidental fall from snowboard: E885.4  
Accidental fall from other slipping tripping or 
stumbling: E885.9  
Accidental fall on same level from collision 
pushing or shoving by or with other person in 
sports: E886.0  
Other and unspecified accidental falls on same 
level from collision pushing or shoving by or 
with other person: E886.9  
Fracture cause unspecified: E887  
Accidental fall resulting in striking against 
sharp object: E888.0  
Accidental fall resulting in striking against 
other object::E888.1 
Other accidental fall :E888.8 
Unspecified accidental fall: E888.9 
Fall from, out of or through building or structure: W13  
Fall from tree: W14  
Fall from cliff: W15  
Diving or jumping into water causing injury other than drowning or 
submersion: W16  
Other fall from one level to another: W17  
Other fall on same level: W18  
Unspecified fall: W19  
 
 Procedural codes
†
 
Fracture Location CCP Codes CCI Codes            OHIP Fee Codes 
Femoral Shaft 
Fracture 
Reduction: 9104, 9124 
Reduction with fixation: 9054, 
9114, 9134 
Reduction: 1VC73x 
Fixation: 1VC74x 
Immobilization: 1VC03x 
Other repair: 1VC80x 
Reduction: F095, F096, F097 
Immobilization: Z211 
Abbreviations: CCI, Canadian Classification of Health Interventions; CCP, Canadian Classification of Diagnostic, Therapeutic, and Surgical Procedures; ICD-9, 
International Classification of Disease , Ninth Revision;ICD-10-CA, International Classification of Disease, Tenth Revision; OHIP, Ontario Health Insurance Plan 
‡Fracture diagnoses accompanied by trauma codes were included. 
†Procedural codes were required to accompany femoral shaft fractures for the diagnosis to be included as a fracture event.
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Table D. 4.  Summary of validation studies of fracture code algorithms (description of studies) 
Study, 
Country, 
Year 
Study Population Database and 
source of data 
Validation 
Years 
Fracture Location Validated codes Possible Flags 
for Diagnostic 
Codes 
Gold 
Standard 
Hudson et al., 
Multinational, 
(2013) 
-Systematic review 
of validation studies 
 
 
-In-/outpatient 
records 
and pharmacy 
data 
-Group Health 
Plan 
-Local database 
and 
national register 
 
1987-2006 Hip  ICD-9 820-821 Any discharge 
diagnosis 
-Bone 
mineral 
density 
-Chart review 
-Self report 
-Radiology 
and medical 
reports 
 
Jean  et al.,     
Canada, 
(2012) 
-Women ≥50 years  -Quebec 
provincial 
database for 
medical service 
-Outpatient 
records 
2003-2006 -Hip, femur 
 
 
-Forearm, wrist, 
elbow 
 
-Foot, ankle 
 
-Pelvis 
 
- Tibia, fibula 
 
-Vertebra, sacrum, 
coccyx 
 
-Shoulder, humerus 
 
Fracture care 
method  
-open reduction 
-closed reduction 
-immobilization 
ICD-9 820-821 
 
 
ICD-9 8130–8133 
 
 
ICD-9  825 
 
ICD-9  8080–
8089 
 
ICD-9 823  
 
ICD-9 805–806 
 
 
ICD-9   810, 811, 
812 
 
 
At least one 
fracture claim 
combined with 
a  
procedural 
code for 
fracture 
treatment 
OR 
Visit with an 
orthopedic 
surgeon 
 
Chart review 
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Table D.4. (continued) 
Study, 
Country, Year 
Study 
Population 
Database and 
source of data 
Validation 
Years 
Fracture 
Location 
Validated 
codes 
Possible Flags 
for Diagnostic 
Codes 
Gold Standard 
Curtis et al.,      
USA, 
(2009) 
Gen. pop.  ≥18 
 
Insurance company 
(non-profit) 
administrative 
claims data  
2003-2004 Spine ICD 9-CM: 
8052, 8054, 
8058, 73313 
Primary 
diagnosis 
Two reviewers 
independently 
looked at medical 
records and 
radiology reports 
Henderson et 
al.,  
Australia, 
(2006) 
Sample of  
hospital 
admissions from 
Victoria, 
Australia 
Hospital discharge 
data 
2000-2001 Hip ICD 10-AM: 
S720, S721  
 
Discharge 
Diagnostic code 
-Auditors with 
coding experience  
(majority had 10 or 
more years of 
experience) 
Juurlink et al.,     
Canada,  
(2006) 
18 Hospitals 
from Ontario 
Hospital discharge 
data 
2002-2004 Femur 
 
 
Lower leg 
including 
ankle 
 
 
ICD 10-CA: 
S72  
 
ICD 10-CA: 
S82 
Most 
responsible 
Diagnostic 
Code 
Reabstractors  
trained by CIHI 
Joakimsen  
et al., 
Norway, 
(2001) 
-Tromso 
Norway 
residents  
-Male residents 
born between 
1925-1959; 
female residents  
(1930-1959) 
Self-report and 
computer linkage to 
radiographic 
archives from a 
University Hospital 
in Norway 
 
1988-1995 Hip 
 
Forearm 
 
ICD-9: 820  
 
ICD-9:813 
 
 
Discharge 
diagnostic code 
Radiographs 
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Table D.4. (continued) 
Study, 
Country, 
Year 
Study 
Population 
Database and 
source of data 
Validation 
Years 
Fracture Location Validated 
codes 
Possible Flags 
for Diagnostic 
Codes 
Gold 
Standard 
Tamblyn et 
al., 
Canada, 
(2000) 
General 
elderly 
population ( 
≥65 years) 
-Quebec 
outpatient 
physician 
Claims 
1993-1994 Skull & face  
 
Thorax  
 
Pelvis  
 
Scapula/clavicle 
  
Humerus  
 
Radius/ulna 
  
Carpal/hand  
 
Femoral shaft 
  
Patella  
 
Tibia/fibula  
 
Ankle  
 
Foot 
  
Hip 
ICD-9 800-
804 
 
ICD-9 807,809 
 
ICD-9 8-8 
 
ICD-9 810,811 
 
ICD-9 812 
 
ICD-9 813 
 
ICD-9 814-
817 
 
ICD-9 821 
 
ICD-9 822 
 
ICD-9 823 
 
ICD-9 824 
 
ICD-9 825,826 
 
ICD-9 820 
Emergency 
department 
diagnostic code 
Trained 
abstractor 
performed a 
chart review 
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Table D.4. (continued) 
Study, 
Country, 
Year 
Study 
Population 
Database and 
source of data 
Validation 
Years 
Fracture Location Validated codes Possible Flags 
for Diagnostic 
Codes 
Gold 
Standard 
Ray et al., 
USA, 
(1992) 
 
Gen. pop. ≥65 In-/outpatient 
records 
1987 Rib/sternum 
 
 
Pelvis/sacrum/coccyx 
 
 
 
Ankle 
 
Femoral Shaft 
 
Hand 
 
Tibia/Fibula 
 
Skull/face 
 
Foot 
 
Clavicle/Scapula 
 
Patella 
ICD-9:8070-
8074 
 
 
ICD-9: 8056, 
8057, 8066, 
8067, 808 
 
ICD-9: 824 
 
ICD-9: 821 
 
ICD-9: 814-817 
 
ICD-9: 823 
 
ICD-9: 800-804 
 
ICD-9: 825, 826 
 
ICD-9: 810,811 
 
ICD-9: 822 
Diagnostic codes 
unless the code 
meets the 
following 
exclusion criteria: 
- no 
corresponding 
procedural code 
for fracture  
in a clinic 
- absence of 
fracture discharge 
code after 
admission to 
hospital for a 
fracture  
- primary 
diagnosis of 
arthroplasty 
- follow-up 
treatment of an 
old fracture as 
identified through 
procedural codes 
 
Medical 
chart review 
Abbreviations: CIHI=Canadian Institute for Health Information; ICD-9= 9th version of the International Classification for Disease; ICD 9-CM= International 
Classification of Diseases, Ninth Revision, Clinical Modification ; ICD 10-AM= Australian Modification of the International Classification of Diseases, 
10th revision; ICD 10-CA= 10th version of the Canadian Modified International Classification of Disease system 
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Table D. 5 Accuracy of fracture database codes used in validation studies 
Study, 
Country, 
Year 
Database Fracture 
event 
Sample 
Size 
Prevalence 
(%) 
Sensitivity Specificity PPV NPV Kappa 
Hudson 
et al.,  
Multinational, 
(2013) 
Hospital discharge 
data 
Hip 12 studies n.r. 69-97% 
With the 
addition of 
procedural 
codes 83-97 
n.r. 63-96% 
With the 
addition of 
procedural 
codes 86-98 
n.r. n.r. 
Jean  
et al., 
Canada, 
(2012) 
Quebec provincial 
database for 
medical service 
Hip, femur  
Forearm, wrist, 
elbow 
 
Foot, ankle 
 
Pelvis 
 
Tibia, fibula 
 
Vertebra, 
sacrum, coccyx 
 
Shoulder, 
humerus 
 
Fracture care 
method 
Open reduction 
 
Closed 
reduction 
 
Immobilization 
 
41,288 
1506 for 
subsample 
368 (24.4) 
 
396 (26.3) 
 
236 (15.7) 
 
30 (2.0) 
 
83 (5.5) 
 
25 (1.7) 
 
 
238 (15.8) 
 
 
 
454 (30.1) 
 
 
214 (14.2) 
 
 
191 (12.7) 
99 (97-100) 
____________ 
95 (94-97) 
 
 
92 (89-95) 
 
82 (66-98) 
 
91 (87-96) 
 
50 (19-81) 
 
 
93 (90- 96) 
 
 
 
 
 
n.r. 83 (79-87) 
_________ 
 
90 (87-93) 
 
78 (72-83) 
 
63 (46-81) 
 
75 (64-83) 
 
76 (59-93) 
 
 
81 (76-86) 
 
 
96 (94-97) 
 
 
98 (96-100) 
 
 
84 (77-89) 
n.r. n.r. 
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Table D.5. (continued) 
Study, 
Country, 
Year 
Database Fracture 
event 
Sample 
Size 
Prevalence 
(%) 
Sensitivity Specificity PPV NPV Kappa 
Curtis et al., 
USA, 
(2009) 
Insurance 
company (non-
profit) 
administrative 
claims data (USA) 
Spine (vertebral 
compression 
fracture) 
259 63 
(24.3) 
32 
(22-44) 
99 
(96-100) 
91 
(72-97) 
82 
(77-86) 
0.39 
(0.27-0.51) 
Henderson 
 et al., 
Australia, 
(2006) 
A sample of 
Australian 
Hospital 
Discharge 
Data 
Hip 7,631 4579 
(0.60) 
 
95 
(94-96) 
 
856 
(85-87) 
 
91 
(90-92) 
 
92 
(91-93) 
 
0.82 
(0.80-0.84) 
Juurlink 
et al., 
Canada, 
(2006) 
CIHI-DAD Femur 
 
Lower leg 
including ankle 
13 803 356 
(2.6) 
68 
(0.5) 
95 
(93 - 97) 
 
 
99 
(92 - 100) 
n.r. 
 
 
 
n.r. 
95 
(92 -97) 
 
 
99 
(92- 100) 
n.r. 
 
 
n.r. 
0.95 
(0.94-0.97) 
 
 
0.99 
(0.96-1.00) 
Joakimsen  
et al., 
Norway, 
(2001) 
Local Norwegian 
Hospital 
Discharge 
Abstract Database 
Hip 21,441 54 (0.25) 87 
(76-94) 
100 
 
90 
(79-96) 
 
100 0.89 
(0.88-0.90) 
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Table D.5. (continued) 
Study, Country, Year Database Fracture event Sample Size Prevalence (%) Sensitivity Specificity PPV NPV Kappa 
Tamblyn  
 et al.,   
Canada, (2000) 
 
Quebec outpatient physician 
Claims 
Skull & face  
 
 
Thorax  
_____________ 
 
Pelvis  
____________ 
 
Scapula/clavicle 
 ___________ 
 
Humerus  
____________ 
 
Radius/ulna 
___________  
 
Carpal/hand  
___________ 
 
Femoral shaft 
 ____________ 
 
Patella  
___________ 
 
Tibia/fibula  
____________ 
 
Ankle  
____________ 
 
Foot 
 __________ 
 
Hip 
915 15 (1.6) 
 
 
47 (5.1) 
___________ 
 
26 (2.8) 
___________ 
 
13 (1.4) 
___________ 
 
88 (9.6) 
__________ 
 
110 (12.0) 
_________ 
 
44 (4.8) 
__________ 
 
15 (1.6) 
___________ 
 
16 (1.7) 
___________ 
 
18 (2.0) 
__________ 
 
41 (4.5) 
___________ 
 
31 (3.4) 
__________ 
 
178 (19.5) 
 
0a; 27b; 27c 
___________ 
 
0a; 26b; 26c 
___________ 
 
15a;54b;62c 
___________ 
 
62a; 69b; 77c 
___________ 
 
52a; 56b; 69c 
___________ 
 
64a; 41b; 66c 
___________ 
 
50a; 41b; 61c 
___________ 
 
93a; 60b; 93c 
___________ 
 
50a; 56b; 63c 
___________ 
 
56a; 38b; 63c 
___________ 
 
54a; 61b; 73c 
__________ 
 
61a; 42b; 68c 
___________ 
 
94a; 83b; 97c 
 
n.r. n.r. n.r. n.r. 
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Table D.5. (continued) 
Study, Country, Year Database Fracture Event Sample Size Prevalence (%) Sensitivity Specificity PPV NPV Kappa 
Ray  et al., USA, (1992) 
 
Medicaid (Parts A and B) 
 
Hip 
 
 
Radius/ulna 
 
 
Humerus 
 
 
Ribs/sternum 
 
 
Pelvis 
 
 
Femoral shaft 
  
 
Hand 
 
 
Tibia/fibula 
___________ 
 
Foot 
____________ 
 
Clavicle/scapula 
____________ 
 
Patella 
___________ 
 
Ankle 
____________ 
 
All 
1,311 538 (41.0) 
___________ 
 
162 (12.4) 
__________ 
 
109 (8.3) 
___________ 
 
107 (8.2) 
_________ 
 
67 (5.1) 
________ 
 
53 (4.0) 
__________ 
 
43 (3.3) 
__________ 
 
47 (3.6) 
__________ 
 
40 (3.1) 
___________ 
 
21 (1.6) 
 
___________ 
 
17 (1.3) 
__________ 
 
69 (5.3) 
____________ 
 
1311 (100) 
97 
_________ 
 
93 
_________ 
 
90 
_________ 
 
82 
______ 
 
89 
_________ 
75 
 
_________ 
 
87 
_________ 
 
87 
_________ 
 
90 
_________ 
 
91 
 
_________ 
 
100 
_________ 
 
78 
_________ 
 
91 
n.r. 98 
____ 
 
96 
____ 
 
95 
____ 
 
84 
____ 
 
93 
____ 
 
87 
____ 
 
86 
____ 
 
79 
___ 
 
95 
____ 
 
86 
 
____ 
 
82 
____ 
 
96 
____ 
 
94 
n.r. n.r. 
Abbreviations: CIHI-DAD, Canadian Institute for Health Information-Discharge Abstract Database;  ICD-9, international classification of diseases; NPV, negative 
predictive value; n.r.=not reported; PPV, positive predictive value; a-procedure code alone; b- diagnostic code alone; c- procedure or diagnostic code 
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D.1.2  Power 
Based on a recently conducted study using the CORR dataset that applied similar 
inclusion/exclusion criteria to this chapter it was expected there would be over 5000 
kidney transplant recipients eligible for inclusion. It was anticipated that there would be 
over 1,000,000 adults who would meet the eligibility criteria for individuals with no 
kidney disease and with no prior non-vertebral fracture (18).
 
The two-sample independent 
chi-square test which allows for unequal group sizes (1:3) was used to calculate power 
(alpha 0.05) (19). Based on these calculations it was expected there would be >80% 
power. See Table D.6 for a sensitivity analysis of power calculations and Figure D.1 for 
the power formula used in the calculations. Given the large sample size statistical 
significance may not equate to clinical significance. For this reason a priori clinical 
significance was defined as a ≥ 50% relative increase in non-vertebral fracture in kidney 
transplant recipients compared to individuals with no kidney disease and no prior non-
vertebral fracture; this was chosen in consultation with transplant nephrologists and was 
defined as the magnitude of effect needed to influence the clinical care of kidney 
transplant recipients. 
 
______________________________________________________________________________ 
√  |     |=  √  (    )(           )   +   √  (      )          (    )     
 
N= sample size 
  =proportion kidney transplant recipients who fractured  
  = proportion of individuals who do not have kidney disease and have not sustained a prior non-vertebral 
fracture and do not have an osteoporosis diagnosis who fractured  
  = 0.05 
 ̅=     +      
  
    =sample size for kidney transplant recipients 
  
  = sample size for individuals who do not have kidney disease and have not sustained a prior non-
vertebral fracture and do not have an osteoporosis diagnosis.  
  =power to detect a statistically significant difference (this formula was solved for   ) 
 
Figure D.1. Formula for power calculation 
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Table D. 6. Sensitivity analysis for power calculations (Objective 3b) 
Percentage of kidney 
transplant recipients with 
non-vertebral fracture 
Percentage of 
individuals with no 
kidney disease and 
no prior non-
vertebral fracture 
Power achieved* 
1% 0.6% 0.806 
2% 0.6% >.999 
4% 0.6% >.999 
6% 0.6% >.999 
8% 0.6% >.999 
10% 0.6% >.999 
12% 0.6% >.999 
*Based on access to 5000 kidney transplant recipients and randomly selecting 15,000 individuals who do not have 
kidney disease and have not sustained a prior non-vertebral fracture and do not have an osteoporosis diagnosis.  
 
D.1.3 Cohort Creation Additional Details: Kidney Transplant Recipients 
Inclusion Criteria: 
i. Evidence of receipt of a kidney transplant between July 1st, 1994 and 
December 31st, 2009. Rationale: The reason for having the accrual period end 
December 31st, 2009 was to ensure that the incidence rate was useful for 
sample size calculations in future clinical trials; therefore, ending the accrual 
on December 31st, 2009 allowed for the three-year incidence rate of fracture 
to be determined (last date of follow-up December 31st, 2012). The length of 
follow-up in previously conducted systematic reviews on clinical trials 
assessing the relationship between fracture and bisphosphonate use in the non-
transplant population was between one and four years (20-22). Although the 
mean length of follow-up in trials assessing interventions to prevent bone 
disease in kidney transplant recipients was 15 months a meta-analysis 
recommended that the length of follow-up was underestimated resulting in 
inadequate power to determine the effects of fracture prevention treatment on 
fracture rates (23). 
ii.  An age of ≥ 18 years at the date of transplant. Rationale: Adult recipients 
were the sole focus of Chapters 4, 5, and 6 as mechanisms underlying fracture 
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risk in children with decreased kidney function are different and would be the 
subject of other studies (24). 
Exclusion Criteria: 
i. Individuals with an invalid Institute for Clinical Evaluative Sciences (ICES) 
key number (IKN) [each individual has a unique IKN that is used allowing for 
linkage with other databases], missing sex, missing date of birth, and date of 
death prior to index date (date of transplant). Rationale: These were data 
cleaning steps. 
ii. Non-Ontario residents. Rationale: These individuals would be more likely to 
go back to their province of residence after receiving the transplant and 
therefore follow-up data (e.g. death) would not be available for these 
individuals using ICES data sources. 
iii. Recipient of multiple organ transplants (including multiple kidney transplants) 
or combination transplants (e.g. kidney-pancreas) prior to receiving a kidney 
transplant. Rationale: Recipients of multiple/combination transplants may 
have different comorbidities (24, 25). The focus of chapters 4, 5, and 6 was on 
first time kidney-only transplant recipients.  
Figure D.2 describes the cohort selection for kidney transplant recipients. 
Figures D.3, D.4, and D.5 describe the cohort selection for the reference 
groups including: healthy segment of the general population with no previous 
non-vertebral fracture, healthy segment of the general population with a 
previous non-vertebral fracture, and non-dialysis chronic kidney disease. 
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Figure D. 2. Cohort selection for kidney transplant recipients 
Abbreviations: CORR, Canadian Organ Replacement Registry; IKN, Institute for Clinical Evaluative Sciences key 
number 
 
 
5913 Ontario kidney transplant recipients 
listed in CORR from 1994-2009 
4821 Ontario kidney transplant 
recipients included in the analysis 
13 Recipients excluded during data 
cleaning (i.e., missing sex, missing 
date of birth, invalid IKN, death 
date ≤ index date) 
 
1079 Recipients excluded: 
 
7 Non-Ontario residents  
 
255 Age <18 years at index date 
(transplant date) 
 
566 History of any transplant prior to 
index date including previous kidney 
transplant (look back to 1981) 
 
251 Previous multi-organ transplant 
(including kidney-pancreas) 
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Figure D. 3. Cohort selection for the healthy segment of the general population with no 
previous non-vertebral fracture 
Abbreviation: IKN, Institute for Clinical Evaluative Sciences key number 
 
18,194,929 
Ontario individuals in the databases from 1994-2009 
who were not in the kidney transplant recipient cohort 
19,284 Ontario individuals with no 
previous non-vertebral included in the 
analysis after matching 
 
3,464,196 Individuals excluded during 
data cleaning (i.e., invalid IKN, missing 
sex, missing date of birth, non-Ontario 
resident, death date ≤ index date) 
 
4,092,337 Individuals excluded: 
 
3, 494, 309 Age <18 years at index date  
 
137,272 History of chronic kidney 
disease 
 
8427 History of any transplant or 
dialysis code 
 
331,475 History of osteoporosis 
 
119, 769 previous non-vertebral fracture 
in the 5-years prior to index date 
 
1085 Age ≥105 years at index date 
 
10,638,396 Individuals eligible to be 
matched to kidney transplant recipients 
 
257 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure D. 4. Cohort selection for the healthy segment of the general population with a 
previous non-vertebral fracture 
Abbreviation: IKN, Institute for Clinical Evaluative Sciences key number 
 
 
18,194, 929 Ontario individuals in databases 
from 1994-2009 who were not in the kidney 
transplant recipient cohort 
 
4821 Ontario individuals with a 
previous non-vertebral included in the 
analysis after matching 
3,464,196 Individuals excluded during 
data cleaning (i.e., invalid IKN, 
missing sex, missing date of birth, non-
Ontario resident, death date ≤ index 
date) 
 
14,644,961 Individuals excluded: 
 
3, 494, 309 Age <18 years at index 
date  
 
137,272 History of chronic kidney 
disease 
 
8427 History of any transplant or 
dialysis code 
 
11,004,945 with no non-vertebral 
fracture in the 5-years prior to index 
date 
 
8 Age ≥105 years at index date 
 
 
85,770 Individuals eligible to be 
matched to kidney transplant recipients 
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Figure D. 5. Cohort selection for non-dialysis chronic kidney disease (CKD) 
Abbreviation: IKN, Institute for Clinical Evaluative Sciences key number 
481,918 Ontario individuals with 
evidence of a CKD diagnostic code 
from 1994-2009 
19,284 Ontario individuals with non-
dialysis CKD included in the analysis 
after matching 
3245 Individuals excluded during data 
cleaning (i.e., invalid IKN, missing sex, 
missing date of birth, non-Ontario 
resident, death date ≤ index date) 
 
25,740 Individuals excluded: 
 
12,256 Age <18 years at index date 
 
19 Age ≥105 
 
7188 Previous dialysis code 
 
2279 Previous transplant 
 
3998 Selected in the kidney 
transplant recipient cohort 
452,924 Individuals eligible to be 
matched to kidney transplant 
recipients 
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 D.1.4 Confounders 
Age (± one year), sex, and cohort entry date (index date) (± one year) were 
controlled through individual matching with the reference groups. Age and sex were both 
considered potential confounders as numerous studies in both the non-transplant and 
transplant population have found older age and female sex to be associated with an 
increased fracture risk (26-32). Index date was also controlled for as numerous changes in 
clinical practice (e.g. pharmacotherapy) and in the patient population (e.g. increase in 
obesity) have occurred from 1994-2009 (33-36). In an additional analysis diabetes was 
also adjusted for given that diabetes is an established risk factor for fracture (37). The 
reason other confounders were not controlled for was that the rationale for this study was 
to determine if kidney transplant recipients had a high risk of fracture; markers that are 
helpful to determine high risk individuals (e.g. kidney transplantation is a marker of an 
increased fracture risk) can be confounded (38). For example, even if recipients have a 
higher risk of fracture as a result of low activity levels (potential confounder) fractures 
are still more common in individuals with a kidney transplant and therefore potential 
preventative actions (e.g. bisphosphonates) should be considered. Therefore, a true 
statistical relationship even if it is confounded is helpful for public health as it identifies 
individuals who are at a high risk and therefore need to be screened (38). 
D.1.5 Cox Proportional Hazard Analysis 
To ensure that the proportional hazard assumption was met it was assessed using 
two different methods. First, a graphical approach (log-log survival curves) was used to 
visually assess violations of the proportional hazard assumption (Figure D.6) (39).  If the 
log-log survival curves did not appear parallel (e.g. lines cross-over, converged or 
diverged) then the Extend Cox model would be considered (39). Second, a statistical test 
was used to assess the proportional hazard assumption (40); if the p-value was <0.05 then 
the proportional hazard was considered violated. Specifically, the ASSESS option in 
PROC PHREG (SAS) was used which plots the follow-up time against the observed 
score process (41). The proportional hazards assumption was not violated in this chapter. 
However, it is important to note that when the log-log survival curve for CKD and 
transplantation was assessed the curves did cross-over; however, when assessing the 
proportional hazards assumption, using multiple methods, the p-values were all >0.05 
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(Assess method in SAS, P=0.33; time-dependent method, P=0.23; Schoenfeld residuals, 
P=0.29). It is recommended that the extended Cox model should only be used if the 
evidence for non-parallelism is strong (39); therefore, the Cox proportional hazard model 
was used when comparing fractures in CKD and kidney transplant recipients. 
 
Figure D. 6. Log-minus-log survival curves of the primary outcome (non-vertebral 
fracture) for each reference group 
a) General population with no previous non-vertebral fracture 
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b) General population with a previous non-vertebral fracture 
 
c) Non-dialysis chronic kidney disease (CKD) 
 
Note: Although the two curves cross when assessing the proportional hazards assumption using multiple methods the p-
values were all >0.05 (ASSESS method in SAS, P=0.33; time-dependent method, P=0.23; Schoenfeld residuals, 
P=0.29). 
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d) Rheumatoid arthritis 
 
 
 D.1.6 Competing Risk of Death 
To take into account the potential competing risk of death the 3-year cumulative 
incidence of fracture was also calculated using the cumulative incidence function; this 
function estimates the cumulative probability of fracture while taking into account the 
competing risk of death (42, 43). Cumulative incidence estimates were nearly identical 
regardless of the method used. A modified version of the Cox proportional hazard 
analysis for cause-specific hazards proposed by Fine and Gray (1999) was used to assess 
competing risks (43); no substantial difference in hazard ratio estimates were found using 
the two methods; therefore, all results in chapter 4 were presented using standard Cox 
proportional hazard regression. 
 
D.2 Additional Analyses and Results: Rheumatoid Arthritis Reference Group 
Originally, it was proposed to include rheumatoid arthritis as a reference group to 
compare fracture rates with kidney transplant recipients allowing recipients to be 
compared to another group of individuals who are often prescribed steroids (a risk factor 
for fracture) (44). This reference group was not included in the main text of chapter 4. 
However, the methods and results of this analysis are presented below.  
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D.2.1 Rheumatoid Arthritis Cohort Selection 
Databases were reviewed from July 1
st
, 1994-December 31
st
, 2009 for first 
evidence of one hospitalization for rheumatoid arthritis or three OHIP diagnostic codes 
for rheumatoid arthritis with at least one diagnostic code given by a rheumatologist, 
orthopedic surgeon, or general internist within a two year period (sensitivity 97%, 95% 
CI, 94-100%; specificity 85%, 95% CI 81-89%; positive predictive value 76%, 95% CI 
70-82%; negative predictive value 98%, 95% CI 96-100%) (45).  Individuals were 
excluded who met any of the following criteria: <18 years at index date, prior kidney 
disease, previous transplant, or selected for the kidney transplant recipient cohort. Figure 
D.7 describes the cohort selection for rheumatoid arthritis.   
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Figure D. 7. Cohort selection for rheumatoid arthritis 
Abbreviation: IKN, Institute for Clinical Evaluative Sciences key number 
 
117, 539 Ontario individuals with 
rheumatoid arthritis from 1994-2009 
4821 Ontario individuals with 
rheumatoid arthritis included in the 
analysis after matching 
174 individuals excluded during data 
cleaning (i.e., invalid IKN, missing sex, 
missing date of birth, non-Ontario 
resident, death date ≤ index date) 
 
5961 Individuals excluded: 
 
2524 Age <18 years at index date  
 
371 Previous dialysis code 
 
3025 Previous chronic kidney disease 
 
11 Previous transplant  
 
30 Selected in the kidney transplant 
recipient cohort 
 
111,404 Individuals eligible to be 
matched to kidney transplant recipients 
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D.2.2 Rheumatoid Arthritis Results 
After matching (age [± 1 year], sex, and index date [± 1 year]) individuals with 
rheumatoid arthritis to recipients there were a total of 4821 individuals with rheumatoid 
arthritis (matched 1:1). Matching characteristics were similar between individuals with 
rheumatoid arthritis and kidney transplant recipients (Table D.7). Individuals with 
rheumatoid arthritis were followed for 14,200 person-years, 142 died (3.0%), and 30 
(0.6%) sustained a non-vertebral fracture. The 3-year cumulative incidence of non-
vertebral fracture was 0.6% (95% CI 0.4-0.9%) and was highest in women aged ≥ 50 
years (1.6%, 95% CI 0.9-2.5%) (Table D.8). Recipients had a higher 3-year cumulative 
incidence of non-vertebral fracture (1.6%, 95% CI 1.3-2.0%) compared to individuals 
with rheumatoid arthritis (0.6, 95% CI 0.4-0.9%; P-value<0.001 by the log-rank test).  
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Table D. 7. Baseline characteristics of kidney transplant recipients compared to 
rheumatoid arthritis 
Characteristic Kidney transplant 
recipients 
(n=4821) 
Rheumatoid 
Arthritis 
(n=4,821) 
Age, years 50 (38-59) 50 (38-59) 
Women 1781 (36.9%) 1781 (36.9%) 
Era 
1994-1997 
1998-2001 
2002-2005 
2006-2009 
 
914 (18.9%) 
1111 (23.1%) 
1182 (24.5%) 
1614 (33.5%) 
 
908 (18.8%) 
1130 (23.4%) 
1196 (24.8%) 
1587 (32.9%) 
Hypertension 3572 (74.1%) 1282 (26.6%) 
Diabetes 1255 (26.0%) 533 (11.1%) 
Cardiovascular disease
¶
 2068 (42.9%) 551 (11.4%) 
Prior non-vertebral 
fracture
‡ 
106 (2.2%) 
 
55 (1.1%) 
Data are medians (interquartile range) or n(%). 
¶Cardiovascular disease was defined as the presence of peripheral vascular disease, congestive heart failure, or coronary 
artery disease. 
‡Prior non-vertebral fracture defined as a composite of proximal humerus, forearm, hip fractures from 1991 to cohort 
entry. The median number of years (interquartile range) of baseline records prior to cohort entry is as follows: kidney 
transplant recipients, 11.9 years (7.5-15.6); rheumatoid arthritis 11.9 years (7.6-15.5). 
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Table D. 8. 3-year cumulative incidence, incidence rate, and hazard ratios of non-
vertebral fracture (proximal humerus, forearm, or hip) in kidney transplant recipients 
compared to rheumatoid arthritis 
Population 3-year 
cumulative 
incidence, %
 
(95% CI)
 
Incidence rate 
per 1000 
person years
 
(95% CI)
 
Hazard Ratio
‡
 
(95% CI) 
Hazard Ratio⃰  
(95% CI) 
Kidney transplant 
recipients
 
(n=4821) 
1.6 
(1.3-2.0) 
5.6 
(4.4-6.9) 
1.00 
(reference) 
1.00 
(reference) 
 
Rheumatoid 
arthritis 
(n=4821) 
 
 
0.6 
(0.4-0.9) 
 
2.1 
(1.4-3.0) 
 
0.4 
(0.3-0.6) 
 
0.4 
(0.3-0.7) 
‡ Matched on age (±1 year), sex, and index date (±1 year) 
⃰ Matched on age (±1 year), sex, and index date (±1 year) and adjusting for diabetes.
 
 
D.3 Additional Analyses and Results: Dialysis Reference Group 
It was proposed to compare fracture rates in kidney transplant recipients to 
dialysis patients on the kidney transplant waitlist. However, this reference group was not 
included in the main text of chapter 4 because kidney transplant waitlist data was not able 
to be accurately obtained from the ICES data holdings. Initially, kidney transplant waitlist 
data contained in the CORR database was to be used in this analysis; however, upon 
working with the data it was apparent the data was inaccurate with 99.9% of individuals 
on the kidney transplant waitlist receiving a transplant; this is inaccurate as in 2012 there 
were 115 individuals who withdrew from the waitlist and 34 individuals who died on the 
waitlist (46). Moreover, approximately 44% of individuals were missing information on 
whether they were active on the waitlist (eligible to receive a transplant when one 
becomes available) versus inactive (for short period of time medical reasons or other 
reasons prohibit an individual from receiving a transplant) (46).  Only information on 
patients who were on dialysis, without indication of waitlist status, could be obtained. 
However, individuals on dialysis are not an adequate comparator group as many 
individuals are too sick to be on the waitlist and would never qualify for transplantation. 
Therefore, previous studies comparing outcomes in dialysis patients to transplant 
recipients have used waitlist data in an attempt to make the health status comparable 
between the two groups (47, 48). For this chapter multiple strategies were used in an 
attempt to create a “mock waitlist”. For example, the Canadian Society of 
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Transplantation guidelines for transplant eligibility were used in an attempt to create a 
group of individuals who were likely on the waitlist based on eligibility (49). However, 
the guidelines state that transplants are contraindicated under the following conditions: 
active infections, non-adherence to medication, and substance abuse (49); it would be 
difficult to reliably obtain information on active infections and substance abuse from 
ICES databases. Moreover, there would be no way to determine medication adherence. 
Additionally, some of the guidelines depend on severity of disease and information on 
severity of disease is not available in ICES (49). After consultation with several 
transplant nephrologists across the province it was agreed that an accurate representation 
of individuals on the kidney transplant waitlist could not be reliably created. However, 
given it is still of interest to assess whether kidney transplant recipients have a higher 
fracture risk compared to dialysis patients this was conducted as an additional analysis 
and attempts were made to control for the differences in health status between the two 
groups. 
D.3.1 Dialysis Cohort Selection 
The CORR database was reviewed from July 1
st
, 1994- December 31
st
, 2009 for 
first evidence of chronic dialysis. Individuals were excluded under the following 
conditions: 1) <18 years of age at index date, 2) previous transplant, and 3) chronic 
dialysis prior to the index date (to ensure incident patients). The date of cohort entry 
(index date) was defined as the date of the first chronic dialysis code. In an attempt to 
include healthier dialysis patients, for individuals whose index date was within a hospital 
admission the index date became the date of hospital discharge and if the individual died 
during hospitalization they were excluded from the cohort. Moreover, if the discharge 
date was after the study accrual period (December 31, 2009) then these individuals were 
excluded. Figure D.8 describes the cohort selection for dialysis patients. 
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Figure D. 8. Cohort selection for dialysis population 
Abbreviations: CORR, Canadian Organ Replacement Registry; IKN, Institute for Clinical Evaluative Sciences key 
number; OHIP, Ontario Health Insurance Plan 
 
 
  
62,467 
Chronic dialysis codes recorded in CORR from 
1994-2009 
22,539 Ontario individuals on dialysis 
56 Individuals excluded during data 
cleaning (i.e., invalid IKN, missing sex, 
age date of birth, non-Ontario resident, 
death date>index date) 
 
6823 Individuals excluded: 
 
315 Age <18 years at index date 
 
1425 History of any transplant  
 
1544 Previous dialysis in CORR or OHIP 
 
3498 Died in hospital 
 
32 Discharge date from hospital after accrual 
period (never left hospital) 
 
9 Death date before transplant date 
29,418 Unique individuals recorded in 
CORR with a chronic dialysis code 
after restricting to the first date the code 
was recorded (many individuals had 
multiple codes for chronic dialysis) 
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D.3.2 Dialysis Statistical Analysis 
To assess whether kidney transplant recipients had a higher rate of non-vertebral 
fractures compared to dialysis patients a Cox model that allowed for time-dependent 
covariates, known as the Extended Cox model was used (39). This allowed for changes in 
treatment modality (dialysis patients receiving a transplant during follow-up) to be taken 
into account and modeled as a time-dependent covariate  (39). Specifically, if an 
individual did not receive a transplant prior to being censored (censored at fracture, 
death, or end of follow-up [December 31, 2012]) they remained in the dialysis group; 
however, if an individual received a kidney transplant before being censored they were 
placed in the transplant group and followed forward in time for a fracture event. This 
method has been used in previous studies assessing changes in transplant status (50). Age 
at dialysis start date (continuous variable), sex, and index date (dialysis start date) were 
adjusted for in the Extended Cox model. In an additional analysis the Charlson 
comorbidity index (CCI) (continuous variable) was also adjusted for in an attempt to 
make the health status comparable between individuals who remained on dialysis and 
individuals who received a transplant. The CCI is a score that predicts 10-year mortality 
based on the presence of comorbid conditions (e.g. heart disease, dementia, liver disease, 
diabetes, tumor) (51) and has been found to be an accurate tool to assess comorbidities in 
kidney transplant recipients (52) and in dialysis patients (53).  One of the comorbidities 
included in the CCI is presence of end-stage renal disease which is assigned 2 points; 
therefore, all individuals were given a minimum score of 2 (51); if individuals were 
found to have a score of 0 they were given a score of 2 and if they had a score of 1 they 
were given a score of 3. In an additional analysis a modified version of Cox hazard 
regression for cause-specific hazards proposed by Fine and Gray (1999) was used to 
account for the competing risk of death (43). 
D.3.3 Dialysis Results 
After the exclusion criteria was applied there were 22,539 adult Ontario 
individuals who were on dialysis with 19,075 individuals who remained on dialysis 
throughout the study period and 3464 individuals who received a transplant. When 
comparing individuals who remained on dialysis to individuals who received a transplant, 
individuals remaining on dialysis were older (median age 71 vs 48 years) and had more 
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comorbidities (diabetes 54.8% vs 33.7%; coronary artery disease 52.7% vs 23.3%; prior 
non-vertebral fracture 4.1% vs 1.0%) (Table D.9). Individuals on dialysis who never 
received a transplant were followed for 69,264 person-years (average 3.6 years), 14,640 
died (76.7%), and 1645 (8.6%) sustained a non-vertebral fracture. Individuals on dialysis 
who eventually received a kidney transplant were followed for 33,606 person-years 
(average 9.7 years), 788 died (22.8%), and 150 (4.3%) sustained a non-vertebral fracture. 
The incidence rate of non-vertebral fracture in individuals who remained on dialysis was 
23.8 fractures per 1000 person-years (95% CI % 22.6-24.9) (Table D.10). In individuals 
who received a transplant the incidence rate for non-vertebral fracture was 4.6 fractures 
per 1000 person-years (95% CI 3.8-5.2). Individuals who received a transplant during 
follow-up had a significantly lower fracture rate compared to individuals who remained 
on dialysis even after adjusting for comorbidities (HR 0.59, 95% CI 0.49-0.72) (Table 
D.10). Specifically, at any given time, the fracture hazard for an individual who has not 
received a transplant was approximately 1.7 times the hazard of fracture for an individual 
who already received a transplant at that time. However, it is important to remember that 
patients in the dialysis group could receive a transplant later on in follow up. When 
accounting for the competing risk of death the fracture rate was significantly higher in 
kidney transplant recipients compared to individuals who remained on dialysis after 
adjusting for relevant covariates (HR 1.61, 95% C I1.33-1.93) (Table D.10). A potential 
explanation for the change in direction of the hazard is that many dialysis patients died 
prior to being able to observe a fracture or receive a transplant. In the non-competing risk 
model, censoring for death leaves patients open to experiencing a fracture in follow up, 
suggesting that all we know is that the patient did not have a facture at the time of 
censoring (or death).  In the Fine and Gray model, those patients who died are considered 
weighted so that they are not considered “censored” (43). Moreover, without accounting 
for the competing risk of death fracture risk was overestimated in dialysis patients. 
Clinically, it is plausible that kidney transplant recipients may have a higher fracture risk 
due to greater activity levels in recipients compared to dialysis patients (54-57). Ball et 
al. found similar results with kidney transplant recipients having a higher fracture risk in 
the first 630 days after transplant (adjusted relative risk 1.34, 95% CI 1.12-1.61) 
compared to dialysis patients who remained on the kidney transplant waitlist; after this 
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time period patients who continued with dialysis had a higher fracture risk (48). 
However, this study did not state whether they accounted for the potential competing risk 
of death.  
 
Table D. 9. Baseline characteristics of dialysis patients and kidney transplant recipients
†
 
 Dialysis with no 
transplant 
(n=19,075) 
Transplantation 
(n=3,464) 
Total cohort 
(n=22,539) 
Age, years 
 
71 (61-78) 
 
48 (38-57) 
 
68 (56-76) 
 
Women 8035 (42.1%) 1232 (35.6%) 9267 (41.1%) 
 
Era 
1994-1997 
 
1998-2001 
 
2002-2005 
 
2006-2009 
 
 
 
1764 (9.3%) 
 
5085 (26.7%) 
 
6084 (31.9%) 
 
6142 (32.2%) 
 
 
803 (23.2%) 
 
981 (28.3%) 
 
892 (25.8%) 
 
788 (22.7%) 
 
 
 
2567 (11.4%) 
 
6066 (26.9%) 
 
6976 (31.0%) 
 
6930 (30.7%) 
Diabetes 10,444 (54.8%) 1167 (33.7%) 
 
11,615 (51.5%) 
 
Hypertension 15,911 (83.4%) 2712 (78.3%) 18,623 (82.6%) 
 
Peripheral vascular disease 
 
1899 (10.0%) 
 
146 (4.2%) 
 
2045 (9.1%) 
 
Congestive heart failure 
 
8485 (44.5%) 
 
350 (10.1%) 
 
8835 (39.2%) 
 
Coronary artery disease 
 
10,057 (52.7%) 
 
806 (23.3%) 
 
10,863 (48.2%) 
 
Fracture (hip, forearm,  
or proximal humerus) from 
1991 to cohort entry
¥
 
 
783 (4.1%) 
 
36 (1.0%) 
 
819 (3.6%) 
 
Race 
Caucasian 
 
Black 
 
Asian 
 
Other
‡
  
 
Unknown 
 
 
13091 (72.9%) 
 
777 (4.1%) 
 
1097 (5.8%) 
 
1818 (9.5%) 
 
1482 (7.8%) 
 
 
 
2467 (71.2%) 
 
215 (6.2%) 
 
214 (6.2%) 
 
373 (10.8%) 
 
195 (5.6%) 
 
 
16,373 (72.6%) 
 
994 (4.4%) 
 
1311 (5.8%) 
 
2193 (9.7%) 
 
1677 (7.4%) 
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Cause of end-stage renal 
disease 
Glomerulonephritis 
 
Cystic kidney disease 
 
Diabetes 
 
Renal vascular disease 
 
Other 
 
Unknown/missing 
 
              
1994 (10.5%) 
 
554 (2.9%) 
 
7347 (38.5%) 
 
4441 (23.3%) 
 
2467 (12.9%) 
 
2272 (11.9%) 
 
          
1086 (31.4%) 
 
436 (2.6%) 
 
874 (25.2%) 
 
322 (9.3%) 
 
429 (12.4%) 
 
317 (9.2%) 
 
 
3080 (13.7%) 
 
990 (4.4%) 
 
8221(36.5%) 
 
4763 (21.1%) 
 
2896 (12.9%) 
 
2589 (11.5%) 
 
Pre-transplant dialysis 
Hemodialysis 
 
Peritoneal dialysis 
 
15,025 (78.8%) 
 
4050 (21.2%) 
 
2235 (64.5%) 
 
1229 (35.5%) 
 
17,260 (76.6%) 
 
5279 (23.4%) 
 
Dialysis vintage 
 
 
 
2.8 (1.4- 4.9) 
 
 
Charlson Comorbidity Index 3 (2-5) 
 
2 (2-3) 
 
3 (2-4) 
 
Data are median (interquartile range) or n(%) 
† Baseline characteristics were determined looking backwards in time from the dialysis start date. For example, age is 
shown as age placed on dialysis for both groups. 
¥The median number of years (interquartile range) of baseline records prior to cohort entry (defined as date placed on 
dialysis) is as follows: dialysis patients with no transplant, 12.3 years (9.0-15.4); transplant, 10.2 years (6.8-14.2); total 
cohort, 12.0  years (8.6-15.2). 
‡ Other was defined as a composite of  Indian Sub-Continent, Pacific Islander, Aboriginal,  Mid East/Arabian, Latin 
American, Other/Multiracial. 
 
Table D. 10. 3-year cumulative incidence, incidence rate, and hazard ratio of non-
vertebral fracture (hip, forearm, or proximal humerus) in kidney transplant recipients 
compared to dialysis patients 
 Dialysis 
(n=19,075) 
Transplantation 
(n=3464) 
Cumulative incidence
¥
, %
 
(95% CI) 
 
11.1 
(10.0-12.2) 
7.3 
(6.1-8.7) 
Incidence rate per 1000  
person years
 
(95% CI) 
23.6 
(22.4-24.7) 
 
4.6 
(3.8-5.2) 
 
Hazard ratios not accounting for the competing risk of death 
Hazard ratio 
(95% CI)
* 
 
1.00 0.29 
(0.24-0.35) 
Hazard ratio
¶
 
(95% CI) 
 
1.00 0.57 
(0.47-0.69) 
Hazard ratio
‡
 
(95% CI) 
1.00 0.59 
(0.49-0.72) 
Hazard ratios accounting for the competing risk of death 
Hazard ratio 1.00 1.00 
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(95% CI)
* 
 
(0.85-1.18) 
Hazard ratio
¶
 
(95% CI) 
 
1.00 1.61 
(1.33-1.93) 
Hazard ratio
‡
 
(95% CI) 
1.00 1.57 
(1.30-1.89) 
¥Cumulative incidence was calculated using the cumulative incidence function was takes into account the competing 
risk of death. 
*Hazard ratio was unadjusted. 
¶Hazard  ratio was adjusted for age placed on dialysis, sex,  and date placed on dialysis. 
‡ Hazard ratio was adjusted for age placed on dialysis, sex, date placed on dialysis, and Charlson comorbidity index at 
the date placed on dialysis. 
  
It is important to note that these results should be interpreted with caution. As 
discussed in section D.3, information on dialysis patients who were on the kidney 
transplant waitlist was not able to be obtained; therefore, many individuals in the dialysis 
patient group who never transplanted may have been too sick to be eligible for a 
transplant, potentially impacting our findings. For example, Stehman-Breen et al., found 
that dialysis patients had a higher fracture risk compared to kidney transplant recipients 
(58); however, the authors noted that fracture risk in recipients may have been 
underestimated as they included all dialysis patients, not just individuals on the waitlist; 
therefore dialysis patients would be less healthy compared to individuals on transplant 
waitlist (48).   
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APPENDIX E: Chapter 5 Details
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E.1 Detailed Methods 
E.1.1 Data Sources 
A description of the databases and codes used to determine risk factors for 
fracture are shown in Table E.1. 
 
Table E. 1. Database codes used to determine risk factors for fracture 
Variable  ICD -9 ICD-10 OHIP Other 
Age    RPDB 
Sex    RPDB 
Prior Major Fracture
*
 Codes and validity of codes described in Appendix D  
Prior Fall  
 
 Codes described in Appendix D 
 
 
Race
£
    CORR 
 
Diabetes not as cause of 
ESRD
β 
 
 
 
250 
 
E10, E11,E13, 
E14 
 
DX:  
250  
 
Fee code: 
K045, K046 ,K029, 
K030,Q040  
 
Donor Type  
  
   CORR 
Dialysis Modality  
 
   CORR 
End-stage Renal Disease 
Cause
∞ 
 
 
   CORR 
Length of time on dialysis 
prior to transplant  
 
   CORR 
Donor age/ donor sex    CORR 
Abbreviations: CORR= Canadian Organ Replacement Registry; Dx, diagnostic code; ICD=International Classification 
of Diseases; OHIP=Ontario Health Insurance Plan; RPDB=Registered Persons Database 
*Previous major fracture defined as a composite of proximal humerus, forearm, clinical vertebral, or hip fracture 
occurring from 1991 to cohort entry (date of transplant).  
£ CORR validation study found agreement between CORR and the medical chart, assessed using the κ statistic, for race 
was 58%; many of the differences occurred when  race was recorded in CORR but race was recorded as unknown in 
the medical chart. Source: Moist LM, Richards HA, Miskulin D, Lok CE, Yeates K, Garg AX, et al. A validation study 
of the Canadian Organ Replacement Register. Clin J Am Soc Nephrol. 2011;6:813-818.  
β Defined diabetes as one hospital admission code for diabetes or one diagnosis code for OHIP or one OHIP fee code 
for diabetes in the 5 years prior to the transplant date.  
∞ CORR validation study found that the agreement, assessed using the κ statistic, between CORR and medical chart 
review for the primary cause of ESRD was: glomerulonephritis (82.8, 95% CI 74.9-90.7); cystic kidney disease (89.1, 
95% CI 77.0-100.0); hypertension/other vascular (66.7, 95% CI 56.5-77.0); diabetes (78.3, 95% CI 70.8-85.8); etiology 
uncertain or unknown (46.6, 95% CI 35.9-57.4); other (64.2, 95% CI 48.6-79.8). Source: Moist LM, Richards HA, 
Miskulin D, Lok CE, Yeates K, Garg AX, et al. A validation study of the Canadian Organ Replacement Register. Clin J 
Am Soc Nephrol. 2011;6:813-818. 
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E.1.2 Missing Data 
Originally several additional risk factors that have been found to be associated 
with fractures in the non-transplant population were going to be assessed, including: body 
mass index (BMI), rheumatoid arthritis, smoking (chronic obstructive pulmonary disease 
used as a proxy), and high alcohol intake (alcoholism used as a proxy). However, there 
were several issues with including these variables. First, BMI had a considerable amount 
of missingness (76.2% missing for height and 80.9% missing for weight). Moreover, 
there were a large number of implausible values (e.g. BMI > 50 kg/m
2
). Additionally, 
there was no date recorded for when the height and weight measurements occurred with 
many measurements occurring during dialysis. Therefore, the BMI could have changed 
considerably if the measurement was taken several years prior to transplant. Changes in 
BMI are common in ESRD patients due to changes in nutritional status and wasting (1). 
For example, one study found that approximately 16% of ESRD patients had a weight 
change ≥ 5% over a three month time frame (2). Regarding smoking, rheumatoid 
arthritis, and high alcohol intake there were too few individuals to assess with ≤ 5 
individuals with these comorbidities experiencing a fracture event. Several transplant 
specific risk factors were also originally going to be assessed but were not due to the 
large amount of missingness, including: number of human leukocyte antigen mismatches 
(missing 41.8%)  and cold ischemic time (missing 48.7%).  
As described in chapter 5 missing data for categorical variables was handled by 
randomly assigning values based on the distribution of variables that were not missing 
(single imputation). For the cause of ESRD, prior to randomly assigning values, we 
looked for evidence of a diabetes diagnosis code or fee code in OHIP or a diagnosis code 
in CIHI in the five years prior to the transplant date; if there was evidence of diabetes the 
cause of ESRD was coded as diabetes. For donor age (continuous variable) the median 
age was used to supplement missing values. Table E.2 demonstrates the pattern of 
missingness before and after handling the missing values. 
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Table E. 2. Distribution of missing data before and after handling missing data 
Variable Before 
(n=2723) 
After 
(n=2723) 
Cause of end-stage renal disease 
Glomerulonephritis  891 (32.7%) 990 (36.4%) 
Cystic 365 (13.4%) 416 (15.3%) 
Diabetes
⃰
  525 (19.3%) 597 (21.9%) 
Renal Vascular  269 (9.9%) 317 (11.6%) 
Other 358 (13.2%) 403 (14.8%) 
Missing/unknown 315 (11.6%) 0 
Race 
Caucasian  1748 (64.2%) 1948 (71.5%) 
Asian  184 (6.8%) 216 (7.9%) 
Black  180 (6.6%) 205 (7.5%) 
Other  320 (11.8%) 354 (13.0%) 
Unknown   291 (10.7%) 0 
Donor type 
Living 1133 (43.9%) 1195 (43.9%) 
Deceased 1449 (56.1%) 1528 (56.1%) 
Missing 21 (0.77%) 0 
Donor age 
Median age 46 (36-54) 46 (36-54) 
Missing 60 (2.2) 0 
Donor Sex 
Female 1350 (49.6%) 1363 (50.1%) 
Male 1349 (49.5%) 1360 (49.9%) 
Missing 24 (0.88%) 0 
Data are median (interquartile range) or n(%). 
⃰ Initially there were 501 recipients with diabetes as their primary cause of ESRD; however, after looking for previous 
evidence of diabetes there were 525 individuals with diabetes as their primary cause of ESRD. The primary cause of 
ESRD was then imputed based on the distribution of ESRD cause. 
 
E.1.3 Proportional Hazards 
To ensure that the proportional hazard assumption was met it was assessed using 
multiple methods. First, a statistical test was used to assess the proportional hazard 
assumption for both continuous and categorical variables; if the p-value was <0.05 then 
the proportional hazard was considered violated. Specifically, the ASSESS option in 
PROC PHREG (SAS) was used which plots the follow-up time against the observed 
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score process (3,4). Second, for categorical variables, a graphical approach (log-log 
survival curves) was also used to visually assess violations of the proportional hazard 
assumption (5).  If the log-log survival curves did not appear parallel (e.g. lines cross-
over, converged or diverged) then the Extend Cox model would be used (5).  Third, for 
continuous variables (e.g. age) the proportional hazard assumption was assessed using the 
time-dependent variable approach which includes an interaction term comprised of the 
time-independent variable and time (e.g., age*log[time]); a p-value <0.05 was considered 
to violate the proportional hazard assumption (5). There were no violations of the 
proportional hazards assumption. 
E.1.4 Departures from Linearity  
To ensure  there were no departures from linearity (e.g., threshold, quadratic) 
martingale residuals were assessed for each continuous risk factor (6), as implemented in 
the PROC PHREG ASSESS statement (SAS) which plots the cumulative martingale 
residuals against each continuous covariate; a p-value <0.05 was used as criteria for 
violation of linearity (6,7). To visually assess departures from linearity a martingale 
residual plot was created using the SAS command PROC PHREG which did not include 
the exposure variable for which the functional form was being assessed (8,9). A lowess 
line was then fit through the martingale residuals (8).  
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